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(i) Novel biomarkers of gastric preneoplasia following infection with Helicobacter 
pylori 
 
Despite steady decline in incidence, gastric cancer remains a major global cause of 
morbidity and mortality and is responsible for over 700,000 deaths worldwide per 
annum. The commonest form arises following infection with the bacterium 
Helicobacter pylori. For reasons which remain poorly understood, a small proportion 
of infected individuals develop gastric epithelial remodelling which follows a well-
defined sequence of changes culminating in cancer development. Our group and 
others have described the role of various gastric mucosal proteins in carcinogenesis 
following H. pylori infection. We hypothesised that these proteins might be 
upregulated in gastric preneoplasia and might in turn be used as biomarkers of the 
same. 
 
We recruited patients attending hospital for diagnostic upper gastrointestinal 
endoscopy. Gastric biopsies were taken to determine the presence and extent of 
preneoplastic lesions by histology; H. pylori status; and the abundance of mRNA for 
putative biomarkers by real-time polymerase chain reaction. Blood was drawn to 
determine the serum concentrations of H. pylori IgG antibodies, fasting gastrin and 
pepsinogens 1 and 2. Genomic DNA was extracted from blood samples. For each 
subject, we performed genotyping for nine single nucleotide polymorphisms in the 
MMP-7 gene to determine whether these polymorphisms might increase the 
expression of mucosal MMP-7 or increase the risk of developing gastric 
preneoplasia. 
 
In our study population, the ratio of pepsinogens 1 and 2 (PG1/2 ratio) performed 
well as a diagnostic test for gastric mucosal preneoplasia. In combination with 
fasting serum gastrin concentration and H. pylori serology, the diagnostic accuracy 
was improved suggesting a role for these markers in clinical practice. 
 
We have demonstrated that the gene transcript abundance of one mucosal protein – 
matrix metalloproteinase-7 (MMP-7) – was significantly increased in the presence of 
gastric preneoplasia. This effect was greater for disease phenotypes associated with 
higher cancer risk. These novel findings confirm the increased expression of MMP-7 
in gastric epithilial preneoplasia and offer insight into areas of development for the 
future including the use of MMP-7 as a noninvasive biomarker of gastric 
preneoplasia. We also found that gastric preneoplasia was significantly more 
common in minor allele homozygotes for SNP rs17352054 than for major allele 
homozygotes and that carriage of the minor allele of SNP rs11225297 is associated 
with gastric preneoplasia amongst H. pylori seropositive individuals. We have also 
shown a significant influence on mucosal MMP-7 relative mRNA abundance of SNP 






ii) A pilot study of the novel gastrin antagonist netazepide (YF476) for the 
treatment of type 1 gastric neuroendocrine tumours 
 
Patients with autoimmune chronic atrophic gastritis develop hypergastrinaemia as a 
result of gastric hypochlorhydria. Hypergastrinaemia can induce hyperplasia of 
enterochromaffin-like (ECL) cells in the gastric mucosa. In a small proportion of 
patients, this progresses to dysplasia and the development of type 1 gastric 
neuroendocrine tumours (NETs). The majority of these tumours behave indolently 
but a small proportion exhibit rapid growth and metastasise. The current treatment 
for larger (>1cm) tumours is surgical antrectomy which obviates the source of 
hypergastrinaemia and causes tumour regression in many cases. We hypothesised 
that pharmacological inhibition of the gastrin/CCK2 receptor would have a similar 
effect. 
 
We conducted a phase 2, open-label pilot study in 8 patients with chronic atrophic 
gastritis and type 1 gastric NETs. This was conducted in two stages. In the first, 
subjects received 50mg netazepide daily for 12 weeks. We performed a baseline 
gastroscopy to measure and count visible NETs and to take gastric mucosal biopsies. 
We also measured baseline serum chromogranin A (CgA) and fasting plasma gastrin 
concentrations. We repeated gastroscopy and biopsy after 6 and 12 weeks of 
treatment, and serum CgA and plasma gastrin every 3 weeks. We measured 
abundances of CgA and histidine decarboxylase (HDC) mRNA in gastric biopsy 
samples by reverse transcription polymerase chain reaction (RT-PCR). We assessed 
drug safety and tolerability by monitoring clinical and blood parameters. In the 
second stage, all 8 patients were treated with netazepide for 52 weeks in the same 
manner as the first stage. Study visits were performed as in the first stage but at 3 
monthly intervals and endoscopy was performed at baseline and after 24 and 52 
weeks of treatment.  
 
In stage 1, 7 of 8 patients exhibited a decrease in the size and/or number of NETs but 
none showed complete tumour regression. Serum CgA concentrations decreased in 
all subjects during treatment, but fasting gastrin concentrations were unchanged. 
The abundances of CgA and histidine decarboxylase mRNA in gastric mucosal 
biopsies also decreased significantly whilst on treatment. In stage 2, after 12 months 
of netazepide treatment, we observed a further decrease in largest tumour size and 
tumour number. Serum CgA concentrations also decreased after restarting 
treatment. Netazepide was well tolerated in both stages in all subjects and no 
serious adverse effects were reported. 
 
The present study suggests that netazepide is a promising, well-tolerated new 
medical treatment for type 1 NETs. Further trials involving longer treatment 
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1.1 The Human Stomach 
 
The human stomach is a hollow, dilated segment of the upper gastrointestinal (GI) 
tract. It extends from the oesophagus at its proximal margin to the duodenum 
distally and has three main digestive functions: a) the short-term storage of ingested 
food, b) the mechanical disruption of food to be mixed with gastric secretions 
(including digestive enzymes) to form semifluid chyme and c) control of the rate of 
delivery of chyme into the proximal small intestine in order to facilitate its efficient 
digestion and subsequent absorption. 
 
1.1.1 Gross anatomy 
 
The organ lies in the left hypochondrial, epigastric and umbilical regions of the 
abdominal cavity and is typically described as “J-shaped”. The “lesser curve” forms 
the right-most border and is suspended from the liver by the lesser omentum and 
the “greater curve” comprises the left border. The greater omentum forms the 
gastrosplenic ligament superiorly and extends to the spleen whilst extending 
inferiorly to the transverse colon. 
As in the rest of the GI tract, the gastric epithelium is superficial to a supportive layer 
of connective tissue, immune cells and blood and lymph vessels – the lamina propria. 
Both are separated from the submucosa by the muscularis mucosa, a thin layer of 
smooth muscle. Beneath the connective tissue of the submucosa lies the muscularis 
externa layer. In the stomach, this layer differs from elsewhere in the GI tract in that 
there is an additional layer of smooth muscle – the inner oblique layer. 
The stomach is anatomically divided into four distinct regions (Figure 1-1): the 





Figure 1-1 Topographical anatomy of the human stomach. 
 
1.1.2 Neural anatomy 
 
The enteric nervous system innervates the stomach by extension of the autonomic 
nervous system and comprises intrinsic neurons as well as processes of extrinsic 
neurons, both efferent and afferent. Sympathetic innervation is via preganglionic 
spinal nerve fibres and postganglionic coeliac plexus fibres. Parasympathetic 
innervation is derived from the vagus nerve whose gastric branches synapse with 
postganglionic fibres in the submucosal and myenteric plexuses. These fibres are 
distributed to secretory apparatus.  
 
1.1.3 Mucosal structure & histology 
 
The gastric mucosa is thick, vascular and rugose. Its epithelial layer is comprised of 
five main cell types: mucous cells, acid-producing parietal cells, enzyme-producing 




Throughout the stomach, the surface epithelium is made up of “surface” mucous 
cells. These are tall (20 to 40µm) and columnar with basal nuclei. Invaginations of 
this layer – gastric pits – represent the luminal orifice of the gastric glands. These 
discrete functional units are lined with specialised cells, the nature of which varies 
depending upon their position in the gland and the anatomical location of the gland 
in the gastric epithelium.  
 
The pits themselves are lined with superficial mucous cells – continuous with the 
superficial epithelium. These give way to the upper margin of the gland proper which 
is described in three sections: the isthmus, the neck and the base. The isthmus is 
narrow and lined with immature stem cells whose proliferation and subsequent 
migration maintains the population of mucous cells above and of the various 
secretory cells below. The glandular neck is characteristically composed largely of 
mucous cells similar to the superficial cells though smaller and of heterogeneous 
morphology. At the base of the gland, the cellular composition is dependent on the 
site of the gland. In the cardiac mucosa, mucous cells with occasional 
enteroendocrine and parietal cells are found with increasing frequency toward the 
corpus. Corpus glands (illustrated in Figure 1-2) contain parietal cells and – deeper in 




Figure 1-2 Cartoon depicting the cellular composition of a gastric oxyntic-type gland. 
 
Antral glands (illustrated in Figure 1-3) exhibit a greater concentration of endocrine 
cells and increase in density closer to the pyloric sphincter. 
 




The more proximally located cardiac glands are distinguishable by their lack of either 
parietal or chief cells. Aside from immature, undifferentiated cells, only mucous and 
endocrine cells are seen in these glands. 
 
1.1.4 Mucus and bicarbonate secretion 
 
Mucous cells form the surface of the glandular gastric mucosa. These cells are largely 
responsible for the protection of the gastric mucosa from the deleterious effects of 
ingested substances, secreted gastric acid, digestive enzymes and duodenal 
refluxate. This is achieved by their secretion of an adherent, viscous, gelatinous layer 
of mucus composed of mucin 5AC (MUC5AC). The secretion of mucin 6 (MUC6) 
predominantly by mucous cells within gastric glands adds a second, superficial and 
loosely adherent mucus layer(1). The mucus layer provides a barrier, which slows the 
diffusion of hydrogen ions from gastric acid towards the epithelial surface. In 
addition to this physical barrier, surface mucous cells are also thought to play an 
important role in the secretion of bicarbonate by means of a Cl-/HCO3- exchange 
transporter on the cell membrane(2), setting up a pH gradient from the lumen (low 
pH) to the epithelium (higher pH). Not only does this prevent physical damage to the 
mucosal from gastric acid, the activity of the secreted enzyme pepsin is diminished 
as it diffuses slowly towards the epithelium and away from its optimal operating pH 
range. 
 
Cosecreted with mucin molecules by mucus neck cells are trefoil factors (TFF). These 
small, enzyme-resistant proteins are found in two main forms in the mammalian 
stomach – TFF1 and TFF2. They act to increase mucous gel stability and viscosity and 
have been shown to contribute to epithelial repair, anti-apoptosis and tumour-
suppression(3,4). They modulate immune responses to microbes and have 






1.1.5 The Enterochromaffin-like Cell 
 
Enterochromaffin-like (ECL) cells are the predominant enteroendocrine cell type of 
the mammalian stomach and constitute approximately one-third of oxyntic 
endocrine cells in humans. They are said to be “closed” endocrine cells as their 
secretory apparatus is not seen to open into the glandular lumen suggesting their 
paracrine and endocrine roles in gastric secretory regulation. Typically occupying the 
lower third of the gastric gland, ECL cells are commonly located in close contact with 
parietal and chief cells(6). Their nomenclature has its origins in the notion that in 
certain physiological states, they are structurally and histologically similar to 
enterochromaffin cells(7). The cells are spherical in shape with occasional digital 
extensions and multiple cytoplasmic vesicles(8). The ECL cells can be thought of as 
relay stations in the regulation of gastric acid secretion and their major product is 
histamine – the most important stimulus of parietal cell acid secretion humans. 
 
Histamine is produced by decarboxylation of L-histidine by the enzyme histidine 
decarboxylase (HDC)(9). It is then stored in secretory vesicles by the action of 
vesicular monoamine transporter-2 (VMAT2)(10). The hormone gastrin binds to the 
CCK2-receptor (CCK2R), a G-protein coupled receptor (GPCR). Downstream signalling 
from CCK2R is mediated by Gαq/11, leading to activation of phospholipase C with 
subsequent increases in intracellular calcium via inositol trisphosphate mobilisation 
and activation of protein kinase C via diacylglycerol(11) amongst other protein 
kinase pathways(12). Gastrin regulates the transcription and activity of HDC(13) and 
VMAT-2(10) as well as chromogranin A (CgA)(14). This matrix protein is expressed in 
neuronal cells of the central nervous system and neuroendocrine cells of the 
stomach, pancreas, intestine and adrenal glands. It is stored along with the other 
major cellular products in the secretory vesicles. CgA is thought to influence 
intracellular granule stability, and prohormone processing(15,16). Its cleavage 
products include pancreastatin and it participates in the regulation of peptide 




Mammalian ECL cells also express PAC1 receptors whose major ligand is Pituitary 
Adenylate Cyclase-Activating Polypeptide (PACAP), a neurotransmitter that 
stimulates histamine secretion by ECL cells via intracellular Ca2+ dependent 
pathways(19,20). 
 
Both gastrin and PACAP exert trophic effects on ECL cells and have been shown to 
induce proliferative responses(20–25).  
 
1.1.6 The Parietal Cell 
 
The parietal cell is specialised to secrete gastric acid at pH 0.8 which serves to inhibit 
microbial growth and colonisation and to activate proteolytic enzymes(26). Typically 
pyramidal in shape, its limited luminal area is greatly increased by microvilli lined 
invaginations or cannaliculi. H+K+-ATPase – the primary gastric proton pump is the 
most abundantly expressed membrane protein in an extensive system of so called 
“tubulovesicles”. This protein is an α,β heterodimer able to secrete hydrogen ions 
against a steep concentration gradient. H+ ions are exchanged for K+ ions and in the 
process, an intracellular hydroxide ion is generated. This is converted to bicarbonate 
by the carbonic anhydrase enzyme and exchanged at the basolateral membrane for 
chloride.  
The basolateral membrane expresses receptors for stimulation via neural and 
endocrine pathways to stimulate acid secretion(27). 
 
The parietal cell is also the source of intrinsic factor (IF), a glycoprotein required for 
binding of vitamin B12 and its subsequent absorption in the terminal ileum. The 
commonest cause of B12 deficiency is pernicious anaemia – a clinical syndrome 
comprising megaloblastic anaemia, low serum B12 concentration and the presence 
of autoantibodies to parietal cells and/or IF. This disease arises as a result of 
autoimmune destruction of parietal cells in the setting of autoimmune atrophic 




1.1.7 Regulation of acid secretion 
 
Gastric acid is required for the optimal digestion of proteins; the absorption of 
minerals such as iron and calcium; and inhibition of microbial growth. In order that 
acid secretion does not overwhelm the protective mechanisms of the gastric mucosa 
however, the process is under tight control by neuronal, paracrine and endocrine 
systems. Two intracellular signaling pathways are thought to participate in H+K+-
ATPase activation: a) the Ca2+ pathway – induced by M3 muscarinic receptor 
stimulation by acetylcholine (Ach) (neuronal) and b) the adenylate cyclase pathway – 
induced by H2 receptor stimulation by histamine (paracrine). Parietal cells also 
express CCK2R though the significance on H+K+-ATPase recruitment of parietal 
stimulation by gastrin is subject to some debate(28). The most important regulator 
of acid secretion is the hormone gastrin, which works indirectly (via the intermediary 
ECL cell) (Figure 1-4). The principal inhibitor of acid secretion is somatostatin from 
gastric D cells, which acts in a paracrine fashion. 
 
Stimulation of the G cells, ECL cells and parietal cells begins with the so-called 
cephalic phase of acid secretion during which stimuli arising in the brain (sight and 
smell of food etc.) culminate in efferent vagal stimulation. This induces the release of 
postganglionic neurotransmitters including ACh, PACAP, vasoactive intestinal 
peptide (VIP) and gastrin-releasing peptide (GRP). In the gastric mucosa, ACh exerts 
its stimulatory effect at the parietal ECL and G cells whilst at the same time inhibiting 
somatostatin secretion from D cells. GRP also acts at the G cell to stimulate gastrin 
secretion whilst the ECL cell is subject to PACAP stimulation. Direct stimulation of the 
parietal cell by histamine at the H2 receptor (H2R) is accompanied by inhibition of 
somatostatin secretion via the H3 receptor(29,30). 
 
The gastric phase of acid secretion is characterised by the response of antral G cells 
to the stimuli associated with the ingestion of food. Luminal protein, amino acids 
and calcium ions induce gastrin secretion. Resulting endocrine stimulation of the ECL 
cell to produce histamine is the major regulatory step in acid secretion(28). Gastrin 
release is inhibited by somatostatin from gastric D cells in a paracrine negative 
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feedback fashion(26). Somatostatin secretion is itself stimulated by gastrin in a 
paracrine fashion but also via neuronal pathways in response to decreased gastric 
pH. The latter step is particularly relevant in conditions of impaired gastric acid 
secretion due to pharmacological intervention or parietal cell loss. In this situation, 
somatostatin secretion is inhibited, thus removing the brake on gastrin production 
and leading to hypergastrinaemia with all of its associated effects(28). Parietal cell 
inhibition by somatostatin is also mediated by direct, paracrine binding to parietal 
somatostatin receptors, the result of which is to abrogate intracellular cyclic 
adenosine monophosphate (cAMP) production(27).  
 
 
Figure 1-4 Gastrin mediated control of gastric acid secretion. 
 
1.1.8 Pepsinogen secretion 
 
Pepsinogens (PGs) are polypeptide zymogens secreted in the stomach and activated 
by gastric acid to form pepsins  - the major group of gastric proteases. Pepsins 
themselves can activate PGs in an autocatalytic fashion. In humans, PGs are secreted 
in two major classes – PG1 (or PGI) and PG2 (or PGII). The former comprises 5 
isoenzymes secreted only in the chief and mucous cells of oxyntic mucosa. On 
activation, PG1 forms pepsin 1 (or pepsin I). In contrast, PG2 (comprising 2 
isoenzymes) is secreted by cardiac, oxyntic, pyloric and Brunner’s glands(31) and is 
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activated to form pepsin 2 (or pepsin II). Both forms of pepsin are optimally active in 
acidic environs between pH 1.8 and 3.5. They are reversibly inactivated at pH 5.0 and 




In normal physiology, the antral hormone gastrin stimulates the secretion of acid 
and the proliferation of cells of the gastric epithelium. Excess gastrin production is 
associated with states in which the normal inhibitory mechanisms are lost or 
suppressed (such as with the use of proton-pump inhibitor drugs) or in which there 
is a pathological source of gastrin secretion (such as a secretory ‘gastrinoma’ in the 
Zollinger-Ellison syndrome). The ‘classical’ gastrins are those peptides whose carboxy 
terminus is amidated and they can also be sulphated at their single tyrosine residue. 
The various forms of classical gastrins exhibit similar activity at the CCK2 receptor 
though they vary in half-life.  
 
1.2.1 Biosynthesis and processing 
 
The gastrin hormone is encoded by a single gene located on the long arm of 
chromosome 17(32). It is primarily synthesised in G-cells of pyloric glands in the 
gastric antrum though G-cells are also found in duodenal Brunner’s glands(33). The 
primary precursor – preprogastrin – is synthesised in the endoplasmic reticulum 
where the N-terminal sequence is cleaved to form progastrin for storage in exocytic 
vesicles (Figure 1-5). Here, progastrin is further modified by protease cleavage to 
generate COOH-terminal Gly-extended gastrins (G-Gly). These G-Gly peptides are 
then acted upon by peptidyl-D-amidating mono-oxygenase (PAM) to form COOH-
terminal amidated gastrins, the two major forms of which are G17 and G34 with 17 
and 34 amino acid residues respectively(34). Gastric acidity inhibits gastrin release 
via the secretion of somatostatin by antral D-cells in a negative-feedback fashion. G-
cells release gastrin in response to stimuli associated with food ingestion. Gastric 
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nerves release gastrin-releasing peptide (GRP) and luminal amino acids and calcium 
ions act at luminal receptors on the G-cell.  
 
 
Figure 1-5 Biosynthesis and processing of gastrin. 
 
Gastrins are said to belong to a family of peptide hormones that also includes 
cholecystokinin (CCK) as they both possess the COOH-terminal pentapeptide amide, 
which confers their biological activity. These peptides act at the CCK1- and CCK2 
receptors and whilst CCK exhibits a high affinity for both receptors, gastrin binds to 
CCK2R with an affinity approximately 100-times that of CCK1(35). After ingestion of a 
meal, the circulating concentration of gastrin exceeds that of CCK by 5-10 times and 
so gastrin is thought to be the most important physiological agonist of CCK2R(36). In 
normal physiological states, gastrin is expressed on gastric parietal and ECL-cells as 
well as in the pancreas and brain.  
 
1.2.2 Cellular effects 
 





The other major role of amidated gastrins in normal physiology is in gastric epithelial 
cell proliferation – a phenomenon borne out through clinical observations and in 
numerous laboratory studies. As cellular proliferation is a key step in oncogenesis, 
this behaviour merits further discussion. Perhaps the best-characterised clinical 
effect of hypergastrinaemia is the gastric corpus hypertrophy with ECL-cell tumour 
formation and hyperacidity that is observed in patients with Zollinger-Ellison 
syndrome. In such patients, resection of the gastrin-secreting gastrinoma results in 
normalisation of gastric acid secretion and leads to reversal of parietal cell 
hyperplasia(37,38).  
 
The trophic effect of gastrin was first described in animal models almost 45 years 
ago when the augmenting effects of pentagastrin on protein synthesis and parietal 
cell mass were demonstrated in rats (39,40). This has been studied extensively in 
other animal models. In mice in which the genes encoding either gastrin or its 
receptor (CCK2R) are deleted, there are reduced gastric populations of parietal and 
ECL cells accompanied by hypochlorhydria(41) suggesting that the effect of gastrin is 
to stimulate gastric stem cell proliferation and to influence stem cell differentiation 
towards a parietal or ECL-cell fate(42). In contrast, transgenic mice engineered to 
produce gastrin in pancreatic E-cells (INS-GAS) initially exhibit hyperproliferation of 
gastric epithelium, enhanced populations of parietal and ECL cells and 
hyperacidity(34). Interestingly, the same animals later lose parietal cell mass and 
develop foveolar hyperplasia in a histologically similar fashion to that seen in the 
human disease of chronic atrophic gastritis. The molecular mechanisms responsible 
for the proliferative influence of gastrin have also been explored in vitro. MKN-45 
cells constitutively expressing CCK2R exhibit diminished proliferation when treated 
with a CCK2R antagonist(43). The corollary of this is seen with AGS-B cells stably 
transfected to express CCK2R and treated with gastrin. These cells exhibited more 
rapid proliferation associated with upregulation of cyclin D1(44). 
 
The thesis that classical gastrin acting via CCK2R is responsible for gastric epithelial 
proliferation is however complicated by several observations. First, proliferating cells 
in normal gastric epithelium are not seen to express CCK2R with the exception of 
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ECL-cells and (to a lesser degree) parietal cells(45). Additionally, other cell-line 
studies have illustrated an inhibitory effect of gastrin on proliferation(46,47). 
Previous studies suggested a paracrine role for gastrin-induced ligands for the 
epidermal growth factor receptor (EGF-R) such as heparin-binding epidermal growth 
factor (HB-EGF)(48–50). Our own group examined this by first transfecting gastric 
cancer derived AGS cells with the CCK2R (AGS-GR). Exposure to gastrin inhibited the 
proliferation of these cells but when the same cells were co-cultured with labelled 
AGS cells (AGS-GFP), exposure to gastrin induced proliferation of the latter, CCK2R 
deficient cells suggesting paracrine stimulation. The same study identified that the 
likely mechanism was via gastrin induced shedding of HB-EGF and that this was in-
turn mediated by protein kinase C (PKC) dependent matrix metalloproteinase (MMP) 
activity(51). This mechanism is pertinent to the present study as H. pylori is known to 
induce hypergastrinaemia, MMP activity and the expression of growth factors 
including HB-EGF(48,52–56). Recent work has identified mitogen activated protein 
kinase 1 interacting protein 1 (MP1) as an essential partner in gastrin-induced 
phosphorylation of ERK1 and ERK2 and that this is responsible for gastrin-induced 
proliferation via the mitogen-activated protein kinase (MAP) pathway(57).  
 
These paracrine pathways also appear to be important when considering the effect 
of gastrin stimulation on cellular migration and invasion – also key steps in 
oncogenesis and important when investigating preneoplastic epithelial remodelling. 
Using the same AGS-GR/AGS-GFP co-culture methodology described above, gastrin 
stimulated cell migration both directly (for AGS-GR) and in a paracrine fashion (for 
AGS-GFP). This phenomenon was found to be due to MAPK activity via HB-EGF(53). 
MAPK activity has also been implicated in the induction of MMP-9 expression and 
the gastrin-stimulated invasion of AGS-GR cells through basement membrane in 
vitro(56).  
 
The influence of gastrin on ECL-cell proliferation is one of direct stimulation. In 
rodents, it has been shown that ECL-cells are capable of self-replication(58) and that 
gastrin induces ECL cell proliferation in animals and in vitro(25,59). ECL-cell 
hypertrophy in response to hypergastrinaemia is seen in rats after a few days and 
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reaches a maximum plateau after 20 weeks(60). Pathological hypergastrinaemia in 
humans is considered as either a) primary - as seen in Zollinger-Ellison syndrome 
with excess production of gastrin by a secretory tumour or b) secondary – as seen in 
chronic autoimmune atrophic gastritis (AIG) with oxyntic atrophy, hypochlorhydria 
and loss of the negative feedback influence of gastric acid. The pathophysiology of 
the associated type 1 gastric neuroendocrine tumours is discussed in section 1.6. 
 




Bacterial colonisation of the human stomach was described and debated as early as 
the 19th century but until the first published description of Helicobacter pylori  (H. 
pylori) culture in 1983, the prevailing assumption had been that the hostile, acidic 
environment of the gastric mucosa ensured its sterility(61,62). The organism 
originally labelled Campylobacter pylori by Marshall and Warren is a Gram-negative, 
helical, flagellate, microaerophilic bacillus. It grows slowly and requires highly 
regulated environmental conditions, making its culture in vitro somewhat 
challenging(63). Since its discovery, much of the research interest in H. pylori has 
focused on the factors that determine the outcome of infection. As discussed in 
section 1.3.2, the clinical consequences of gastric colonisation with H. pylori are 
dependent on a complex interaction between bacterial, host and environmental 
factors. 
 
1.3.2 Outcomes of infection with H. pylori 
 
It has been well established that H. pylori infection (of any strain) induces 
inflammation in the gastric mucosa in all infected hosts. Acute infection in adults can 
induce a syndrome comprising marked gastritis and achlorhydria accompanied by 
symptoms of abdominal discomfort and nausea(64,65). The subsequent clinical 
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sequelae of infection are, however, variable. There are three main groups as 
illustrated in Figure 1-6 (66): a) The benign pangastritis phenotype in which there is 
mild inflammation throughout the stomach without symptoms or serious 
complications such as ulceration; b) the antral predominant/peptic ulcer phenotype. 
In approximately 15% of infected subjects, the oxyntic mucosa is relatively spared 
whilst antral inflammation results in hypergastrinaemia and high parietal cell acid 
output. In these subjects, high acidity results in pyloric and duodenal ulceration; and 
c) the corpus predominant/gastric cancer phenotype. In contrast to the “duodenal 
ulcer” phenotype, these individuals exhibit corpus-predominant gastritis with 
sparing of the antrum. In around 1% of infected people, subsequent corpus atrophy 
results in loss of parietal cells and attendant hypochlorhydria. This can be followed 
by a sequence of cellular changes discussed in section 1.4 and which predisposes 
sufferers to the development of gastric adenocarcinoma. The causative link between 
H. pylori infection and the subsequent development of non-cardia gastric 
adenocarcinoma was subject to considerable debate but definitive studies published 
over a decade ago established the connection and illustrated the protective effect of 
eradicating H. pylori in infected subjects including those with established 
preneoplastic conditions(67–69). The International Agency for Research on Cancer 
has classified H. pylori as a type I carcinogen(70). It is estimated that H. pylori confers 
an increased risk of non-cardia gastric adenocarcinoma of between 6- and 8-fold 








Helicobacter pylori is a highly successful pathogen whose relationship with humans is 
thought to date back at least 58,000 years(73). A variety of Helicobacter species can 
be found in other mammals and it has been suggested that organisms of this genus 
are ancestral to mammals in general and that early humans may have been infected 
with H. pylori before evolving into Homo sapiens(74). Though falling in incidence in 
developed countries, the overall prevalence of H. pylori is estimated at greater than 
50% of the global population(75) making it the world’s commonest bacterial 
infection. Prevalence is considerably higher in developing than in developed 




H. pylori infection is thought to occur predominantly in childhood with some 
populations exhibiting 90% carriage rates in children under 10 years old(78–80). 
Close, cohabiting family members are the main source, with the greatest risk factor 
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for infection being maternal H. pylori status(79). Though faecal-oral transmission is 
frequently cited, there are limited data supporting H. pylori survival following 
intestinal transit in healthy individuals. The organism can be cultured in faecal 
samples when diarrhoea is induced in otherwise healthy subjects and vomitus is a 
reliable source of viable organisms, raising the possibility that transmission occurs 
when individuals are exposed to family members with enteric illnesses(81,82). It is 
proposed that oral-oral transmission is the predominant route, though there are 
recent reports implicating maternal vaginal reservoirs of H. pylori colonies which 





Although increasing understanding of the gastric microbiota has now superseded the 
paradigm of the “sterile stomach”, the chemical and mechanical conditions of the 
gastric lumen represent a challenging niche for microbial survival and proliferation. 
H. pylori has evolved a series of highly specialised strategies for survival. H. pylori 
selectively colonises the mucous layer but in order to do so, first induces localised 
buffering of its cytoplasm and immediate surroundings by enzymatically degrading 
urea to generate ammonia and CO2(85). The activity of the cytoplasmic and 
membranous urease enzyme is highly conserved across H. pylori spp. and forms the 
basis for rapid diagnostic tests including the urea breath test and urease gastric 
biopsy rapid assay(86). Components of the urease complex have also been shown to 
induce the upregulation of inducible nitric oxide synthase and the release of nitric 
oxide, prompting speculation that urease also plays a role in the mediation of 
epithelial inflammation(87). 
 
Subsequent survival of H. pylori depends on migration to and colonisation of the 
mucous layer adjacent to the mucosal surface where the pH can be maintained at 
near-neutrality. To facilitate this, a H. pylori bacterium exhibits pH chemotaxis and 
employs its flagellate apparatus to travel to and maintain a position in close 
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proximity to the epithelial surface where critical interactions with host epithelial 
cells can take place(66). The long-held assumption that H. pylori bacteria are able to 
burrow through the viscous mucus-layer adjacent to the mucosa in a corkscrew 
fashion is probably over-simplistic. Recent studies have illustrated the immobility of 
H. pylori in porcine gastric mucus(88) suggesting that in humans, the organism is 
actually able to alter the rheology of gastric mucus. It has been shown to achieve this 
by altering its environmental pH (as described above) and by altering mucus 
composition and mucin production directly(88,89). 
 




A small proportion (estimated to be 1-20%) of colonising H. pylori organisms can be 
found adhered to gastric epithelial cells(90–92). The advantages of doing so are 
thought to be related to: a) resistance to mechanical removal and subsequent 
intestinal excretion, b) manipulation of the host cell response to attenuate the 
immune response and c) the acquisition of host cell nutrients(66,90,93). H. pylori 
have more than 30 genes responsible for the expression of outer membrane 
proteins (OMPs), some of which have been classified as adhesins(66). These protein 
complexes are regarded as bacterial virulence factors. The best-characterised group 
of adhesins belong to the Hop family of OMPs and include BabA, SabA, AlpA/B, 
HopQ/Z, and OipA(93). BabA is a membrane-bound adhesin molecule responsible for 
binding the blood-group antigen Lewis b (Leb) on gastric epithelial cells. H. pylori 
strains carrying the babA2+ variant are associated with an increased risk for the 
development of mucosal preneoplastic conditions and subsequent 
adenocarcinoma(94). The sialic acid-binding adhesin SabA binds to epithelial 
sialyated carbohydrate complexes such as sialyl-dimeric-Lewis x(87,94). SabA is also 
implicated in pro-inflammatory neutrophil activation(95). OipA is an outer-
membrane protein and infection with strains expressing this is associated with more 
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severe gastritis, duodenitis and ulceration and higher bacterial colonisation 
densities(87,96). 
 
1.3.6.2 CagA and the cag Pathogenicity Island 
 
Some strains of H. pylori express a genetic sequence known as the cag Pathogenicity 
Island (cag PAI). This 40kb region encodes cagA, a bacterial protein whose presence 
confers an enhanced risk of adverse outcomes including pronounced gastritis, peptic 
ulceration, preneoplastic changes and gastric adenocarcinoma(97). Other coding 
regions of the cag PAI encode components resembling those of a Type 4 secretion 
system (T4SS). H. pylori strains containing the cag PAI account for 60-70% of Western 
strains and almost 100% of those found in East Asia(97). It has been shown that cagA 
positive strains of H. pylori are able to inject CagA into host epithelial cells where it 
undergoes phosphorylation at EPIYA sites by two groups of cellular kinases: SRC and 
ABL. The resulting intracellular CagA products have been shown both to upregulate 
the expression of IL-8, IL-1β and TNF-α; and to activate NF-κB, thus enhancing the 
inflammatory response(66,93,98,99). A recent study has suggested that infection 
with cagA positive strains of H. pylori is associated with the increased production of 
H2O2 and a resulting legacy of oxidative DNA damage(100).  
 
Whilst the precise mechanisms underpinning the effect of CagA phosphorylation on 
H. pylori pathogenicity are unclear, it has been shown that cagA positive strains 
confer a substantially increased risk of gastric cancer development following 




Another well-characterised H. pylori virulence factor is VacA. Unlike the cag PAI, 
VacA expression is highly conserved across strains of H. pylori though expression and 
effects vary depending upon genetic diversity. VacA is secreted via type 5 secretion 
systems whereupon a proportion of the secreted protein assembles at the host cell 
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membrane, inducing the formation of membranous pores(66). VacA has been shown 
to induce host cell apoptosis and disrupt epithelial tight junctions(102). The 
subsequent exposure of T cells to VacA in the lamina propria is thought to alter T cell 
function and inflammation by NF-κB activation and IL-8 upregulation(103). More 
recent studies have illustrated the role played by VacA in the control of gastric 
epithelial cell autophagy. In certain circumstances, VacA inhibits autophagy which 
results in the accumulation of reactive oxygen species(104). Paradoxically, a second 
study demonstrated the induction of gastric epithelial cell autophagy by VacA via 
binding to and activation of low-density lipoprotein receptor-related protein 
(LRP1)(105). This also leads to the accumulation of intracellular reactive oxygen 
species. Both scenarios might be expected to lead to oxidative DNA damage. 
 
As in the case of cagA, the precise mechanisms of VacA dependent pathogenicity 
remain unclear but virulent variants of VacA (s1 type) have been shown to be 
associated with adverse outcomes including peptic ulceration and gastric 
adenocarcinoma(106). 
 
1.3.7 Manipulation of the host immune system 
 
Even for hosts infected with virulent strains of H. pylori, the progression from 
chronic gastric inflammation to cancer development is uncommon. Manipulation of 
the immune response to infection is essential for H. pylori persistence and the 
attenuated inflammatory response has been implicated in carcinogenesis(107). It has 
been suggested that epithelial inflammation is required for H. pylori to requisition 
nutrients, which would otherwise be inaccessible(108). 
 
H. pylori has evolved several strategies to overcome and modify the host immune 
response – both innate and adaptive. For example, the bacteria preferentially induce 
a T-helper cell 1 (Th1) response, usually considered a requirement for immune 
destruction of intracellular organisms(109). H. pylori also exhibits molecular mimicry 
by expressing lipopolysaccharide (LPS) which is able to antagonise toll-like receptor 
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(TLR) 4 signalling, potentially facilitating evasion of the host’s innate immune 
system(110,111).  
 
1.3.8 Host factors influencing the outcome of infection with H. pylori  
 
1.3.8.1 Matrix metalloproteinases (MMPs), their tissue inhibitors (TIMPs) and 
disintegrins and metalloproteinases (ADAMs) 
 
Matrix metalloproteinases (MMPs) are a homologous protein family comprising 23 
zinc-dependent endopeptidases that are classically defined by their role in degrading 
extracellular matrix and basement membrane. In this capacity, they are key 
participants in normal physiological processes including morphogenesis, 
angiogenesis and tissue repair(112). They are non-covalently inhibited by tissue 
inhibitors of metalloproteinases (TIMPs), a group containing 4 members(113). The 
disintegrins and metalloproteinases (ADAMs) are a related family of 24 membrane-
bound peptides responsible for cell adhesion, cell migration, activation of signalling 
pathways and proteolysis(114). 
 
MMPs exhibit proteolytic and non-proteolytic activity against a very broad variety of 
substrates and hence influence many biological processes. When their tight 
regulatory controls are disrupted during carcinogenesis, these peptides are readily 
co-opted to participate in cancer invasion and metastasis(115). Upregulation of 
MMP expression has been demonstrated for a wide variety of human malignancies 
and for some, can reflect tumour stage(116,117). Though MMPs exhibit several 
features which appear to confer suitability for therapeutic targeting, clinical trials of 
MMP inhibition with small molecule inhibitors have proved largely 
disappointing(116,118). 
 
MMP-1 is thought to participate in H. pylori associated gastritis in a cag PAI 
dependent fashion via protein kinase C and is found, co-located with H. pylori at the 




MMP-3 degrades several types of collagen, proteoglycans, fibronectin and laminin. 
Its role (along with MMP-9) in various disease states including inflammatory 
arthropathy, asthma, Alzheimer’s dementia and delayed wound healing has been 
established(120). Though cell-line and murine models suggest an increase in MMP-3 
expression associated with exposure to Helicobacter species, no difference is 
observed in humans(121). This may reflect the role of MMP-3 as predominantly an 
activator of other MMPs(120). 
 
MMP-9 degrades collagen type IV and is implicated in H. pylori associated gastritis 
and carcinogenesis. Its proteolytic activity is observed to increase in H. pylori 
infected gastric epithelia and to diminish following H. pylori eradication(122,123). 
Interleukin-21 (IL-21) is thought to be responsible for upregulation of MMP-2 and -9 
in H. pylori associated gastritis and is found in high concentrations in gastric tissue 
from subjects with H. pylori gastritis. Unlike other MMPs, MMP-2 and -9 are secreted 
by AGS cells in response to stimulation with IL-21(124). Our own group 
demonstrated gastrin-stimulated MMP-9 expression and epithelial cell invasion in 
gastric cancer cells expressing CCK2R (AGS-GR)(56).  
 
MMP-7 is responsible for the degradation of proteoglycans, fibronectin, elastin and 
casein(112) and is produced in epithelial cells (unlike the majority of other MMPs). 
There has been considerable interest in MMP-7 and its participation in the response 
to H. pylori infection as it has been shown to mediate the inflammatory response to 
flagellated bacteria in other epithelial systems(125). Our group previously reported 
that MMP-7 expression is increased in gastric epithelia in response to H. pylori. In 
the same study, MMP-7 exhibited growth factor-like actions attributed to activation 
of other MMPs, MAP kinase and PI-3 kinase pathways. MMP-7 was localised to the 
advancing edge of spreading colonies of gastric epithelial cells (and in AGS gastric 
cancer cell lines) where the rates of migration were higher in H. pylori infected 
cultures compared with controls(53). Following on from this, the same group 
showed that MMP-7 acted via insulin-like growth factor-2 (IGF-2) release to enhance 
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epithelial cell and myofibroblast proliferation, suggesting that MMP-7 is important in 
mediating hyperproliferation of mucosal cells in response to H. pylori infection(126). 
 
Several studies have examined the role of ADAM-10 and -17 in the epithelial 
response to H. pylori infection. In antral biopsies, both are increased in abundance in 
H. pylori infected tissue compared with controls(127). Both influence cell signalling 
via pathways known to be involved in gastric carcinogenesis including via tumour 
necrosis factor-α (TNFα), E-cadherin and the Notch signalling pathway(121). 
 
1.3.8.2 The urokinase plasminogen activator (uPA) system 
 
The urokinase plasminogen activator (uPA) system comprises the serine protease 
uPA, its receptor (uPAR) and a number of inhibitory protease peptides, most notably 
plasminogen activator inhibitors 1 and 2 (PAI-1 and PAI-2). The primary role of uPA 
in normal physiology is the cleavage of its primary substrate - plasminogen - to its 
active form – plasmin. Plasmin is also a serine protease and has several recognised 
substrates. It is capable of promoting ECM degradation both by direct proteolysis of 
fibronectin, vitronectin and fibrin; and via the activation of several of the 
MMPs(128). In this manner, uPA bound to uPAR is thought to have a role in initiating 
the chain of proteolysis which facilitates cancer cell invasion and metastasis(129). 
 
Expression of uPAR has been characterised in a number of human cancers and cell 
lines and for gastric cancer, this correlates with features of tumour ‘aggressiveness’ 
including invasiveness and capacity to metastasise(130,131). In an early series of 
gastric cancer patients, increases in both uPA and PAI-1 expression in tumour 
biopsies were shown to be independent prognostic parameters(131). 
 
The evidence for an association between H. pylori infection and activation of the uPA 
system is increasingly clear. A study of gastric cancer cases found that in non-cancer 
gastric mucosa uPAR was more frequently expressed in the epithelial cells of H. 
pylori infected specimens than those free from infection(132). Our own group has 
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reported that H. pylori infection stimulated the expression of all three of uPA, uPAR 
and PAI-1 in gastric epithelial cells in vitro and that this was accompanied by uPA 
dependent cell proliferation via HB-EGF stimulation. In the same study, the authors 
reported increased uPA, uPAR and PAI-1 expression in the gastric corpus tissue of 
individuals with H. pylori infection compared to those without(133). 
 
1.3.8.3 Insulin-like growth factors (IGFs) 
 
Insulin-like growth factors-1 (IGF-1) and -2 (IGF-2) are predominantly synthesised in 
the liver. Growth-hormone (GH) stimulated IGF-1 is the major regulator of post-natal 
growth whilst GH independent IGF-2 is important for normal foetal 
development(134). 
 
Expression of both IGFs and their receptors has been described for gastric cancer cell 
lines(135–137) and in human gastric cancer tissue(138). Gastric cancer cell growth in 
vitro is potentiated by the addition both of IGF-1 and IGF-2(135,136). 
 
Our group has previously demonstrated that stromal-cell mediated inhibition of IGF-
2 via transforming growth factor beta-induced (TGFB1) abrogated IGF-2 stimulated 
cancer cell migration and proliferation(139). A study published in 2004 set out to 
determine the effect on circulating IGFs in response to acute infection with H. pylori. 
The authors reported a significant decrease in the serum concentrations of both IGFs 
and this was attributed to an acute-phase response(140). This study would appear to 
have little bearing on the role of IGFs in H. pylori associated gastric preneoplasia and 
carcinogenesis. Another study reported reduced serum concentrations of the major 
circulating IGF binding protein, IGFBP-3 in patients with gastric preneoplasia than in 
controls. The same authors showed increased frequency in subjects with antral 
intestinal metaplastic preneoplasia of an IGFBP-3 gene promoter polymorphism 
known to reduce IGFBP-3 production compared with controls. Finally, these authors 
also reported increased IGFBP-3 expression in gastric cancers of ‘well or moderately 
differentiated’ histology compared with tumours of the ‘poorly differentiated’ type. 
 
47 
They therefore concluded that IGFBP-3 might be protective against gastric cancer 
development(141), though their findings may have actually been reflective of a 
difference in phenotype of gastric preneoplasia and subsequent gastric cancer type. 
In a recently published study, 54 patients with H. pylori had serum concentrations of 
IGF-1 and IGFBP-3 measured before and after H. pylori eradication. The authors 
reported that there was a significant decrease in the serum concentration of IGF-1 
following proven H. pylori eradication. In this small series, it was not possible to 
determine an association between IGF-1 and/or IGFBP-3 and gastric 
preneoplasia(142).  
 
1.3.8.4 Host genetic factors 
 
The host response to H. pylori infection is largely mediated via cytokine release. As 
well as the bacteria specific variables described above, the magnitude of cytokine 
release can also be affected by host genetic polymorphisms.  
 
The best studied are polymorphisms in the interleukin-1β gene (IL1B) and in the 
interleukin-1 receptor antagonist gene (IL1RN). These are associated with increased 
mucosal IL1β and inflammation(143) following H. pylori infection. Individuals with 
the so-called ‘pro-inflammatory’ genotypes exhibit an increased propensity for the 
development of both preneoplastic lesions and non-cardia adenocarcinoma(66). As 
might be anticipated, the summative effect of ‘pro-inflammatory’ IL1B 
polymorphisms and bacterial virulence factors confer a markedly greater risk (as 
much as fifty-fold increase) for cancer development(144). Other polymorphisms 
associated with increased H. pylori-related inflammation and risk of non-cardia 
gastric cancer include those in the TNFA gene encoding TNFα and in genes encoding 
innate immune factors such as TLR4. It has been suggested that individuals carrying a 
compound genotype comprising ‘pro-inflammatory’ genotypes for several immune 
factors are prone to the development of the pangastric/corpus predominant, 
hypochlorhydric pattern of H. pylori gastritis most likely to proceed to preneoplasia 
and gastric cancer development(66). 
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1.4 Gastric Cancer 
 
1.4.1 Epidemiology & classification 
 
Despite several decades of declining incidence, gastric cancer remains the fifth 
commonest cancer and the second commonest cause (after pulmonary malignancy) 
of cancer mortality worldwide(145–147). Approximately 9% of cancer deaths 
globally are attributed to the disease with an estimated 952,000 new cases and 
723,000 deaths in 2012(147). Gastric cancer incidence reports illustrate the skewed 
geographical distribution of the disease. Over 50% of cases occur in East Asia (mostly 
China). In contrast, European cases make up only 15% of the total(148). Incidence is 
also divided along socioeconomic lines with higher rates typically being observed in 
developing than in developed nations and in lower socioeconomic groups within 
individual nations and ethnic groups(148–150). Age-standardised rates for males are 
approximately double those for females(147). In the United Kingdom, gastric cancer 
is the thirteenth commonest malignancy (2.5% of all cancers) with an age-
standardised incidence rate of 8.6 per 100,000 persons. There are almost 8,000 new 
cases of gastric cancer diagnosed annually and over 5,000 deaths(151). Global 
incidence and mortality rates have diminished steadily since the middle of the 20th 
century and the UK is no exception. Here, the mortality rate has fallen by 70% since 
the 1970s(152). This global decline is attributed to a number of environmental 
factors including improved hygiene, increased intake of fresh fruit and vegetables, 
diminished tobacco use, serendipitous H. pylori eradication with antibiotic use and 
decreased dietary intake of salt(153–157). Interestingly, against this background of 
globally diminishing rates of gastric cancer, there appears to be a subpopulation of 
younger people in whom non-cardia, intestinal-type gastric adenocarcinoma is 
increasing in incidence(158–160). This phenomenon has been characterised in 
several European countries and in North America. The mechanism responsible for 
this paradoxical observation is unclear. It has been suggested that the widespread 
use of antisecretory drugs including proton-pump inhibitors and H2-receptor 
antagonists might be partly responsible. Other authors have suggested increased 
 
49 
pathogenicity of H. pylori; either by the introduction of more virulent strains with 
population migration; or by a loss of diversity in the gastric microbiome due to 
antibiotic use and better sanitation which allows H. pylori to expand its niche in the 
absence of competition(161,162). 
 
Perhaps unsurprisingly, gastric cancer predominantly affects older people. Fewer 
than 8% of cases are diagnosed in the under-55 year old age group and the rate rises 
steeply after the age of 60 years(151). The attendant comorbidities of this older 
patient population combined with the propensity of the condition to present later in 
its natural history result in poor survival rates. Despite steady improvement, the UK 
5-year survival rate stands at just 15%(163). 
 
By far the commonest form of gastric malignancy is adenocarcinoma. This accounts 
for approximately 95% of gastric neoplasms with the remainder comprised of 
lymphomas, neuroendocrine and stromal tumours(164,165). Gastric 
adenocarcinoma is most commonly categorised according to the Laurén 
classification. This recognises two histological types: intestinal and diffuse(166). 
Intestinal-type carcinoma is characterised by the presence of gland-like tubular 
structures, resembling intestinal glands, and is found more commonly in men 
(male/female ratio = 2:1) and older patients. It is this type which is more closely 
related to environmental risk factors and which has been seen to decline in 
frequency over the last five decades. In contrast, diffuse-type carcinoma has a near-
uniform frequency across the world(165). This variant is characterised histologically 
by poorly differentiated, non-cohesive tumour cells and is more frequently located in 
the proximal stomach. There is a sub-type: signet-ring cell adenocarcinoma that is 
characterised by rounded cells with abundant intracellular mucin flattening the 
nuclei at the cell periphery. It is thought that the signet-ring cell variant of diffuse-
type gastric cancer is increasing in incidence, accounting in part for the increase in 
incidence of proximal gastric cancer(167). 
 
A second system for categorisation of gastric carcinoma is by topographical site. 
Though traditionally grouped together in registries and clinical trials, proximal gastric 
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(also referred to as cardia or gastro-oesophageal junctional) and distal gastric (also 
referred to as non-cardia) adenocarcinoma exhibit quite distinct clinical and 
molecular features. Adenocarcinomas of the distal stomach i.e. non-cardia cancers 
are primarily caused by infection with H. pylori. Proximal adenocarcinoma i.e. cardia 
cancer is a more heterogeneous disease. A proportion of these tumours exhibit the 
clinical, histological and molecular characteristics of non-cardia adenocarcinoma 
(intestinal or diffuse). The remainder more closely resemble oesophageal carcinoma 
and these are associated with gastro-oesophageal reflux disease (GORD) and 
obesity. Proximal gastric cancer has a more pronounced predisposition in males (5:1) 
and increases in frequency with socioeconomic status(165,168). Recently published 
work has identified the targeted sequencing of cancer-associated genes in cases of 
proximal gastric adenocarcinoma as being a potentially useful method of 
distinguishing between molecular phenotypes and potentially directing targeted 
therapies(168). 
 
1.4.2 Risk factors 
 
1.4.2.1 Genetic predisposition 
 
Polymorphisms associated with increased risk of cancer development in response to 
H. pylori infection have been discussed in section 1.3.8.4. 
 
Inherited susceptibility to the development of gastric cancer is implicated in 1-3% of 
cases and is more often seen in diffuse-type cancers than in the intestinal-type(169). 
The difference in familial aggregation is such that in first-degree relatives of patients 
with diffuse-type cancer, there is a 7-fold increase in risk as compared with a 1.4-fold 
increase for relatives of patients with the intestinal phenotype. Hereditary Diffuse 
Gastric Cancer (HDGC) is a rare syndrome most commonly associated with germline 
mutations in the E-cadherin gene (CDH1) and which predisposes carriers to early-
onset (mean age at diagnosis 40 years) diffuse-type gastric cancer, often of the 
signet-ring subtype(170–172). Recently published consensus guidelines recommend 
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testing for CDH1 germline mutations in high-risk groups which include: a) individuals 
with diffuse-type gastric carcinoma under the age of 40 years; b) those with relevant 
family histories; and c) people with a personal or family history of diffuse-type 
gastric cancer and lobular breast cancer(169). As only 25-30% of families with HDGC 
carry a germline CDH1 mutation, those with normal genetic screening but high-risk 
family histories are advised to undergo annual surveillance gastroscopy. For CDH1 
mutations, the penetrance is considered so high (>80%) that prophylactic 
gastrectomy is advised(169). 
 
Several other genetic disorders are associated with an increased risk of developing of 
gastric adenocarcinoma. Lynch syndrome is one of the major autosomal dominant 
forms of inherited colorectal cancer and is caused by germline mutations in four 
mismatch repair genes. There is an established risk of gastric cancer in carriers of 
these mutations, and particularly in the genes MLH1 or MSH2(173). Peutz-Jehgers 
syndrome is caused by a germline mutation in LKB1 inhibiting its function as a 
tumour suppressor gene. There are a number of reports of affected individuals 
developing gastric cancer at a young age(174,175). 
 
Outside of these specific and uncommon examples, familial clusters of gastric cancer 
may be related to true genetic predisposition or to exposure to common 
environmental factors. In a study of 100 first-degree relatives of patients with 
proven gastric cancer, the prevalence of hypochlorhydria and gastric atrophy was 
increased but only amongst those with H. pylori infection(176). In a German case-
control study, an association between H. pylori and family-history of gastric cancer 
was identified but it was also shown that family-history was an independent risk 
factor for gastric cancer development(177). Furthermore, a meta-analysis of studies 
examining the risk of gastric mucosal preneoplastic lesions in first-degree relatives of 
individuals diagnosed with gastric cancer found a significantly higher prevalence of 






1.4.2.2 Helicobacter pylori 
 
Bacterial factors associated with increased risk of gastric cancer development have 
been discussed in detail in section 1.3. 
 
For gastric adenocarcinoma (as for gastric MALT lymphoma), Helicobacter pylori is 
the leading aetiological factor. Conservative estimates suggest that approximately 
75% of cases are attributable to infection(179,180). Other authors have reported 
much higher rates of H. pylori involvement in gastric cancer development. The 
Eurogast-EPIC study (in a European population) suggested that 93% of cases were 
associated with H. pylori infection(181) and a recent Japanese study reported that 
fewer than 1% of cases were not associated with this bacterium(182). Generally 
speaking, areas of high non-cardia gastric adenocarcinoma prevalence correspond to 
areas of high H. pylori prevalence. There are exceptions to this observation including 
areas of sub-Saharan Africa and South Asia where the high H. pylori infection rates 
are not associated with high gastric cancer incidence rates. This is assumed to be a 
reflection of the complex interactions between host, environmental and bacterial 
factors(183,184). 
 
1.4.2.3 Diet, lifestyle and gastric cancer risk 
 
Epidemiological studies have shown that high dietary intake of salt is thought to 
increase the risk of cancer(185). The exact mechanisms remain unclear though a 
synergistic effect with H. pylori to enhance gastric inflammation perhaps mediated 
through altered epithelial mucous viscosity has been proposed(185). A recent meta-
analysis of prospective studies determined that relative risk of gastric cancer 
increases with the magnitude of dietary salt intake and that this effect seemed to be 
greater in Japanese populations(186). The effect is seen for all histological variants 
and appears to be independent of other variables including H. pylori infection and 




The reverse effect is seen with dietary intake of fresh fruit and vegetables. A meta-
analysis of cohort studies reported an inverse relationship between dietary intake of 
fruit and the incidence of (but not mortality from) gastric adenocarcinoma. The same 
study reported a similar, inverse relationship between vegetable intake and the 
incidence and mortality rates of gastric cancer(188). The World Cancer Research 
Fund systematic review also highlights limited evidence that suggest a protective 
effect from the consumption of legumes and selenium-containing foods whilst chilli, 
processed meat, and smoked/broiled foods may increase the risk of developing 
gastric cancer(189).  
 
The major lifestyle factor implicated in gastric carcinogenesis is tobacco smoking, 
where the evidence for increased risk in unequivocal and dependent on the 
magnitude of tobacco consumption(190). In those with a long or heavy exposure to 
cigarette smoking, it is estimated that the risk of gastric cancer is almost 
doubled(189). No convincing epidemiological association between alcohol intake 
and gastric cancer has been identified(191). Similarly, and although established as a 
risk factor for oesophageal adenocarcinoma, no epidemiological association 
between obesity and non-cardia gastric cancer has been demonstrated(192). 
Interestingly, a recent meta-analysis has demonstrated a possible independent 
augmenting effect of pre-existing diabetes mellitus on the risk of gastric-cancer 
development. The authors report an increase in risk of approximately 19% but did 
not conduct subgroup analyses to examine the effect of obesity in this higher-risk 
cohort(193). 
 
1.4.3 Gastric preneoplasia 
 
As for several other epithelial malignancies, the pathway to developing intestinal-
type gastric cancer has been well described. The multistep model - developed by 
Correa et al. – postulates that there is a sequence of pre-malignant mucosal changes 
culminating in the development of adenocarcinoma(194). The development of 
diffuse-type cancer is less well described and the links between this and the 
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precursor lesions of intestinal-type cancer are unclear. That said, it seems clear that 
both phenotypes share a close link to the index change in the gastric mucosa; that of 
H. pylori associated inflammation(154).  
 
The multistep pathway from H. pylori associated gastritis to gastric adenocarcinoma 
formation (Correa’s multistage cascade of gastric oncogenesis) emerged as a result 
of epidemiological studies performed in the 1970s in Colombia(194). It includes 
sequential stages of mucosal remodelling that precede or coexist with gastric 
adenocarcinoma (Figure 1-7). In this model, chronic inflammation leads to loss of 
gastric glands (chronic atrophic gastritis or gastric atrophy) and/or metaplastic 
transformation of the indigenous glandular structures (intestinal metaplasia). The 
subsequent step in the cascade is ‘de-differentiation’ of the metaplastic epithelium 
and acquisition of neoplastic cellular characteristics (dysplasia or intra-epithelial 
neoplasia (IEN)). Dysplasia leads on to stromal invasion and the development of 
invasive adenocarcinoma. A national cohort study in the Netherlands showed that 
the risk of gastric cancer development increased with each step in severity of the 
cascade. Chronic atrophic gastritis (CAG), intestinal metaplasia (IM), low-grade 
dysplasia and high-grade dysplasia conferred risks of developing gastric 
adenocarcinoma in a subsequent five year follow-up period of 0.1%, 0.25%, 0.6% 
and 6% respectively(195). A recent meta-analysis demonstrated regression of 
atrophy in the gastric corpus of patients following eradication of H. pylori. The same 
study found that gastric antral atrophy and gastric intestinal metaplasia (IM) did not 
improve following H. pylori eradication, suggesting that IM might represent a 
histopathological “point of no return”(196).  
 




1.4.3.1 Chronic atrophic gastritis and gastric intestinal metaplasia 
 
Recently published consensus guidelines on the management of gastric preneoplasia 
adhere to the convention observed for diseases elsewhere in the gastrointestinal 
tract in distinguishing between ‘precancerous conditions’ and ‘precancerous 
lesions’(197). The eminent gastrointestinal pathologist Basil Morson defined the 
former as ‘a clinical state associated with a significantly increased risk of cancer’ and 
contrasted this with the definition of the latter as ‘a histological abnormality in 
which cancer is more likely to occur’(198). CAG and IM are regarded as precancerous 
conditions whereas dysplasia/intraepithelial neoplasia of any grade is regarded as a 
precancerous lesion. 
 
CAG is characterised histologically by a ‘loss of appropriate glands’(199) and an 
accompanying loss of gastric secretory function. ‘Loss of appropriate glands’ 
encompasses two phenotypes of mucosal remodelling. Native glandular units might 
be lost and replaced by fibrous expansion of the lamina propria or glands might be 
replaced by metaplastic variants (i.e. not ‘appropriate’ glands). Hence this definition 
of gastric atrophy can include intestinal metaplasia. The distinction between these 
phenotypes is addressed in histopathological systems of nomenclature discussed 
below.  So-called ‘extensive’ CAG involving the lesser curvature of the gastric corpus 
and fundus and resulting in achlorhydria is the specific variant associated with 
increased cancer risk(195,197,200). 
 
Epithelial metaplasia is defined as a ‘potentially reversible change from one fully 
differentiated cell type to another’(201) and its development implies cellular 
adaptation to environmental stimuli. Considered a step further in severity according 
to the Correa cascade, IM has been shown to confer a substantial risk of gastric 
cancer development which exceeds that of CAG alone(5,202). Metaplastic 
remodelling of the gastric epithelium is an inhomogeneous pathological process and 
several subtypes are recognised (by several systems of classification). Amongst the 
various types, pseudopyloric or spasmolytic polypeptide-expressing metaplasia 
(SPEM) and IM are associated with a higher risk of gastric cancer development with 
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the former considered a precursor for the latter(203). IM itself is subdivided by its 
histological characteristics. Complete IM describes gastric epithelium which exhibits 
the histological features of small intestinal epithelium, with classical enterocytes and 
goblet cells; whereas in incomplete IM, the features resemble those of the colonic 
epithelium. An additional system of nomenclature describes three types of IM with 
differing expression profiles of mucin. Type I IM (complete) expresses only 
sialomucins and type III IM (incomplete) only sulfomucins. Type II IM expresses both 
and is regarded as a mixed or indeterminate type. Several authors have reported 
higher rates of gastric cancer development in type III (or incomplete) IM(178,204) 
and a recent systematic review found that IM subtyping is a potentially important 
predictor of gastric cancer risk(205). IM is said to demonstrate a proclivity for 
developing first at the gastric incisura angularis before subsequent extension along 
the lesser curve to the corpus above and antrum below. The topographical extent of 
IM has been shown to correlate closely to its type i.e. extensive gastric IM comprises 
mostly type III (incomplete) IM and carries a significantly greater risk of 
carcinogenesis(206). For this reason, it has been suggested that topographical 
distribution of IM might serve as a surrogate for histopathological typing in 






There is disparity in nomenclature of dysplasia/intraepithelial neoplasia dependent 
on geographical location and area of observer interest but for the purposes of this 
thesis, we will adhere to the ‘traditional’ (World Health Organisation 2000) 
terminology of low- and high-grade dysplasia. 
 
Dysplasia is regarded as a ‘precancerous lesion’ and was originally defined in terms 
of its histological phenotype(198). Molecular characterisation of gastric dysplastic 
lesions has reinforced the paradigm that such lesions are biologically contiguous 
with invasive cancer and that dysplastic cells derived from epithelia following their 
transformation to IM(207). The recognition of this close similarity between the 
morphological and genotypic characteristics of dysplastic lesions and invasive cancer 
essentially highlights the key distinguishing feature between them as being the 
ability of cancer epithelial cells to invade the stroma. Gastric dysplasia is 
characterised by epithelial atypia reflective of abnormal differentiation, loss of 
original glandular specialism and disorganised mucosal architecture (197,207).  
 
Accurate diagnosis and grading of gastric dysplasia is regarded as important because 
these can be used to determine both the risk of cancer development in the lesion in 
question and the occurrence of metachronous cancer development(197). Reported 
rates of progression to cancer formation vary between 0% and 73%. Such variation 
presumably reflects both the heterogeneity of the disease and the wide variation in 
definitions and assessment of dysplasia(197,207,208). 
 
1.4.4 Diagnosis and staging of gastric mucosal preneoplasia 
 
The approach to the diagnosis and management of gastric preneoplasia is arguably 
dependent on the epidemiological features of the population in question. In some 
high-risk populations such as those seen in East Asian countries, diagnosis is 
frequently made as the result of population screening. In these endemic areas, 
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familiarity with diagnostic modalities and access to the requisite services for 
subsequent treatment and/or surveillance is likely to be well established. These 
measures are likely to be responsible for the high rates of early gastric cancer 
diagnosis and comparatively good survival rates seen in countries such as South 
Korea and Japan, where programmes for population screening for gastric cancer are 
well-established(209–211). 
 
In low-risk populations however, population-based screening is unlikely to be cost-
effective given the comparatively low burden of gastric cancer in these areas. 
Nevertheless, individuals in these populations still stand to benefit from strategies 
aimed at early cancer diagnosis and arguably from the diagnosis of premalignant 
conditions. For example, surveillance programmes for Barrett’s oesophagus are well 
established in Western countries including the United Kingdom and the United 
States of America. Barrett’s oesophagus is an interesting comparison as it also 
represents a condition that predisposes an individual to gastrointestinal epithelial 
adenocarcinoma development via an analogous inflammation-metaplasia-dysplasia-
cancer pathway. Additionally, and as for gastric adenocarcinoma, survival rates for 
invasive adenocarcinoma at this site is very poor. The rates at which Barrett’s 
oesophagus progresses to adenocarcinoma are unclear but two recent population-
based studies conducted in Northern Ireland and Denmark, estimate the annual 
rates to be 0.38% and 0.12% respectively when restricted to those individuals with 
proven intestinal metaplasia(212,213). There are limited data regarding the rate of 
progression of gastric IM to cancer and published estimates vary considerably as a 
result of the wide variability in study design, nomenclature and population 
characteristics. One European study suggested an annual progression rate of 0.18%, 
which would suggest a similar magnitude of risk to that posed by Barrett’s 
oesophagus(195). There would be considerable practical obstacles to introducing a 
surveillance protocol along the lines of Barrett’s oesophagus however. In the first 
instance, securing an initial diagnosis is considerably more problematic (as discussed 
in the following sections). Not only this but the affected mucosal area for 
surveillance is much larger. It may therefore be more practical in these populations 
to consider more targeted screening (perhaps based on the presence of other risk 
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factors). The following sections outline how individual risk stratification might be 




It is widely accepted that conventional white-light video endoscopy is of limited 
benefit in identifying either H. pylori gastritis or gastric preneoplastic 
lesions(197,214,215). 
 
Emerging strategies to improve detection of these lesions (and others including early 
gastric cancer) seem to show promise. High-resolution video endoscopes(216), 
advanced imaging modalities(217–220) and magnification endoscopy with or 
without chromoendoscopy(221–223) result in improved accuracy in some studies 
but all are dependent on operator expertise and there are – as yet – no large 
multicentre studies supporting their widespread use(197). 
 
1.4.4.2 Gastric biopsy sampling and histological assessment 
 
Though gastric preneoplasia is sometimes referred to as a ‘field change’, implying 
involvement of the entire mucosal surface in precancerous remodelling, there is 
good evidence to support the assertion that these lesions are in fact multifocal and 
often patchy in their distribution(224,225). The most widely applied 
histopathological scoring system for gastric mucosal preneoplasia is the updated 
Sydney system(199). This recommends the sampling of five arbitrarily selected 
gastric sites – greater and lesser curve of the antrum, greater and lesser curve of the 
corpus and the angularis incisura. The recently published ‘Management of 
precancerous conditions and lesions in the stomach (MAPS)’ guideline advocates 
adherence to the modified Sydney protocol of two antral and two corpus biopsies 




Though the modified Sydney score remains the best-known and most widely applied 
system for the uniform reporting of gastric preneoplastic lesions, it lacks the ability 
to offer prediction of the risk for gastric cancer development(199). To address this 
shortcoming, a validated scoring system was developed based upon the degree of 
gastric atrophy evident in biopsy specimens taken from the gastric antrum (including 
an angularis incisura sample) and that seen in specimens taken from the 
corpus(Table 1-1). This framework was produced by an international group of expert 
gastroenterologists and pathologists (the Operative Link for Gastritis Assessment 
(OLGA))(226).  
 
Table 1-1 Operative link for gastritis assessment (OLGA) scoring matrix(226). 
Atrophy score: 
0 – no atrophy in biopsy specimens 
1 – atrophy in 1-30% of specimens 
2 – atrophy in 31-60% of specimens 
3 – atrophy in >60%% of specimens 
Corpus biopsy specimens - atrophy score 
2 samples from corpus 
0 1 2 3 
Antrum biopsy 
specimens – atrophy 
score 
 
2 samples from antrum 
1 sample from incisura 
0 Stage 0 Stage I Stage II Stage II 
1 Stage I Stage I Stage II Stage III 
2 Stage II Stage II Stage III Stage IV 
3 Stage III Stage III Stage IV Stage IV 
 
 
Using this system, individuals with gastric atrophy can be categorised as ‘low-risk’ 
(Stages I and II) or ‘high-risk’ (Stages III and IV). The presence or absence of H. pylori 
organisms is included in the standardised report as is the presence of inflammatory 
lesions suggestive of undetectable H. pylori infection. The authors propose the 
surveillance of patients in the ‘high-risk’ category and this has been adopted in the 
previously mentioned MAPS guidelines(197) and validated as being an accurate 
predictor of prognosis of gastric preneoplasia in a 12-year follow-up study(227). 
 
The reporting of gastric atrophy generally is prone to interobserver 
variation(207,228). To ameliorate this effect, Capelle et al. proposed a modified 
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system (operative link for gastric intestinal metaplasia (OLGIM)) based upon the 
presence of IM(229) for which interobserver reporting agreement is significantly 
greater(225,228). The authors proposed that an additional advantage of the OLGIM 
approach was that the number of patients categorised as ‘high-risk’ appeared to be 
lower, potentially reducing the number of individuals for whom surveillance would 
be indicated. In a subsequent prospective study however, although the OLGIM 
system (shown in Table 1-2) did exhibit the highest degree of interobserver 
agreement, a large proportion of individuals with high-risk gastric preneoplasia were 
excluded from the high-risk group suggesting insufficient sensitivity. In the same 
prospective study of 835 patients undergoing upper GI endoscopy the authors 
recommended a combination of OLGA and OLGIM scoring for staging chronic 
gastritis(228).  
 
Table 1-2 Operative link for gastric intestinal metaplasia scoring matrix(229). 
Intestinal metaplasia score: 
0 – no IM in biopsy specimens 
1 – mild IM in specimens 
2 – moderate IM in specimens 
3 – severe IM in specimens 
Corpus biopsy specimens - IM score 
2 samples from corpus 
0 1 2 3 
Antrum biopsy 
specimens – IM score 
 
2 samples from antrum 
1 sample from incisura 
0 Stage 0 Stage I Stage II Stage II 
1 Stage I Stage I Stage II Stage III 
2 Stage II Stage II Stage III Stage IV 
3 Stage III Stage III Stage IV Stage IV 
 
 
1.4.4.3 Noninvasive diagnosis and staging of gastric preneoplasia 
 
Whilst endoscopy, adequate mucosal biopsy and rigorous histological assessment 
represent the best validated means of diagnosing and staging gastric preneoplasia, 
this approach does not meet the requirements of a screening test given its cost and 
inconvenience. For high-risk populations, noninvasive screening methods for the 
detection of gastric cancer are well established and include radiology and serological 
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tests(209,230). Whilst radiological modalities might be useful for detecting gastric 
mucosal abnormalities suggestive of cancer, they are not applicable to the diagnosis 
of gastric preneoplasia. Serological testing methods include serum pepsinogen 
concentrations and electrophoresis; the blood quininium resin test; H. pylori 
serology and serotyping and serum gastrin concentration. 
 
The best-studied noninvasive markers of gastric mucosal preneoplasia are serum 
pepsinogens (PGs). Their usefulness in detecting CAG depends on the difference in 
topographical sites of secretion between PG1 and PG2 (see section 1.1.8). PG1 is 
secreted from oxyntic mucosa and PG2 by pyloric and duodenal mucosa. Gastritis 
leads an increase in serum concentrations of both pepsinogens but more so for PG2 
hence PG1/2 ratio decreases. As CAG develops, loss of the normal oxyntic glands 
leads to a decrease in the concentration of PG1 and a more precipitous decrease in 
PG1/2 ratio is observed. A low serum PG1 concentration, PG1/2 ratio or both 
combined is therefore suggestive of CAG(231,232). The performance of PG1 
concentration and PG1/2 ratio for detecting preneoplasia has been extensively 
investigated and widely varying results have been reported (233). A large, recent 
study in a high-risk population (South Korea) of 2558 individuals attending for 
population-based screening (for gastric cancer) by upper GI endoscopy also had 
serum pepsinogen 1 and 2 concentrations measured(234). The sensitivity and 
specificity of PG1/2 ratio for histologically proven CAG was 63.7% and 60.9% 
respectively (using a cutoff <3.0). Several groups have also examined the effect of 
adding H. pylori serological testing and/or serum gastrin (G17) concentration on the 
ability to detect preneoplasia. ‘Compound’ tests of this sort have been shown to 
improve test sensitivity and specificity in some series(235–237).  
 
H. pylori serology is a useful contributor to the individual assessment of risk of the 
development of gastric cancer. It gives an indication not only of current H. pylori 
infection but also of previous infection and is independent of the gastric population 
of H. pylori bacteria. In patients with CAG, H. pylori infection may have been 
immunologically or medically cleared; or the bacterial population diminished as the 
microbial niche is lost during mucosal remodelling. In these higher-risk scenarios, 
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stool antigen or urea breath test methods may give negative results. H. pylori testing 
alone is recommended in the form of a ‘test-and-treat’ strategy in the Maastricht 
Consensus guidelines(238) for the management of younger patients with dyspepsia. 
This approach has been adopted by various national specialty organisations but 
rejected by some authors who point out the risk of early-onset gastric cancer in high-
risk populations presenting with dyspepsia(239,240). 
 
Serum G17 concentrations are relevant for two reasons: firstly the serum gastrin 
concentration offers an additional indicator for corpus atrophy and hypochlorhydria, 
where the absence of acid releases the negative-feedback ‘brake’ on gastrin 
secretion resulting in hypergastrinaemia. Secondly, low serum gastrin concentrations 
can offer some indication of antral atrophy – itself a preneoplastic ‘condition’.  
 
Several recent studies examining the usefulness of these combined tests – 
sometimes referred to as the ‘serological biopsy’ – for gastric preneoplasia have 
utilised a commercially available diagnostic kit. GastroPanel (Biohit Oyj, Helsinki, 
Finland) comprises serum ELISA kits for the determination of H. pylori IgG antibody 
concentration, serum G17 concentration and PG 1 and 2 concentrations; and their 
subsequent interpretation using a software-based analytical tool. The usefulness of 
this panel of noninvasive biomarkers is yet to be convincingly validated. A series in a 
European population (Spain) comprising 91 patients including 15 with CAG 
concluded that the diagnostic performance of the panel was inadequate for clinical 
use with sensitivity and specificity values of 50% and 80% respectively(241). These 
findings contrast with a larger, earlier series in Italy where the sensitivity and 
specificity of the GastroPanel for CAG in dyspeptic patients was 80% and 96% 
respectively. 
 
1.4.4.4 Surveillance of gastric preneoplasia 
 
Data supporting a specific follow-up regimen for gastric preneoplasia and its cost-
effectiveness are scarce and demonstrative of considerable variation(197). The 
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aforementioned MAPS guideline provides a useful summary of current opinion on 
this subject. 
 
High-grade dysplastic lesions are associated with a high-risk of metasynchronous 
invasive cancer or its early subsequent development(242). As such, they are staged 
and managed in much the same way as invasive cancer. 
 
Low-grade dysplasia carries a lower risk of cancer development (in the region of 7% 
overall)(195,197) and so surveillance is recommended. The MAPS guideline suggests 
surveillance intervals of 12 months or less. 
 
CAG and IM are relatively common and carry a relatively low risk of cancer 
development and so universal surveillance is not recommended. In the subgroup of 
patients with higher-risk preneoplasia (extensive CAG or IM) and/or with a family 
history of gastric cancer, surveillance is advised. Extent of CAG/IM should be 
determined histologically using the OLGA/OLGIM systems and/or serological 
phenotyping as discussed above. The guidelines suggest endoscopic assessment 
every 3 years(197). 
 
1.5 Autoimmune atrophic gastritis 
 
In section 1.4.3.1, I described the classical definition of gastric mucosal atrophy as 
representing a histological state in which there is a ‘loss of appropriate glands’(199). 
In that section, I went on to describe the pathological entity of CAG, which results 
from chronic gastric mucosal inflammation (usually due to infection with H. pylori) 
and consists of loss of native glandular structures, which are replaced either with 
fibrosis or metaplastic glands. 
 
A second, and distinct clinical entity in which chronic inflammation gives rise to 
chronic gastric atrophy is autoimmune atrophic gastritis (AIG). In this condition, 
autoantibody mediated T-cell destruction of parietal cells gradually leads to corpus-
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specific atrophy with glandular metaplasia of varying types(243). The antrum is 
spared except in the relatively uncommon scenario in which chronic H. pylori 
infection has led to concomitant multifocal CAG. 
 
1.5.1 Pernicious anaemia 
 
Pernicious anaemia (PA) is the term given to the clinical syndrome to which AIG 
belongs. It is defined as the presence of anaemia, macrocytosis, low serum 
concentration of vitamin B12, AIG and the presence of autoantibodies to intrinsic 
factor (IF) and/or gastric parietal cells (GPCs). The syndrome arises as a direct result 
of the gastric mucosal insult and the loss of intrinsic-factor secreting parietal cells 
culminates in failure of dietary B12 absorption. The associated symptoms are usually 
attributable to chronic vitamin B12 deficiency. Gastric hypochlorhydria often leads to 
failure of adequate dietary iron absorption and so associated iron deficiency is a 
common finding(244,245). Anti-GPC antibodies are found in 80-90% of cases with 
decreasing frequency as the disease progresses and GPC antigens are lost(246,247). 
These antibodies are commonly found in older individuals and in the context of 
other autoimmune diseases and so are not regarded as specific for PA. Anti-IF 
antibodies on the other hand are regarded as specific for the diagnosis(248). These 




Traditionally considered a disease of older, northern European women, AIG and PA is 
now recognised as having a broadly similar prevalence in all ethnicities and 
geographical locations though there is a female preponderance(243). The complexity 
of the diagnosis and frequency with which the syndrome is thought to go 
undiagnosed would suggest that prevalence figures are underestimated. A recent 





1.5.2.1 Risk of adenocarcinoma 
 
As the metaplastic transformation seen in AIG comprises a similar spectrum of 
histopathological lesions as in CAG (IM and SPEM etc.), it seems reasonable to regard 
AIG as a preneoplastic condition. The risk of gastric adenocarcinoma however 
remains unclear with many small studies reporting conflicting data. A systematic 
review published in 2012 analysed six studies conducted in Europe and concluded 
that the annual risk of adenocarcinoma development was 0.27% with an overall 
relative risk of 6.8(251). There are no reliable data on which to base a strategy for 
endoscopic or non-invasive surveillance. 
1.5.3 Development of type 1 gastric neuroendocrine tumours in autoimmune 
atrophic gastritis 
 
Type 1 gastric neuroendocrine tumours are discussed in detail in section 1.6.3. 
 
 
The risk of developing Type 1 gastric neuroendocrine tumours (NETs, carcinoids) as a 
result of AIG is unclear. Four European series have been published describing the 
incidence of type 1 gastric NETs in cohorts of individuals with established PA or AIG. 
The incidence rates in these cohorts varied from 3.6% to 7% at the first upper GI 
endoscopy. 
 
1.6 Gastric neuroendocrine tumours 
 
Gastric neuroendocrine tumours (NETs, carcinoids) are a heterogeneous group of 
neoplasms exhibiting dramatically varied natural histories and prognoses. They are 
increasing in incidence, presumably as upper GI endoscopy is becoming more 






Three subtypes of gastric NET are widely recognised (Table 1-3)(252) though they are 
also classified according to the 2010 WHO classification of gastrointestinal 
neuroendocrine neoplasms (Table 1-4) which describes tumours by histological 
grade and mitotic and proliferative indices(253). The former classification takes into 
account clinical, biochemical and endoscopic variables and is more helpful in terms 
of prognostication. Although several gastric epithelial neuroendocrine cell types are 
recognised, gastric NETs are usually composed of ECL-cells(254) with G-cell and 
enterochromaffin cell tumours occurring vary rarely(253). 
 
Table 1-3 Characteristics of the three types of gastric NET. AIG=autoimmune atrophic gastritis; PA=pernicious 
anaemia; ZES=Zollinger Ellison syndrome; MEN-1=multiple endocrine neoplasia type 1. Adapted from Burkitt et 
al.(255). 
 Type 1 Type 2 Type 3 Type 4 
Associated pathology AIG and PA ZES and MEN-1 Sporadic Sporadic 
Proportion of gastric 
NETs (from La Rosa et al.(256)) 46% 6% 15% <1% 
Site Corpus/Fundus Corpus/Fundus Any Any 
Typical number Multiple Multiple Single Single 
Typical size of tumours <10mm <10mm 20-50mm >20mm 
Serum gastrin 
concentration Increased Increased Normal Normal 
Gastric acid production Decreased Increased Normal Normal 
Prognosis Very good Good Poor Very poor 





Table 1-4 2010 WHO classification of gastric neuroendocrine neoplasms. NEC=neuroendocrine carcinoma; 
MANEC=mixed adenoneuroendocrine carcinoma. Adapted from La Rosa et al.(254). 
WHO grade Mitoses (per x10 HPF) Ki67 index 
Grade 1 <2 ≤2% 
Grade 2 2-20 3-20% 
NEC >20 >20% 




The incidence of gastric NETs is increasing and they now represent approximately 4% 
of all NETs(257). A recent literature and cancer database review suggested that the 
annual incidence estimates from 10 European countries and the USA vary between 
0.05 to 0.92 per 10,000 population(258). The same review estimated population 
prevalence in Japan of 0.05 per 10,000 people and in the USA of 0.3 per 10,000 
people. 
 
1.6.3 Type 1 gastric neuroendocrine tumours 
 
1.6.3.1 Description and pathophysiology 
 
Type 1 gastric NETs are usually found incidentally and arise on a background of AIG. 
As might be expected given the proclivity of AIG and PA for older females, type 1 
gastric NETs are more commonly seen in older women(259). AIG results in parietal 
cell loss and hypochlorhydria. The negative feedback mechanism responsible for 
regulating gastrin secretion (described in section 1.1.7) - and which is dependent on 
gastric acid secretion - is lost. This results in G-cell hypertrophy and 
hypergastrinaemia, which in-turn leads to ECL-cell hyperstimulation, hypertrophy 
and proliferation. In the majority of AIG patients, micronodular ECL-cell hyperplasia 
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is observed(260). Interestingly, only a small minority of patients with AIG and 
hypergastrinaemia progress to the development of ECL-cell dysplasia and neoplasia. 
It is proposed therefore that hypergastrinaemia alone is insufficient for dysplastic 
transformation of ECL cells and several co-factors have been proposed.  
 
The best characterised of these is the loss of heterozygosity (LOH) in the MEN-1 
gene. This gene encodes menin - a tumour suppressor. The best evidence for its 
contribution to NET formation comes from MEN-1 associated Zollinger-Ellison 
syndrome (ZES) in which an autosomal dominant defect in MEN-1 leads to enhanced 
tumourigenesis. In this condition, gastric NET development is commoner than in the 
sporadic variant. LOH at 11q13-14 in MEN-1 has been reported not only in MEN-1 
associated ZES but in type 1 and type 3 gastric NETs(261). Growth factors 
contributing to dysplastic transformation include: α-human chorionic gonadotrophin 
which is found expressed in ECL-cell dysplasia but not in the ECL-cells of 
normogastrinaemic subjects(262); basic fibroblast growth factor (bFGF) and  




Type 1 gastric NETs rarely metastasise and patients managed by surveillance and 
appropriate lesion resection have been shown to have 100% disease-survival(265). 
Without treatment of hypergastrinaemia however, this is a recurring tumour. 
Median recurrence-free survival is estimated at 24 months and an overall rate of 




There are limited data to guide management but guidelines published in 2012 offer a 
useful framework(265). A general approach of conservative management is 
recommended with regular endoscopic follow-up and lesion resection when 
indicated. Though some authors advise endoscopic resection of visible tumours, 
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there is no evidence that small (≤10mm) tumours exert unfavourable outcomes if 
simply monitored. For larger (>10mm) tumours, endoscopic ultrasound to exclude 
local invasion or nodal involvement is recommended prior to endoscopic or surgical 
resection. In the presence of local invasion or distal spread, it is advised that 
management should proceed along the same lines as for gastric cancer. 
 
For larger tumours, surgical antrectomy (with or without tumour resection) to 
remove the source of hypergastrinaemia has been shown to effectively reduce both 
ECL-cell hyperplasia and gastric carcinoid tumour size and number in a proportion of 
patients(267,268). One drawback to this approach is the difficulty of predicting in 
advance whether or not the tumours in question are still ‘gastrin-dependent’ or if 
they have ‘escaped’ gastrin control and are proliferating independently. A strategy 
to stratify cases accordingly was proposed based upon the use of the octreotide 
suppression test. Our group reported a series of five cases in which the octreotide 
suppression test predicted response to antrectomy. In that series, one of the cases 
did not exhibit tumour regression despite a decrease in the serum gastrin 
concentration after surgery(269). It may be that response to novel gastrin/CCK2R 
antagonists might aid in the prediction of which patients might benefit from 
antrectomy. 
 
Medical treatments for type 1 gastric NETs are still the subject of some debate. Jianu 
et al. reported the use of long-acting release octreotide for the treatment of type 1 
gastric NETs for one year in five patients. Tumour load and ECL density was 
decreased on treatment and the effect was maintained after one year of follow-up. 
After five years of follow-up however, all five patients exhibited disease progression 
and one had developed an invasive cancer. The authors recommended that in 





1.6.4 Type 2 gastric neuroendocrine tumours 
 
Type 2 gastric NETs often complicate the natural history of ZES. In sporadic cases, 
they occur in fewer than 1% of cases whereas in ZES associated with MEN-1, there is 
a 20-30% risk of gastric NET development(270,271). These tumours share clinical and 
histological characteristics with the type 1 variant and are similarly dependent on 
hypergastrinaemia. They are distributed in the proximal stomach and are typically 
small (10-20mm) and multiple. Most cases behave (like type 1 NETs) indolently. One 
review suggested a lymph node involvement rate of 30%(271) and there is a risk of 
malignant transformation with rates of metastatic disease of up to 20% of cases; 
these are usually associated with the pro-tumourigenic MEN-1 variant(272,273). 
 
Treatment of disease confined to the stomach is similar to that described for type 1 
gastric NETs. Larger tumours can be resected endoscopically or surgically and 
multiple tumours have been effectively treated with somatostatin 
analogues(252,274). In suitable patients, localisation and resection of the culprit 
gastrinoma(s) is undertaken. In these cases, dependent gastric NETs are reported to 
have resolved following surgery(275). 
 
1.6.5 Type 3 gastric neuroendocrine tumours 
 
Sporadic type 3 gastric NETs are usually solitary and large (>20mm). They arise in 
non-atrophic gastric mucosa and are not dependent on hypergastrinaemia for 
development. They occur more commonly in males over the age of 50 years. Liver 
and lymphatic metastases are common and their presence correlates to tumour size 
in most cases. Metastatic disease is reported to occur in 50-70% of well-
differentiated tumours and in up to 100% of poorly-differentiated tumours(252). In 
localised disease, the mainstay of treatment is surgical resection after appropriate 




1.7 Netazepide (YF476) 
 
1.7.1 Description and history 
 
As outlined in section 1.5.4, both inhibition of gastrin synthesis (by targeting the 
somatostatin receptor with SSAs) and removal of gastrin producing tissue (by 
antrectomy) have been shown to be effective in treating type I gastric NETs in the 
short-term. The difficulty in administration (by regular, intramuscular injections) of 
SSAs weighed against the relative indolence of the condition diminishes its appeal as 
a long-term management strategy. Similarly, for small and (by implication) benign 
tumours, the risk of surgery would seem to outweigh the benefits for most patients. 
Alternative pharmacological strategies have been investigated including antagonists 
of the gastrin receptor. 
 
Gastrin receptor antagonists (GRA) have been developed and trialled with limited 
success to date. Most have been limited by poor affinity with the CCK2 receptor, 
limited bioavailability, and inactivity when administered enterally. A recently 
developed compound - JNJ-26070109 – has been shown in animal models to have 
good receptor selectiveness and affinity, and high oral bioavailability(276). It inhibits 
gastric acid secretion and prevents PPI-induced rebound hyperacidity in rat 
models(277). This compound has yet to be tested in humans. 
 
YF476 ((R)-1-2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2'-pyridyl)-1H-1, 4-
benzodiazepin-3-yl-3-(3-methylamino-phenyl)urea) was developed in the UK by 
Ferring Pharmaceuticals from a series of benzodiazepine compounds(278) and later 
named ‘netazepide’. It is a highly potent, highly selective competitive antagonist of 
gastrin/CCK2R(279–281).  
 
The drug was shown to inhibit pentagastrin stimulated gastric acid secretion in 
beagles(280). A study in healthy human volunteers taking netazepide twice daily for 
7 or 14 days showed that the drug increased gastric pH in the first 24 hours of 
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administration in keeping with inhibition of gastric acid secretion. For reasons that 
remain unclear, when gastric pH was measured again after 7 days of dosing, the 
effect on pH had been lost despite ongoing elevation of plasma gastrin 
concentration(282). 
 
Evidence for its potential effectiveness as a treatment for type I gastric NETs comes 
from animal models. The Mastomys rodent (Praomys natalensis) exhibits an 
accelerated response of the ECL cell to hypergastrinaemia. In response to the 
administration of H2-receptor antagonists (H2RAs) or PPIs, these animals develop 
ECL-cell tumours after approximately 2 months. In one study, four groups of animals 
were administered YF476 and Loxitidine (an H2RA, to induce hypergastrinaemia) 
alongside controls. The groups were designed to assess whether a) YF476 could 
prevent ECL-cell changes in response to hypergastrinaemia (YF476 & Loxitidine 
coadministered for 16 weeks); b) YF476 could prevent progression from hyperplasia 
to dysplasia or neoplasia both with (Loxitidine alone for 8 weeks followed by 
Loxitidine/YF476 coadministered for 8 weeks) and without (Loxitidine alone for 8 
weeks followed by YF476 alone for 8 weeks) on-going hypergastrinaemia; c) YF476 
could induce regression of ECL-cell neoplasia after a prolonged period of 
hypergastrinaemia (Loxitidine alone for 16 weeks followed by YF476 alone for 8 
weeks). Gastrin and histamine were measured in peripheral plasma whilst gastric 
tissue was subjected to histological assessment and qPCR for ECL cell products (as a 
marker of ECL-cell activity). The outcomes were encouraging: there was a 60% 
reduction in tumour development and decreased ECL-cell activity in the group 
coadministered YF476 and Loxitidine. In animals treated with YF476 after a period of 
hypergastrinaemia, there was a reduction in tumour development compared with 




1.8 Study aims and objectives 
 
1.8.1 Novel biomarkers of gastric preneoplasia following infection with 
Helicobacter pylori 
 
Infection with H. pylori induces chronic gastric mucosal inflammation which can 
progress to gastric carcinogenesis. We designed an observational, cross-sectional 
study to investigate the role of gastric mucosal genes and proteins in the 
development of gastric preneoplasia and in so doing, identify novel biomarkers of 
these conditions.  
 
Having identified one such potential biomarker (MMP-7) we then set out to 
determine the effect on its gastric mucosal expression of varying genotypes of 
genetic polymorphisms in the MMP-7 gene. 
 
1.8.2 A pilot study of the novel gastrin antagonist netazepide (YF476) for the 
treatment of type 1 gastric neuroendocrine tumours 
 
Type 1 gastric NETs arise on a background of AIG and gastric hypochlorhydria as a 
result of hypergastrinaemia. Most behave indolently but some undergo malignant 
transformation, grow rapidly and give rise to metastases. Current treatment is 
conservative in the case of small tumours and surgical antrectomy to remove 
gastrin-secreting G-cells for the treatment of larger tumours. Medical treatment has 
been unsatisfactory to date. Netazepide (YF476) is a novel, potent, bioavailable ad 
orally-active gastrin/CCK2R antagonist.  
 
We designed a phase 2, open-label pilot study to investigate the effectiveness in 8 
patients of netazepide treatment for type 1 gastric NETs by means of endoscopic 




2 Materials and Methods 
 
2.1 Investigating biomarkers for gastric mucosal preneoplasia development 
following chronic Helicobacter pylori infection 
 
The study described here and in chapters 3, 4 and 5 was funded by the National 
Institute for Health Research (NIHR) via the Liverpool Biomedical Research Centre 
(BRC) and sponsored by the Royal Liverpool and Broadgreen University Hospitals 
NHS Trust (R&D No. 3592) and the University of Liverpool. Prior to initiation, local 
ethics committee (Liverpool (Adult) Research Ethics Committee REC:08/H1005/37) 
approval was obtained. Patients were recruited and samples processed by Dr. S. 
Murugesan (SM, Department of Gastroenterology, University of Liverpool, Liverpool, 
UK) (patient code numbers BRC1 – BRC1017) and Dr. A. R. Moore (ARM, author) 
(patient code numbers BRC1018 – BRC1400). SM performed serum gastrin 
radioimmunoassay (RIA) for all 1017 patients enrolled by him as well as the serum 
CagA enzyme-linked immunosorbent assay (ELISA) for those patients from the same 
cohort found to be H. pylori positive. ARM performed the same assays for the 
remaining patients as well as MMP-7, pepsinogen 1 and pepsinogen 2 ELISA for 
selected patients from the entire study cohort. Ms. L. Rainbow (LR) and Dr. I. A. 
Steele (IAS) (Department of Cellular and Molecular Physiology, University of 
Liverpool, Liverpool, UK) performed gastric tissue processing, mRNA extraction and 
reverse transcription and subsequent qPCR assay for candidate biomarkers. 
 
Case report forms (CRFs) (appendix C) were used to record patient details and were 
securely stored at the Royal Liverpool University Hospital (RLUH) and will be 
destroyed 15 years after study completion. A materials transfer agreement was 
implemented to enable the transfer of biopsy and blood specimens to the 
Department of Cellular and Molecular Physiology, University of Liverpool to be used 




Study recruitment tool place between May 2008 and July 2011. Participants were 
recruited at the Department of Gastroenterology, RLUH before undergoing elective 
outpatient upper GI endoscopy. A patient information leaflet (PIL) explaining the 
study rationale and procedure was provided either by post in advance of the hospital 
attendance or in person upon arrival at the endoscopy unit (appendix B). All 
participants were given sufficient time to read the PIL, discuss the study and ask 
questions before agreeing to proceed. All included participants were aged 18 years 
or older, capable of giving informed written consent and had a clinical indication for 
upper GI endoscopy. The principle exclusion criteria were: haemodynamic instability 
or active bleeding at endoscopy; moribund or established terminal malignancy; 
hepatic cirrhosis; bleeding diathesis or current anticoagulation; pregnancy; HIV, 
hepatitis B or hepatitis C infection or other contraindication to endoscopy. 
 
Patients recruited were referred either by their primary-care general practitioner 
(GP) or by another clinical service at the same hospital. In the case of GP referrals, 
these were subdivided into two groups: “2-week rule” referrals were reserved for 
those cases in which the referring clinician suspected an upper GI malignancy. The 
remainder were “routine” referrals of patients with upper GI symptoms. For each 
patient, a researcher completed a case record form (CRF). The patients identifying 
details (name, date of birth and hospital number) were recorded on both the CRF 
and in a subject enrolments log. All other records were anonymised. The CRFs and 
subject enrolments log were kept securely on hospital premises and accessed only 
by members of the research team. For each patient, a CRF was completed prior to 
endoscopy. This included demographic data, height and weight measurement and 
past medical & social history data {appendix C}. CRF data was subsequently 
transferred to an encrypted Microsoft Excel spreadsheet with only the study patient 
code number attached to each subject record. The results of the various analyses 
and assays described in this section were later added to the same spreadsheet along 




2.2 Collection of biological samples 
 
Patients were fasted for at least 12 hours prior to endoscopy. Enrolled subjects 
underwent routine upper GI gastroscopy using Olympus Evis Lucera H240/H260 
endoscopes (Olympus, Southend-on-Sea, UK) including pinch biopsy (Single-Use 
Radial Jaw 4 - Boston Scientific, Hemel Hempstead, UK) of gastric mucosa. Biopsies 
were obtained from the antrum and corpus (4 per site) for histopathological 
assessment and from the corpus (8 biopsies) for subsequent determination of real-
time polymerase-chain reaction (PCR) abundance of putative biomarkers.  Prior to 
the procedure, we drew 20mL of peripheral venous blood from each subject by 
simple venepuncture or via the intravenous cannula inserted for the purpose of 
sedation-drug administration. In the case of patients unable to tolerate endoscopy 
sufficiently to enable the collection of mucosal biopsies, blood samples were 
retained and analysed as described below though the resulting data was excluded 
from the final analyses. When recruited patients subsequently withdrew consent for 
participation in the study, any biological samples were discarded. 
 
2.2.1 Histopathology specimens 
 
Specimens for histology were first fixed and stored in 10% neutral-buffered formalin 
and then embedded in paraffin for slide preparation and staining with haematoxylin 
and eosin. Slides were prepared and reported on by the hospital histopathology 
service in the first instance. We subsequently cut additional slides from the paraffin 
blocks for submission to the study pathologist. A single, expert gastrointestinal (GI) 
pathologist (Dr. Laszlo Tiszlavicz, Department of Pathology, University of Szeged, 
Szeged, Hungary) examined all study specimens and prepared standardised reports 
(appendix A) incorporating descriptive diagnoses and scores for the modified Sydney 






2.2.2 Helicobacter pylori rapid urease testing 
 
One mucosal biopsy each from the antrum and corpus was used to detect the 
presence of H. pylori by means of a rapid urease test (RUT) (Pronto Dry, MIC, 
Brignais, France). The RUT slides were read an hour after sample collection and the 
results recorded in the CRF. 
 
2.2.3 Mucosal biomarker analysis specimens 
 
In addition, eight biopsies were taken for RNA analysis from the gastric corpus and 
stored in RNAlater (Ambion, Austin, TX, USA). These were stored at -20°C prior to 
RNA extraction in batches (described in section 2.5.1). 
 
2.2.4 Venous blood samples 
 
20mL of peripheral venous blood was drawn as described above (section 2.2). 4.5mL 
was immediately decanted into EDTA tubes (BD Vacutainer – BD, Oxford, UK), 
transported on ice and stored at -20°C for subsequent genomic DNA extraction 
(described in section 2.3). 1mL was ‘spotted’ onto protein saver cards (Whatman 903 
protein saver card – Sigma-Aldrich, Gillingham, UK) and stored at room temperature. 
4.5mL was sent in serum gel tubes (S-Monovette – Sarstedt Ltd., Leicester, UK) to the 
microbiology laboratory at the host hospital for anti-H. pylori IgG ELISA (Biokit, 
Barcelona, Spain). The remaining 10mL was transported on ice in serum gel tubes 
and separated by centrifugation (7 minutes, 4°C, 800G). Three aliquots of the serum 
were stored at -20°C. 
 
2.3 Genomic DNA extraction 
 
Genomic DNA was separated and extracted using a magnetic bead separation 
technique (chemagic Magnetic Separation Module I (MSM-I) with chemagic DNA 
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Blood Kit (CMG-703-1), PerkinElmer chemagen Technologie GmbH, Baesweiler 
Germany). This technique uses proprietary polyvinyl-alcohol magnetic beads whose 
surface is prepared to bind nucleic acids. The MSM-I machine uses electromagnetism 
and mechanical agitation to bind DNA from whole blood and separate it via a series 
of buffers and solvents. Our 4.5mL samples of whole blood were processed in 
batches of 12 and the resulting 500μL aliquots of genomic DNA in elution buffer 
stored at 4°C. DNA concentration was determined using spectrophotometry. Prior to 
SNP genotyping, samples of standardised concentration (20ng/μL) were prepared. 
These were also stored at -20°C. 
 
2.4 Serum sample analyses 
 
2.4.1 Serum gastrin radioimmunoassay 
 
Previously stored serum was used in radioimmunoassay (RIA) to determine the 
fasting serum gastrin concentration for each patient. RIA depends on competition 
for binding of radiolabelled gastrin with endogenous gastrin in the sample with a 
known concentration of gastrin antibody. Samples were assayed in duplicate and in 
batches. For study subjects with the study identification numbers BRC1017 to 
BRC1400, the samples were analysed in nine separate assays. These were performed 
by ARM and each included a serum sample taken from a stock provided by a non-
patient volunteer and which acted as an interassay control. 
 
Sodium barbitone buffer was prepared afresh prior to each assay from sodium azide 
(0.5g) and sodium barbitone (4.12g) dissolved in dH2O and the pH adjusted to 8.4 
before the addition of bovine serum albumin (1mL, Sigma-Aldrich, Gillingham, UK). 
Standards were prepared in concentrations of 1pM, 0.1pM and 0.01pM of synthetic 
human gastrin (synthetic human unsulphated heptadecapeptide gastrin (G17), 
Bachem, Bubendorf, Switzerland) and by serial dilution in sodium barbitone buffer. 
Labelled G17 ([125I]G17, PerkinElmer, Massachusetts, USA) was diluted to a 
standard radiation activity level (20000 com/mL). Charcoal suspension was prepared 
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by adding 10g of activated charcoal to 100mL dH2O and later adding dextran (0.5g, 
D-4751, Sigma-Aldrich, Gillingham, UK) and skimmed fat-free milk powder (0.5g, 
Marvel International Food Logistics Ltd., London, UK) in solution with dH2O. 
Standards and samples were added to the assay tubes with sodium azide buffer, 
label and L2 antigastrin antibody to a volume of 1mL; mixed and incubated at 4°C for 
2 days. Samples were added to each assay tube at a volume of 50μL with 100μL each 
of label and L2 antigastrin antibody and 750μL of buffer up to a total volume of 1mL. 
The three standards were added in different volumes (to generate standards of 10 
different concentrations) and the volume of buffer added varied to ensure that the 
total volume amounted to 1mL.  
 
The assay was then ‘separated’ – 100μL charcoal was added to each tube before 
they were centrifuged (3000rpm, 10 minutes, 4°C). The resulting supernatant 
(containing the antibody-bound label) was poured into a separate tube, leaving the 
charcoal pellet (containing the unbound label). The radioactivity in each was 
measured to give the bound/free label ratio. The sample ratios were corrected for 
non-specific binding (calculated from the non-sample control tubes) and a standard 
curve plotted from the standards. Sample bound/free ratios were plotted against the 
standard curve (line of best fit, manually) to give the serum gastrin concentration. An 
example standard curve is shown in Figure 2-1. ‘High’ results, lying outside the linear 
portion of the standard curve were diluted and reanalysed in subsequent assays. 





Figure 2-1 Standard curve from radioimmunoassay for subjects BRC1262-1346 inclusive 
 
The mean serum gastrin concentration in the interassay control was 74.7pM (SEM 
2.7, SD 8.2) with a coefficient of variation of 11.0%. 
 
2.4.2 Serum CagA IgG enzyme-linked immunosorbent assay (ELISA) 
 
CagA status of H. pylori was determined for all subjects with a ‘positive’ test result 
(histology, serology or gastric biopsy urease testing). We used a commercially 
available solid-phase sandwich-type ELISA kit (CagA IgG ELISA kit (GD33) Genesis 
Diagnostics Ltd, Littleport, UK) and conducted the assay according to the 
manufacturer’s instructions. The kit comprises 96-well plates each well of which is 
coated with fixed, recombinant CagA protein. Standards of known concentrations of 
recombinant anti-CagA IgG were provided for inclusion in each assay and for the 
purposes of producing a standard curve. 
 
Patient samples were diluted in the provided diluent to 1:200, and 100μL of diluted 
samples, standards or controls added to assay wells in duplicate. These were 
incubated at room temperature for 30 minutes before thorough washing with the 
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provided wash solution. 100μL of leporine anti-human CagA IgG antibodies 
conjugated to horseradish peroxidase (HRP) – the conjugate – was then added to 
each well and incubated for a further 30 minutes before repeated washing. In the 
final step, 100μL of tetramethylbenzidine (TMB) substrate was added and the plate 
incubated for 10 minutes. The reaction was terminated using provided sulphuric acid 
and the resulting colour change quantified by optical densitometry using a 
microplate reader (Tecan GENios Plus with XFLUOR4 software v4.51 – Tecan UK Ltd., 
Reading, UK) at an absorption wavelength of 450nm. Results were corrected against 
the blank absorbance value and plotted against the standard curve (line of best fit 
using GraphPad Prism v5.0a statistical software). Each sample was then categorised 
as being CagA positive (>7 U/mL), negative (<5.5 U/mL) or indeterminate. An 
example standard curve is shown in Figure 2-2. Samples yielding indeterminate 
results were reassayed. If found to be indeterminate a second time, they were 
grouped with negative samples for the purposes of data analysis.  
 
 
Figure 2-2 Standard curve from CagA ELISA for H. pylori positive subjects BRC1303-1387 inclusive 
 
Each assay included positive and negative control samples and the former was used 
as an interassay control. There were a total of 13 assays performed including 584 
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samples from study subjects. The mean CagA IgG concentration was 33.3u/mL (SEM 
0.95u/mL, SD 3.41u/mL). The coefficient of variation was 10.3%. 
 
2.4.3 Serum MMP-7 enzyme-linked immunosorbent assay (ELISA) 
 
We used another commercially available solid-phase sandwich-type ELISA kit 
(Human Total MMP-7 Quantikine ELISA Kit (DMP700) R&D systems, Abingdon, 
United Kingdom) and conducted the assay according to the manufacturer’s 
instructions. 
 
In this kit, recombinant MMP-7 was provided for reconstitution in dH2O to give a 
solution of known concentration (100ng/mL). This was serially diluted to generate 
the standards required for production of a standard curve. These were added to the 
plate in the same way as the study serum samples. 
 
Serum samples were diluted in the provided ‘calibrator diluent’ (100μL sample, 
100μL diluent) and 50μL of the resulting solution added to the plate in duplicate 
along with 100μL of the provided ‘assay diluent’. The assay plate was then incubated 
at room temperature for 2 hours on an orbital shaker (500rpm) before thorough 
washing with the provided wash buffer. 200μL of MMP-7 conjugate was added to 
each well and incubated for another 2 hours as before. After repeated washing, 
200μL of the ‘substrate solution’ was added to each well and the plate incubated in 
the dark at room temperature for 30 minutes after which the reaction was 
terminated by the addition of the provided ‘stop solution’. The resulting colour 
change was quantified by optical densitometry using a microplate reader (Tecan 
GENios Plus with XFLUOR4 software v4.51 – Tecan UK Ltd., Reading, UK) at an 
absorption wavelength of 450nm and using a reference wavelength of 620nm. 
Results were corrected against the blank absorbance value and plotted against the 





Figure 2-3 Standard curve from serum MMP-7 ELISA for selected subjects (assay number 1) 
 
We performed 25 assays and included samples from 606 study subjects as well as 
samples from the subjects of other trials (including the netazepide trial whose 
results are reported in chapter 6). A serum sample taken from a stock provided by a 
non-patient volunteer was included in each assay and acted as an interassay control. 
The mean concentration in these controls was 1.90ng/mL (SEM 0.04ng/mL, SD 0.21). 
The coefficient of variation was 11.1%. 
 
2.4.4 Serum Pepsinogen 1 enzyme-linked immunosorbent assay (ELISA) 
 
We used another commercially available sandwich-type, solid-state ELISA kits 
(Pepsinogen I ELISA Kit (601010) - Biohit Healthcare Ltd. Ellesmere Port, United 
Kingdom) and conducted the assay according to the manufacturer’s instructions. 
 
Solutions of known concentrations of pepsinogen 2 (PG2) were provided to enable 
the production of a standard curve. Study subject serum samples were diluted 1 to 5 
in the provided diluent buffer (100μL serum and 400μL buffer). 100 μL of the sample 
solutions and standards was added in duplicate to relevant wells, covered and the 
plate incubated for 1 hour at room temperature. After this, the wells were washed 
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thoroughly with the provided ‘washing buffer’ and 100 μL of the ‘conjugate solution’ 
added to each for incubation at room temperature for another hour. After repeated 
washing, 100 μL of the ‘substrate solution’ was added to each well and the plate 
incubated for a further 30 minutes in the dark at room temperature. The reaction 
was then terminated by the addition to each well of the provided ‘stop solution’. The 
resulting colour change was quantified by optical densitometry using a microplate 
reader (Tecan GENios Plus with XFLUOR4 software v4.51 – Tecan UK Ltd., Reading, 
UK) at an absorption wavelength of 450nm. Results corrected for blank absorbance 
were plotted against the standard curve (line of best fit using GraphPad Prism v5.0a 
statistical software). An example standard curve is shown in Figure 2-4. 
 
 
Figure 2-4 Standard curve from serum pepsinogen 1 ELISA for selected subjects (assay number 1) 
 
We completed 10 assays and included samples from 397 study subjects. Each kit 
included a control sample of known concentration and which acted as an interassay 
control. The mean concentration of PG1 was 35.3μg/l (SEM = 0.47μg/l, SD = 




2.4.5 Serum Pepsinogen 2 enzyme-linked immunosorbent assay (ELISA) 
 
We used a commercially available sandwich-type, solid-state ELISA kits (Pepsinogen 
2 ELISA Kit (601020) - Biohit Healthcare Ltd. Ellesmere Port, United Kingdom) and 
conducted the assay according to the manufacturer’s instructions. 
 
Solutions of known concentrations of pepsinogen 2 (PG1) were provided to enable 
the production of a standard curve. Study subject serum samples were diluted 1 to 
10 in the provided diluent buffer (50μL serum and 450μL buffer). 100 μL of the 
sample solutions and standards was added in duplicate to relevant wells, covered 
and the plate incubated for 1 hour at 37°C. After this, the wells were washed 
thoroughly with the provided ‘washing buffer’ and 100 μL of the ‘conjugate solution’ 
added to each for incubation at 37°C for 30 minutes. After repeated washing, 100 μL 
of the ‘substrate solution’ was added to each well and the plate incubated for a 
further 30 minutes in the dark at room temperature. The reaction was then 
terminated by the addition to each well of the provided ‘stop solution’. The resulting 
colour change was quantified by optical densitometry using a microplate reader 
(Tecan GENios Plus with XFLUOR4 software v4.51 – Tecan UK Ltd., Reading, UK) at an 
absorption wavelength of 450nm. Results corrected for blank absorbance were 
plotted against the standard curve (line of best fit using GraphPad Prism v5.0a 




Figure 2-5 Standard curve from serum pepsinogen 2 ELISA for selected subjects (assay number 1) 
 
We completed 10 assays and included samples from 397 study subjects. Each kit 
included a control sample of known concentration and which acted as an interassay 
control. The mean concentration of PG1 was 33.5μg/l (SEM = 0.12μg/l, SD = 
0.37micg/l). The coefficient of variation was 1.1%. 
 
2.5 Gastric mucosal biopsy sample RNA extraction and reverse transcription 
 
2.5.1 RNA extraction 
 
Gastric mucosal biopsy samples taken at endoscopy were stored in RNAlater as 
described in section 2.2.3. Prior to RNA extraction, samples were thawed and 
separated from RNAlater by blotting. We used an adaptation of the TRI Reagent 
Protocol(286). Samples were homogenised in Tri reagent (Sigma-Aldrich, Gillingham, 
UK) until no visible tissue particles remained. The resulting suspension was allowed 
to settle at room temperature for 5 minutes before 0.2mL chloroform was added 
and the samples shaken. The sample was allowed to settle for a further 5 minutes 
before centrifugation (5 minutes, 12000G, 4°C). The clear, aqueous phase of the 
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resulting separated suspension was transferred to a plastic tube and 0.5mL of 
isopropanol added. After standing for 5 minutes at room temperature, this solution 
was centrifuged (10 minutes, 12000G, 4°C) and the supernatant discarded to leave a 
‘pellet’ of precipitated RNA. This was ‘washed’: first with 1mL 75% ethanol (-20°C) 
and centrifuged (5 minutes, 12000G, 4°C); then with 0.5mL 100% ethanol (-20°C). 
The ethanol was then poured off and the pellet allowed to air dry for 15 minutes. 
The RNA pellet was then dissolved in 50μL diethylpyrocarbonate (DEPC)-treated 
(DEPC) water (Sigma-Aldrich, Gillingham, UK). RNA concentration in the resulting 
solution was determined by spectrophotometry. Sufficient solution was immediately 
drawn for reverse transcription (section 2.5.2) and the remainder stored under 
ethanol in 2 aliquots. 
 
2.5.2 Reverse transcription of extracted RNA 
 
For reverse transcription, sufficient RNA solution to provide 2μg of RNA was added 
to a plastic tube. We added Oligo(dT) primer (Oligo(dT) primer 15 – Promega, 
Southampton, UK) and DEPC-treated water to a total volume of 39μL. The solution 
was briefly centrifuged to collect all liquid at the bottom of the tube and then 
incubated in a heating block for 5 minutes at 70°C after which the sample was 
allowed to cool in the block to 40°C to achieve RNA and primer annealing. 
 
The cooled tube was then removed from the block and we added reaction buffer 
(12μL, 5X AMV buffer - Promega); deoxynucleotide solution set (5μL, 100mM DNTP 
set - Sigma-Aldrich, Gillingham, UK); ribonuclease inhibitor solution (1μL, RNAsin 
recombinant ribonuclease inhibitor - Promega); and reverse transcriptase solution 
(3μL, AMV reverse transcriptase – Promega). The solution was briefly centrifuged to 
collect all liquid at the bottom of the tube and then incubated in a heating block for 
1 hour at 42°C. The reaction was terminated by briefly heating the reaction tube to 
80°C in the heating block before cooling on ice. The resulting cDNA solution was then 
divided into 13 aliquots of 4.3μL and stored at -20°C. For this study, LR and IAS 
performed all RNA extraction and reverse transcription. 
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2.6 Quantitative (real-time) polymerase chain reaction for gastric mucosal gene 
products 
 
We used quantitative (real-time) polymerase chain reactions (qPCR) to determine 
the abundance of putative biomarkers of gastric mucosal neoplasia. For this study, 
LR and IAS performed all qPCR assays using the Applied Biosystems 7500 real time 
PCR system (with 7500 System SDS software v1.4) using TaqMan chemistry double 
dye (5’-FAM, 3’TAMRA) probes. 
 
2.6.1 Assay design 
 
Primers and probes were selected using DNASTAR PrimerSelect software (DNASTAR 
Inc., Wisconsin, USA) and are shown in Table 2-1. Standards were produced by first 
amplifying the gene of interest by PCR before ligating this into pGEM-T Easy vector 
plasmid (Promega). Following restriction enzyme digestion and clone selection, 
Escherichia coli (E. coli DH5α, Invitrogen, Paisley, UK) were transformed to 
incorporate the plasmid. Plasmid-inclusive colonies were selected (by pGEM-T Easy 
blue/white selection), cultured and harvested. Resulting plasmid products were 
sequenced to confirm the presence of the genes of interest and were diluted to 
create standards of 6 known concentrations (100pg/μL, 10pg/μL, 1pg/μL, 0.1pg/μL, 
0.01pg/μL and 0.001pg/μL). qPCR was used to optimise the concentrations of probes 
and of forward and reverse primers. Assay design, standard production and PCR 
optimisation was performed by IAS.
Table 2-1 Primer and probe sets employed in qPCR for determination of relative abundance of mucosal gene products.  
Gene Probe Forward primer Reverse primer 
GAPDH CGTCGCCAGCCGAGCCACA GCTCCTCCTGTTCGACAGTCA ACCTTCCCCATGGTGTCTGA 
IGF-1 ACATGCCCAAGACCCAGAAGGAAGTACA TGTATTGCGCACCCCTCAA ACTCCCTCTACTTGCGTTCTTCA 
IGF-2 CCCAGATACCCCGTGGGCAAGTTC CCGTGCTTCCGGACAACTT GGACTGCTTCCAGGTGTCATATT 
MMP-1 TTGCAGCTCATGAACTCGGCCATTC CCAACAATTTCAGAGAGTACAACTTACAT TGAAGGTGTAGCTAGGGTACATCAAA 
MMP-3 TTGCTGCTCATGAAATTGGCCACTCC ACAAAGGATACAACAGGGACCAA  TAGAGTGGGTACATCAAAGCTTCAGT 
MMP-7 CCTGTATGCTGCAACTCATGAACTTGGC GGATGGTAGCAGTCTAGG GATTAACT GGAATGTCCCATACCCAAAGAA 
PAI-1 AGTTCAACTATACTGAGTTCACCACGCCCG TGCCCATGATGGCTCAGA GCAGTTCCAGGATGTCGTAGTAATG 
PAI-2 CCAATGCAGTTACCCCCATGACTCCA GGCCAAGGTGCTTCAGTTTAAT TGAACCCACAGCTGGTAAAGTTC 
TIMP-1 CCAGAACCGCAGTGAAGAGTT GACGGCCTTCT CAATTCC GGTATAAGGTGGTCTGGTTGACTTC 
TIMP-3 CCGACATCGTGATCCGGGCC CCAGGACGCCTTCTGCAA CCCCTCCTTTACCAGCTTCTTC 
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2.6.2 Real-time qPCR conditions 
 
All reactions were performed using the Applied Biosystems 7500 and TaqMan 
chemistry double dye probes as described above. We used Precision 2x qPCR 
MasterMix (Primerdesign Ltd., Southampton, UK) and total reaction volumes per 
well of 25μL. Reactions were conducted in 96-well plates with adhesive covers 
(MicroAmp Optical 96-well reaction plate and MicroAmp Optical Adhesive Film – 
Applied Biosystems). Each plate included non-template controls (NTCs), standards 
(for both the selected housekeeper gene, glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) and for the gene of interest) and study subject cDNA 
samples (for quantification of both housekeeper gene and gene of interest 
abundance) in triplicate. The thermal cycling conditions used are shown in Table 2-2. 
 
Table 2-2 Thermal cycling conditions for qPCR assays. 
Stage Cycles Temperature (°C) Time (mins:secs) 
1 1 50 02:00 




3 (ii) 60 01:00 
 
2.6.3 qPCR assay analysis 
  
We used the ‘standard curve’ data analysis protocol from the Applied Biosystems 
SDS v1.4 software to control, monitor and harvest results from the qPCR assays. The 
software generates a standard curve from the wells designated as containing a 
standard of known concentration plotted as threshold cycle (CT) against 
concentration. An example standard curve is shown in Figure 2-6. The standard 
curve was used to determine the DNA concentration both of the housekeeper gene 
and the gene of interest in the reaction samples. From these values, a ratio of the 





Figure 2-6 Standard curve from qPCR for GAPDH. 
 
2.7 Determining the effect of MMP-7 gene SNP polymorphisms on the 
development of gastric mucosal preneoplasia 
 
2.7.1 SNP selection 
 
The present study was designed and funded to include genotyping for between five 
and ten individual SNPs. As our resources were therefore limited, we attempted to 
identify SNPs that were a) previously described in the literature as being associated 
with epithelial disease in humans or b) predicted to be ‘functional’ and c) useful as 
‘tagger’ polymorphisms. SNP selection was performed by referring to several 




2.7.1.1 Literature search 
 
We searched the NCBI PubMed database (http://www.ncbi.nlm.nih.gov/pubmed, 
accessed November 2011) for reports of clinically relevant SNPs in the MMP-7 gene. 
Our principal search combined the following terms (with various suffixes shown in 
parentheses): “matrix metalloproteinase (7, -7)”; “matrix metallopeptidase (7, -7)”; 
“MMP (7, -7)” and “matrilysin” with: “polymorphism”; “variant’ and “SNP”. We also 
searched for reports of polymorphisms in the genes of other MMPs and TIMPs. We 
made note of the organ and disease associated with each reported polymorphism. 
 
2.7.1.2 SNP database search 
 
We interrogated the NCBI SNP database 
(http://www.ncbi.nlm.nih.gov/projects/SNP/, accessed November 2011) for listed 
SNPs in the MMP-7 gene. Geneview was utilised to identify SNPs in the MMP-7 gene 
with both a) predicted ‘functionality’ i.e. those expected to alter the expression or 
structure of the MMP-7 protein and b) a minor allele frequency of greater than 0.05 
in the reference European population. The results were saved for further analysis in 
Haploview. 
 
2.7.1.3 SNP characteristics 
 
Finally, we used Haploview haplotype analysis software(287) to further characterise 
our list of candidate SNPs. We examined the SNP linkage disequilibrium map and 
identified ‘tagging’. In identifying these SNPs, the presence of other polymorphisms 




2.7.2 SNP genotype assays 
 
Genomic DNA was extracted and diluted to an assay concentration of 20ng/μL as 
described in 2.3. We used generic 96-well plates in which to store a supply of the 
working solution of DNA for use in the series of SNP genotyping assays. These were 
laid out in such a way that each was identifiable by its pattern of blank wells. We 
included 10% random repeats to act as intra-assay controls. Prior to each assay, we 
prepared a generic 384-well PCR plate by pipetting 1μL of the working DNA solution 
from its 96-well storage plate. This method allowed us to combine samples and 
controls from four 96-well plates on one 384-well reaction plate. After pipetting the 
controls and samples, the solution was allowed to dry at room temperature for 12-
24 hours, covered with lint-free tissue paper. Immediately before the assay was 
performed, we prepared an assay mix allowing for a reaction volume 5μL per well 
and comprising 2.5 μL TaqMan PCR master mix (Life Technologies Ltd.); 0.25μL 20x 
genotype assay mix (Life Technologies Ltd.) and 2.25μL micro-filtered dH2O. The SNP 
genotype assay details are shown in Table 2-3. This was added to the wells and the 
plate sealed with optical adhesive covers (MicroAmp). The plate was read in an 
Applied Biosystems 7900 Fast real-time PCR system and with the supplied SDS 
software v2.2 before PCR. The thermal cycling conditions were identical to those 
described in Table 2-2. The plate was kept cool before repeat reading by the same 
software. The TaqMan allelic discrimination assays contain primer and probe sets to 
detect the SNP target of interest; and two distinct, allele-specific fluorescent dyes. 
The PCR system is able to detect the presence of one or both of these dyes in each 
well and so determine the SNP genotype of the sample in question. An example of 
these results is illustrated graphically in Figure 2.7. 
Table 2-3 SNP genotyping assay context sequences. 
SNP rs number Celera ID Context sequence 
rs11568818 hCV27852953 ATTGGCAGGAAGCACACAATGTATT[C/T]GTCTTTCAAAGGATTTTTTTTTCTG 
rs17352054 hCV34384229 GGTATCCTTAGTCAGAGTTTGACAT[A/G]TGATAAGGTGCACCATAAATATTTG 
rs12285347 hCV32018626 AAAATGGCTTTTTATAGTCCTTTAA[C/T]GTGTGATGCAGAGCTGGTTATCTTC 
rs11225297 hCV32018616 AAGTCTTATGGACTTCTATAAATAC[A/T]TAGTACCCTGGCTTTGGAATACAGA 
rs11225307 hCV32018630 AAGTCTTATGGACTTCTATAAATAC[A/T]TAGTACCCTGGCTTTGGAATACAGA 
rs17098318 hCV34384238 GGTATCCTTAGTCAGAGTTTGACAT[A/G]TGATAAGGTGCACCATAAATATTTG 
rs10502001 hCV3210838 GGGCTTCTGCATTATTTCTATGACG[C/T]GGGAGTTTAACATTCCAGTTATAGG 
rs10750646 hCV3210839 TAAATGTTTTGGGGAGAATTACACT[A/G]TACACTTTATAAAGCCTAGAAGTGT 











2.8 Investigating the use of netazepide (YF476) for the treatment of type 1 
gastric neuroendocrine tumours 
 
The study described here and in chapter 6 was funded by Trio Medicines Ltd. 
(London, UK). ARM conducted patient recruitment, study visits and sample 
collection. The study was conducted in accordance with the ICH guidelines for Good 
Clinical Practice and the Helsinki Declaration of human studies. Approval was 
obtained from Cambridge East Research Ethics Committee and the Medicines and 
Healthcare Regulatory Authority (MHRA). All patients gave written informed consent 
prior to enrolment. The trial was registered at ClinicalTrials.gov, identifier 
NCT01339169, European Union Drug Regulating Authorities Clinical Trials (EudraCT) 
number 2007-002916-24. 
 
2.8.1 Subject enrolment 
 
Patients were recruited from a single centre (the professorial neuroendocrine 
gastroenterology clinic at the Royal Liverpool University Hospital, Liverpool, UK). 
They were considered eligible for inclusion if they had previously been diagnosed 
with histopathologically confirmed type I gastric NETs and chronic atrophic gastritis. 
Exclusion criteria included previous gastric surgery; treatment with somatostatin 
analogues; evidence of Zollinger-Ellison syndrome; prolonged QTc interval and 
pregnancy; and lactation or steroid contraceptive use in female subjects. The study 
was conducted in two stages as described in chapter 6. 
 
Patients were eligible for enrolment into the second stage (extended dosing stage) if 
they had completed the first and were considered to have benefited from treatment 
with netazepide. We recruited 8 subjects for participation in the first stage and all of 
these completed both trial stages. The study (both stages) was conducted between 




2.8.2 Study design 
 
We conducted an open-label, phase 2, pilot study. Trio Medicines Ltd. Supplied 
netazepide 25mg capsules. In both stages, patients were asked to take 50mg 
netazepide daily, orally and after breakfast. Patients were issued with diary cards in 
which they were asked to record the time of each dose along with the details of any 
deviation from the prescription, unexpected symptoms or new concomitant 
medicine use. 
 
2.8.2.1 Stage 1 
 
Stage 1 comprised 12 weeks of treatment with netazepide 50mg daily and a 12-week 
follow-up period (after discontinuing netazepide treatment). There were 6 study 
visits in this stage. The investigations performed at each visit are illustrated in Table 
2-4. 
 
Table 2-4 Investigations performed at stage 1 study visits. 
Weeks 0 3 6 9 12 24 
On treatment  y y y y  
Blood tests y y y y y y 
Endoscopy y  y  y y 
 
Following enrolment and informed consent, patients attended for a baseline (week 
0) assessment visit during which a detailed medical history was taken and a clinical 
examination was performed. This included the recording of vital signs, a 12-lead 
electrocardiograph (ECG) and urinalysis. As for all subsequent visits, the patients 
were fasted from food and fluids for at least six hours. A venous blood sample was 
taken for assessment of full blood count (FBC), urea & electrolytes (U&E), liver 
function tests (LFT), lipid profile, plasma glucose, plasma Chromogranin A (CgA) and 
serum gastrin concentrations. A baseline upper GI endoscopy was performed during 
which visible gastric NETs were counted, measured and photographed before pinch 
biopsies were taken from the mucosa of the gastric antrum, corpus and tumours. 
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Following this initial visit, patients were prescribed Netazepide 50mg once daily and 
issued with a diary card in which to record times of administration, side effects or 
symptoms and new concomitant medications. 
 
Subsequent visits were conducted at three-week intervals (weeks 3, 6, 9 and 12). At 
each visit, a 12-lead ECG and urinalysis was performed and all blood tests were 
repeated. In addition, trough/peak plasma netazepide levels were measured. The 
diary card was reviewed and a capsule-count performed to evaluate drug 
compliance. A medical history and examination was carried out. After six and twelve 
weeks of treatment, upper GI endoscopy was performed as described below. 
 
A final visit was carried out twelve-weeks after completion of the Netazepide course 
of treatment. At this visit, blood tests and endoscopy were repeated. 
 
2.8.2.2 Stage 2 
 
Stage 2 comprised 52 weeks of treatment with netazepide and 5 study visits. At 0, 
12, 24, 36 and 52 weeks, we collected blood for gastrin, CgA, and netazepide assays 
along with ‘safety’ monitoring as before. We performed gastroscopy at baseline (0 
weeks), 24 and 52 weeks as before. There was no formal follow-up study visit after 
this stage and patients were returned to routine clinic follow-up. The investigations 
performed at each study visit are summarised in Table 2-5. For one patient (patient 
8), the interval between completing stage 1 and starting stage 2 was less than 6 
months and for this individual, endoscopy was not repeated at week 0, stage 2. 
 
Table 2-5 Investigations performed at stage 2 study visits. 
Weeks 0 12 24 36 52 
On treatment  y y y y 
Blood tests y y y y y 





2.8.2.3 Informal follow-up 
 
On completion of stage 2, patients were returned to routine follow-up in the 
neuroendocrine gastroenterology clinic. All 8 underwent routine endoscopy 
approximately one year after study completion and for completeness; we also report 
the findings from these procedures though they do not strictly fall within the remit 
of this study. 
 




Upper GI endoscopy was performed using Olympus Evis Lucera H240/H260 
endoscopes (Olympus, Southend-on-Sea, UK). Procedures were carried out by the 
same endoscopist (Prof. D. M. Pritchard, Department of Gastroenterology, University 
of Liverpool, Liverpool, UK) and assistant (ARM) at each visit and for each patient. 
Visible tumours were photographed and their diameter estimated by comparison 
with an opened pair (9mm) of biopsy forceps (Single-Use Radial Jaw 4 - Boston 
Scientific, Hemel Hempstead, UK). Mucosal pinch biopsies were then taken from the 
gastric antrum, corpus and visible tumours for routine histopathology (four biopsies 
per site). Eight additional biopsies were taken from the gastric corpus and stored in 
RNAlater (Ambion, Austin, TX, USA) for subsequent assessment of biomarker mRNA 
abundance. 
 
2.8.3.2 Histopathology and immunohistochemistry 
 
Biopsy samples were fixed in 10% neutral buffered formalin and paraffin embedded 
prior to staining with haematoxylin and eosin. Samples were also processed for 
immunohistochemical detection of synaptophysin, Ki67 and chromogranin A using 
monoclonal mouse antihuman synaptophysin antibody at 1:80 (NCLSynap299, Leica 
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Microsystems Inc. IL, USA), monoclonal mouse antihuman Ki67 antibody at 1:200 
(NCL-Ki67-MM1, Leica Microsystems Inc. IL, USA) and polyclonal rabbit antihuman 
CgA antibody at 1:8000 (A0430, Dako, Denmark) respectively. Specimens were 
reported by the same, expert gastrointestinal histopathologist (Prof. F. Campbell, 
Royal Liverpool University Hospital, Liverpool). 
 
2.8.3.3 Plasma Chromogranin A Concentration 
 
4ml venous blood was collected in EDTA tubes and centrifuged to separate plasma 
(4°C, 1500G for 10min) which was stored at -80 °C until assay. Plasma CgA 
concentration was measured using ELISA (Chromogranin A ELISA Kit K0025, DAKO, 
Denmark). Hammersmith Medicines Research, London, UK, performed CgA ELISA 
assays. 
 
2.8.3.4 Serum Gastrin Concentration 
 
2.5ml venous blood was collected in serum tubes and allowed to clot at room 
temperature for at least 20 minutes. Serum was then separated by centrifugation 
(4°C, 1500G for 10min) and stored at -20°C until assay. Serum samples were assayed 
for total amidated gastrin concentrations by RIA and ELISA. ELISA was performed 
using the Siemens Immulite2000 Gastrin chemiluminescent, enzyme-labelled 
immunometric assay (Siemens Healthcare Diagnostics Inc., NY, USA). These were 
performed by Hammersmith Medicines Research, London, UK. RIA was performed 
by ARM at the University of Liverpool and as described in section 2.4.1. 
 
2.8.3.5 Gastric Mucosal Biomarkers 
 
Gastric corpus mucosal biopsies were stored in RNAlater at -20°C before undergoing 
RNA extraction and reverse transcription as described in section 2.5. Real-time qPCR 
was performed using TaqMan chemistry and the 7500 real-time PCR system as 
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described in 2.6. Histidine decarboxylase (HDC), CgA and MMP-7 mRNA abundances 
were determined relative to GAPDH. The primer and probe sets employed are listed 
in Table 2-6. For stage 1, RNA extraction, reverse transcription and biomarker qPCR 
assays were performed by ARM who also designed and produced primers and 
probes for the histidine decarboxylase qPCR assay. For stage 2, Dr. B. N. Parsons 
(Department of Gastroenterology, University of Liverpool, Liverpool, UK) performed 
RNA extraction, reverse transcription and qPCR assays.
Table 2-6 Primer and probe sets employed in qPCR for determination of relative mRNA abundance of mucosal gene products.  
Gene Probe Forward primer Reverse primer 
GAPDH CGTCGCCAGCCGAGCCACA GCTCCTCCTGTTCGACAGTCA ACCTTCCCCATGGTGTCTGA 
MMP-7 CCTGTATGCTGCAACTCATGAACTTGGC GGATGGTAGCAGTCTAGG GATTAACT GGAATGTCCCATACCCAAAGAA 
CgA CCAGCCCCATGCCTGTCAGCC GATACCGAGGTGATGAAATGCA TCCTTCAGTAAATTCTGATGTCTCAGA 
HDC CTCTGTTAAACTCTGGTTCGTGATTCGGTCC CCCTGAGCCGACGGTTT GTACCATGTCTGACATGTGCTTGA 
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2.8.3.6 Serum Netazepide Concentration 
 
4ml venous blood was collected in lithium-heparin tubes and centrifuged to separate 
plasma (4°C, 1500G for 10min) within 30 minutes of sampling. Trough samples were 
collected along with other fasting blood samples. Peak samples were collected 1 
hour after observed administration of 50mg Netazepide. Plasma was stored at -20 °C 
until assay. Plasma Netazepide concentrations were measured at Huntingdon Life 
Sciences, UK, by a validated liquid chromatographic-tandem mass spectrometric 








The gram-negative bacterium Helicobacter pylori colonises the stomachs of 
approximately half of the world’s population(289). It universally induces a state of 
chronic inflammation in the gastric mucosa of its host and whilst most infected 
individuals remain asymptomatic, a minority go on to develop additional mucosal 
diseases such as peptic ulceration and mucosa-associated lymphoid tissue (MALT) 
lymphoma. A further 1% of hosts exhibit mucosal remodelling which culminates in 
the development of gastric adenocarcinoma. The disease phenotype displayed 
following infection is dependent on the interaction between bacterial, host and 
environmental factors.  
 
We designed a cross-sectional study of patients referred to the Royal Liverpool 
University Hospital, Liverpool, UK for upper GI endoscopy. Our aims were: 1) to 
establish the prevalence both of H. pylori infection and of gastric preneoplasia in this 
select population; 2) to collect data pertaining to relevant environmental 
contributors to gastric epithelial disease and 3) determine the transcript abundance 
of several genes and their proteins involved in H. pylori induced gastric preneoplasia 
with a view to developing a clinically applicable biomarker of the same. 
 
3.2 Materials and Methods 
 
The study methodology is described in detail in chapter 2 and is summarised here for 
convenience. Patients attending the Royal Liverpool University Hospital for 
outpatient upper GI endoscopy were recruited prior to undergoing the procedure. 
They answered a questionnaire (appendix C), which included demographic 
information, height and weight, past medical history, family history, concurrent 
medication use, tobacco and alcohol use and previous H. pylori testing or treatment. 
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Study participants provided fasting samples of blood and gastric mucosal biopsies in 
addition to those obtained as part of the routine endoscopy. 
 
Gastric corpus and antral biopsies were fixed, cut and stained before examination by 
a single, expert gastrointestinal pathologist. This study pathologist produced 
standardised reports including categorization by modified Sydney score and Vienna 
classification. 
 
Serum was stored in aliquots at -20°C. Anti-H. pylori IgG antibody serotype was 
determined by ELISA. Study subjects with one or more positive test results for H. 
pylori were also serotyped for CagA by ELISA. Fasting serum gastrin concentration 
was determined by radioimmunoassay (RIA). We selected smaller groups of study 
participants based on H. pylori and pathology results for serum pepsinogen 1 and 2 
concentration analyses. These were also determined by ELISA. 
 




Over the time period described, 1400 patients were recruited. These were 
predominantly female (57.5%) and Caucasian (98.4%). The mean age was 58 years, 
the median 60 years and the interquartile range 48-70 years.  
 
3.3.2 Mode of referral and symptoms 
 
Most patients were referred by their GP (56%) rather than from another department 
at the hospital. Of these 764 outside referrals, 66% were referred using the so-called 
“2-week rule” – an administrative mechanism to ensure that patients with 




We recorded the symptoms reported by the patients and given as indications for 
upper GI endoscopy. Most patients (55.6%) reported a single, predominant 
symptom. The commonest symptom to be reported alone was dysphagia, closely 
followed by the rather less specific symptoms of dyspepsia, heartburn and 
abdominal pain. The relative frequency with which solitary symptoms were reported 
is shown in Figure 3-1. Overall, these three non-specific symptoms were the most 
commonly reported. The overall frequency with which all symptoms were reported 






Figure 3-1 Frequency with which solitary symptoms were reported. 
 
 



















































































































3.3.3 Previous medical history 
 
We asked participants about their previous surgical and medical histories. In addition 
to recording major, general comorbidities, we specifically asked about previous 
upper gastrointestinal surgery; diabetes mellitus; ischaemic heart disease; 
cerebrovascular disease; inflammatory arthritis and pulmonary disease. 
 
Previous upper GI surgery was reported by 67 patients (4.8%). The largest proportion 
of these (48%) comprised of procedures performed to address the complications of 
peptic ulcer disease (PUD). The relative frequencies of indications for surgery are 
shown in Figure 3-3. Of the upper GI malignancies (n = 17), most were gastric 
adenocarcinoma (7) with 2 cases of gastric stromal tumours and one of a gastric 
neuroendocrine tumour. There were 4 cases of oesophageal malignancy and 3 of 
pancreatic cancer treated by Whipple’s procedure.  
 
 
Figure 3-3 Indications for surgery. 
 
Diabetes mellitus (DM) featured in the medical histories of 164 patients (11.7%). All 
but 9 of these reported Type-2 DM. Ischaemic heart disease was reported by 124 
(8.9%) patients and cerebrovascular disease by 51 (3.6%). In these ‘cardiovascular 


































reported by 215 (15.4%) of patients. Only 10 patients (0.7%) gave a history of 
inflammatory arthropathy. 
  
Previous malignancy was reported by 65 (4.6%) patients. The tumour sites are listed 
in Table 3-1.There were also 32 (2.3%) patients with inflammatory bowel disease and 
7 (0.5%) with coeliac disease. Prior to the endoscopy for which they were attending 
hospital, 12 (0.9%) patients were known to have Barrett’s oesophagus. 6 (0.4%) 
patients gave a history of Familial Adenomatous Polyposis (FAP).  
 
Table 3-1 Previous malignancies by site. 
Primary Neoplasia Site Number of patients - total Number of patients - current 
Breast 18 1 
Colorectal 14 0 
Prostate 7 7 
Lung 2 1 
Gastric 11 0 
Oesophageal 6 0 
Pancreas 3 0 
Other 4 0 
 
3.3.4 Family & Social history 
 
We recorded family history of gastric pathology and asked about tobacco and 
alcohol use.  
 
A family history of upper GI pathology was given by 302 (21.6%) subjects. Included in 
this group were the 69 (4.9%) patients who had a first degree relative with gastric 
malignancy and an additional 28 (2%) who reported gastric malignancy in a second 
degree relative. Also included were 162 (11.6%) patients who reported a first or 
second degree relative with a history of peptic ulceration, though of these only 18 




Regular use of alcohol was reported by 776 (55.4%) patients – 47.3% of women and 
65.4% of men. Of the female participants, 53 (6.6%) admitted to drinking more than 
the UK recommended weekly limit (14 units/week for women, 21 units/week for 
men(290). The same figure for male patients was 77 (12.9%). 
 
Tobacco smoking was reported for 730 (52.1%) including 346 (24.7%) who were 
current smokers. Smoking history is summarised in Table 3-2. 
 
Table 3-2 Smoking history. 
 Non- smoker Ex-smoker Smoker 
Female 408 (50.7%) 191 (23.7%) 206 (25.6%) 
Male 262 (44.0%) 193 (32.4%) 140 (23.6%) 
Total 670 (47.9%) 384 (27.4%) 346 (24.7%) 
 
 
3.3.5 Concomitant medications 
 
We specifically asked about the use of proton-pump inhibitors; H2-receptor 
antagonists, aspirin, clopidogrel and non-steroidal anti-inflammatory analgesics. 
 
If patients reported the use of one of these classes of drug, we also noted the dose 
and the time of last use. 50 (3.6%) patients reported recent use of non-steroidal anti-
inflammatory analgesics (NSAIDs) and 211 (15.1%) patients reported recent aspirin 
use. Although these agents typically have half-lives of less than 24 hours, their 
effects on the gastric mucosa may persist for several weeks(291). For this reason, we 
considered patients to be NSAID users if they reported having taken a non-aspirin 
NSAID within 4 weeks of the study endoscopy. The drugs whose use was reported 
are listed in Table 3-3. 211 (15.1%) patients reported recent aspirin use and 9 





PPI use was reported by 732 (52.3%) subjects. Again, PPIs typically have short half-
lives (<12 hours), but their effects on GI physiology and the resultant mucosal 
changes might be present for much longer. We included anyone reporting PPI use 
within 2 weeks. The drugs reported are listed in Table 3-4. 
 
Table 3-3 Number of patients who reported NSAID use. 
NSAID Number of patients % of total 
Diclofenac 3 0.21 
Diclofenac/Misoprostol 3 0.21 
Celecoxib 15 1.07 
Etoricoxib 3 0.21 
Ibuprofen 16 1.14 
Meloxicam 2 0.14 
Naproxen 8 0.57 
 
 
Table 3-4 Number of patients who reported PPI use. 
PPI Number of patients % of total 
Esomeprazole 57 4.07 
Lansoprazole 368 26.29 
Omeprazole 290 20.71 
Pantoprazole 10 0.71 





3.4 Endoscopic findings 
 
Of the study cohort of 1400 patients, 12 provided blood samples but did not 
undergo a complete endoscopy examination, either because they withdrew consent 
early during the procedure or because a proximal lesion precluded access to the 
stomach. For the remaining 1388 patients, significant endoscopy findings as 
reported by the endoscopist were recorded in the database. For the purposes of our 
analyses, these were then reclassified into “primary findings” and “others”. A 
“primary finding” was a significant mucosal abnormality reported at endoscopy in 
the stomach or duodenum. We also included Barrett’s oesophagus and oesophageal 
malignancy in this category. Where two such abnormalities were observed, we 
counted only the major abnormality e.g. if gastric ulceration and duodenitis were 
both present, we counted that case as gastric ulceration(292). Non-mucosal findings 
(e.g. hiatus hernia) thought unlikely to have a bearing on our subsequent analyses 
were counted as “others”. The primary findings along with the frequency with which 
they were reported are listed in Table 3-5. 
 
It was hypothesised at the outset that Barrett’s oesophagus might exhibit a similar 
relationship to the expression of our proposed biomarkers to that seen in gastric 
preneoplasia. As the table illustrates, we identified 67 suspected cases of Barrett’s 
oesophagus by endoscopy alone, though 44 of these accompanied another upper GI 
abnormality. For clarity, we have given both the total number of cases reported at 




Table 3-5 Primary endoscopic findings. 
Primary endoscopic findings 
Number of patients 
n % 
Normal 443 31.9 
Gastric malignancy 12 0.9 
Oesophageal malignancy 9 0.6 
Gastric atrophy and/or intestinal metaplasia 14 1.0 
Barrett’s oesophagus ONLY 23 1.7 
Gastritis and/or duodenitis 684 49.3 
Gastric and/or duodenal ulcer(s) 54 3.9 
Gastric polyp(s) 64 4.6 
Duodenal atrophy 6 0.4 
Duodenal polyp(s) 1 0.1 
Duodenal stenosis 1 0.1 
Oesophagitis ONLY 61 4.4 
Vascular lesion(s) 13 0.9 
Gastrointestinal stromal tumour 3 0.2 






3.5 Helicobacter pylori status 
 
As described above, patients were tested for H. pylori using three methods: 
serological analysis, rapid urease testing (RUT) of a pinch-biopsy specimen of gastric 
mucosa and by histopathological staining and examination.  
 
There were 17 patients entered into the database from whom we obtained samples 
of blood but no gastric biopsies because the patient withdrew consent before these 
were taken (n=15) or because a proximal lesion precluded access to the stomach 
(n=2). 16 patients underwent the gastroscopy procedure, but a rapid urease test 
result was not recorded. In 3 cases, the histology was not reported because of 
mishandled samples. 9 patients were entered into the database despite our being 
unable to obtain a blood sample. A further 39 patients did not have an H. pylori 
serology result reported because of mishandled or mislabeled samples. 
 
Taking into account these “not done” H. pylori tests, we have a complete set of 
results for 1322 (94.4%) study patients. These results are shown in Table 3-6. The 
hospital laboratory reports the H. pylori antibody IgG serology result qualitatively. In 
cases where the antibody titre is neither sufficiently high to be considered “positive” 
nor sufficiently low to be considered “negative”, then the result is reported as 
“indeterminate”. 46 (3.3% of total cohort) such results were returned and in our 
analyses, we regarded these results as being “negative”. 
 
 
Table 3-6 H. pylori test results. n=number of patients. 
n=1322 Urease Histology Serology 
 n % n % n % 
Positive 245 18.5 288 21.8 573 43.3 






Comparisons between the various testing methodologies are shown in Figure 3-4. 
 
 
Figure 3-4 Comparison between three methods of H. pylori test. a) In seropositive, b) in histology positive and c) 
in RUT positive patients 
 
 
As might be expected, approximately half (48.7%) of seropositive patients exhibited 
no evidence of active H. pylori infection by histology or RUT. Though some false-
positive serology (and false-negative histology/RUT) results might be expected, this 
figure largely reflects the rate at which H. pylori has been cleared either by host-
immunity or with antimicrobial eradication treatment. In our study, 158 subjects 
reported previous eradication therapy for H. pylori of whom only 100 (63.3%) were 
seropositive. Of these, 27 (27%) were found to be infected with H. pylori on 





































































































Using histology as the “gold standard”, the overall sensitivity and specificity of RUT in 
our study cohort were 76.0% and 97.5% respectively. In those patients taking a PPI, 
sensitivity of RUT was 60.4% compared with 84.5% in those not taking such agents. 
Similarly, in patients with positive CagA serology, RUT sensitivity was 83.9% 
compared with 71.0% in CagA negative H. pylori infected subjects. We observed no 
effect on RUT performance of the presence of preneoplastic mucosal changes. 
 
3.5.1 Topographical distribution of H. pylori colonisation 
 
As outlined in chapter 2, our sample collection protocol described separate antrum 
and corpus mucosal biopsies for histological assessment both by our study 
pathologist and by the local hospital pathologists. Based on this, we were able to 
estimate the topographical distribution of H. pylori organisms in infected subjects 
(Table 3-7) 
 
Table 3-7 Topographical distribution of H. pylori colonisation on histological examination. 
Site of infection 
Number of patients 
n % 
Pangastric 199 69.1 
Corpus only 59 20.5 
Antrum only 30 10.4 
 
 
3.5.2 CagA status in H. pylori infected patients 
 
CagA serology was performed on 584 patients whose H. pylori testing had yielded at 
least one positive result. 210 (36.0%) were seropositive for CagA. Of the 306 with 
evidence of current infection (RUT and/or histology positive), 129 (42.1%) were CagA 
positive. For those individuals with positive H. pylori serology, but no evidence of 
current infection (RUT and histology negative) i.e. “previous” infection, the number 





Figure 3-5 CagA status in patients with current and previous evidence of H. pylori infection. 
 
 
3.6 Gastric mucosal inflammation and preneoplasia 
 
Gastric mucosal biopsy specimens were obtained during endoscopy as described 
above (section 2.2). Of the 1400 patients in the study database, 19 had no histology 
reported by the study pathologist. An additional 11 had analyses reported from 
antral mucosal samples only and 18 from the corpus only. Of the antral-only set, one 
patient had antral intestinal metaplasia (IM) and one had gastric adenocarcinoma 
and IM. Of the corpus-only set, one patient had atrophy and one had atrophy and 
IM. Excluding the patients without histology data, there are 1381 patients included 
in the following analyses. 
 
In total, there were 338 (24.5%) patients with gastric mucosal preneoplastic changes, 
dysplasia or cancer. These are listed in Table 3-8 in order of increasing severity. 
Patients with more “severe” mucosal changes have been counted only in the most 
severe category e.g. if a sample was reported to exhibit both “atrophy” and “low-
grade dysplasia”, it has been included only in the “low-grade dysplasia” category. 
Similarly, if pathology was reported in both antrum and corpus specimens, that case 



























Table 3-8 Primary findings at histopathological assessment. 
Primary histopathological findings 
Number of patients 
n % 
Atrophy - antrum 19 1.4 
Atrophy - corpus 45 3.3 
Atrophy - pangastric 5 0.4 
Intestinal metaplasia - antrum 156 11.3 
Intestinal metaplasia - corpus 42 3.0 
Intestinal metaplasia - pangastric 45 3.3 
Low-grade dysplasia - antrum 6 0.4 
Low-grade dysplasia - corpus 5 0.4 
Low-grade dysplasia - pangastric 0 0.0 
High-grade dysplasia - antrum 0 0.0 
High-grade dysplasia - corpus 0 0.0 
High-grade dysplasia - pangastric 3 0.2 
Gastric adenocarcinoma 12 0.9 
 
3.6.1 Age and gastric preneoplasia 
 
We examined the rates of preneoplasia in the different age groups of patients 
recruited to our study. We divided patients by age into the following groups: <20, 
20-29, 30-39, 40-49, 50-59, 60-69, >69 years old. The proportion of patients with 
preneoplasia increased with age as shown in Figure 3-6a. The mean age of patients 
with preneoplasia was 64 years (median = 66 years) and was significantly higher 
(mean = 56, median = 57 years) than that of patients without preneoplasia 




Figure 3-6 a) Proportion of patients with gastric preneoplasia by age group and b) mean age in patients with and 
without gastric preneoplasia (two-tailed Mann-Whitney test). 
 
3.6.2 H. pylori and gastric preneoplasia 
 
H. pylori infection was identified by at least one test in 231 (68.3%) of the 338 
patients with histologically confirmed preneoplasia or cancer. 131 (38.8%) had 
evidence of current H. pylori infection and 100 (29.6%) were positive by H. pylori 
serology only, suggesting previous infection. 107 (31.7%) gave negative results for all 
three modes of H. pylori testing. In comparison, of 1062 patients without 
preneoplasia or cancer, 384 (36.6%) were H. pylori positive – 191 (18.0%) for current 




























































pylori infection between the two groups was significant (p<0.0001, OR 3.812, 95% CI 
2.248-3.378, two-sided Fisher’s exact test) and the data are illustrated in Figure 3-7. 
 
 
Figure 3-7 Proportions of patients with evidence of current, previous or no H. pylori infection in groups with and 
without preneoplasia (two-tailed Mann-Whitney test). 
 
As has been previously reported, the tendency to develop H. pylori associated 
preneoplastic changes in gastric mucosa is enhanced by more virulent strains of the 
organism. In our cohort, of 338 patients with preneoplasia or cancer, 174 (51.5%) 
were cagA serology positive. Of the 532 patients without preneoplasia or cancer who 
were tested for cagA, only 168 (31.6%) were seropositive. The association between 
cagA positivity and preneoplasia was significant (p<0.0001, OR 2.125, 95% CI 1.495-









































Figure 3-8 Proportion of patients with CagA seropositivity in groups with and without preneoplasia (two-tailed 
Mann-Whitney test). 
 
3.6.3 Serum gastrin concentration and gastric preneoplasia 
 
All but 13 of the 1400 patients recruited into the study had their serum analysed for 
gastrin concentration by radioimmunoassay as described in chapter 2. Patients were 
classified into three groups based on fasting serum gastrin concentration: normal 
(<40pM), moderately elevated (40-100pM) or high (>100pM). The data are 
summarised in Figure 3-9. The proportion of patients with fasting serum gastrin 
concentrations above “normal” i.e. >40pM was significantly higher in those with 
preneoplasia or cancer (56.8%) than in those without (40.8%) (p<0.0001, OR 1.764, 
95% CI 1.375-2.261, two-sided Fisher’s exact test). The association between high 
(>100pM) fasting serum gastrin concentrations and preneoplasia or cancer was also 
significant (p<0.0001, OR 2.355, 95% CI 1.722-3.220, two-sided Fisher’s exact test). 
The mean fasting serum gastrin concentrations in the preneoplasia and control 
groups were 121.5pM (median = 46.0pM) and 62.1pM (median = 31.0) respectively 





Figure 3-9 a) The proportion of patients with fasting serum gastrin concentration in normal, moderately elevated 
and high ranges in those with and without gastric preneoplasia and b) mean gastrin concentration in patients 
with and without gastric preneoplasia (two-tailed Mann-Whitney test). 
 
Of the patients in our cohort with histologically proven preneoplasia, 317 had both 
complete histology data and a serum gastrin concentration recorded. 158 had 
preneoplastic pathology identified only in antral biopsy specimens compared with 84 
only in corpus samples and 75 in both (pangastric). The mean concentrations of 
fasting serum gastrin in these groups were 65.7pM, 230.0pM and 107.6pM (median 
= 36.0pM, 90.0pm and 50.0pM) respectively. The difference between each of these 
three groups was significant (<0.0001, repeated two-tailed Mann-Whitney tests). 
There was no significant difference in mean serum gastrin concentration between 





Figure 3-10 Comparison of mean fasting serum gastrin in preneoplasia groups by site (repeated two-tailed Mann-
Whitney tests). 
 
Other causes of hypochlorhydria have also been shown to induce 
hypergastrinaemia(293). Perhaps most relevant to our study are PPI use and H. 
pylori infection. We therefore evaluated the effects of these variables in our study 
population as follows: 
 
We firstly examined the effect of PPI use in both subjects with normal gastric 




Figure 3-11 Mean fasting serum gastrin concentration with and without PPI use in a) subjects with normal gastric 
histology and b) subjects with gastric preneoplasia (two-tailed Mann-Whitney tests). 
 
In the ‘normal’ histology group, the mean fasting serum gastrin concentration in PPI 
naïve subjects was 39.6pM (median 20.0pM, SEM 6.5), compared with 75.6pM 
(median 50.0pM, SEM 4.6) in PPI users and the difference was highly statistically 
significant (p<0.0001, two-tailed Mann-Whitney test). Similarly, in the ‘preneoplasia’ 
group, mean fasting serum gastrin concentration in PPI naïve subjects was 107.7pM 
(median 30.0pM, SEM 19.2) and 131.6pM (median 61.8pM, SEM 19.6) in PPI users. 
The difference here was also highly statistically significant (p<0.0001, two-tailed 
Mann-Whitney test). 
 
To determine the effect of H. pylori infection on fasting serum gastrin concentration, 
we performed similar analyses. Subjects were regarded as currently infected if H. 
pylori organisms were reported on study histology. In such cases, the 
histopathological changes induced are commonly referred to as ‘gastritis B’.  We 
compared mean fasting serum gastrin concentration in the ‘normal’ histology group 
with that in the ‘gastritis B’ group (Figure 3-12a). In the preneoplasia group, we 




Figure 3-12 Mean fasting serum gastrin concentration for a) subjects with normal histology and those with H. 
pylori associated gastritis and b) H. pylori negative and H. pylori positive patients with coexisting preneoplasia 
(two-tailed Mann-Whitney tests). 
 
In the group comprising H. pylori negative subjects with normal gastric histology, the 
mean fasting serum gastrin concentration was 57.6pM (median 29.5pM, SEM 4.1), 
compared with 65.7pM (median 36.0pM, SEM 9.2) in the ‘gastritis B’ group and the 
difference was statistically significant (p=0.0127, two-tailed Mann-Whitney test).  
 
There was an unexpected pattern observed in patients with histologically proven 
gastric preneoplasia. Here, the mean fasting serum gastrin concentration in H. pylori 
negative subjects was 148.5pM (median 46.8pM, SEM 21.3) and was greater than 
that observed in H. pylori positive subjects where the equivalent value was 72.2pM 
(median 39.0pM, SEM 7.9). The difference was also statistically significant (p=0.0495, 
two-tailed Mann-Whitney test). 
 
Revisiting our earlier comparison of ‘normal’ and ‘preneoplasia’ groups but excluding 
H. pylori positive subjects or PPI users amplifies the observed effect of preneoplasia 
on fasting serum gastrin concentration (Figure 3-13). In the ‘normal’ histology group, 
the mean serum fasting gastrin concentration was 39.7pM (median 20.0pM, SEM 
6.8). The value for the preneoplasia group was significantly higher (mean 148.4 pM, 





Figure 3-13 Mean fasting serum gastrin concentration in subjects with gastric preneoplasia compared with those 
with normal histology, excluding H. pylori positive subjects and PPI users (two-tailed Mann-Whitney test). 
 
3.7 Serum pepsinogen 1 and 2 concentration and presence of gastric 
preneoplasia 
 
As outlined above, estimation of the concentration of serum pepsinogens (PG) 1 and 
2 is a well-established method of screening for gastric mucosal preneoplasia – the 
so-called “serological biopsy”. We selected samples from our cohort to represent the 
major preneoplasia pathology groups as well as controls who had normal gastric 
histology. Of the study subjects with complete histology results, we performed PG 1 
and 2 ELISA for 397. The pathology groups and number of patients included are 
shown in Table 3-9. 
 
We excluded all patients with gastric mucosal pathology except gastritis (of any 
aetiology) and compared serum PG1 and PG2 concentrations from those with 
proven, current H. pylori infection and those without. There were 122 subjects 
included in this analysis: normal (n=85), gastritis C (n=5) and gastritis B (n=32). 39 of 
these had yielded a positive test for current H. pylori infection (i.e. rapid urease test 
or histology positive). The mean serum PG1 concentration, PG2 concentration and 
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PG1/2 ratio for the H. pylori negative group were 96.2μg/l, 8.6μg/l and 11.9 (median 
= 89.5 μg/l, 7.9 μg/l and 11.8) respectively compared with the same values for the H. 
pylori positive group which were 133.8 μg/l, 17.1 μg/l and 8.5 (median = 110.5 μg/l, 
13.6 μg/l and 7.8) respectively. The differences between groups were statistically 
significant for serum PG1 concentration (p=0.0011), PG2 concentration (p<0.0001) 
and PG1/2 ratio (p<0.0001, two-tailed Mann-Whitney tests for each). The results are 
shown in Figure 3-14. 
 
Table 3-9 Gastric pathology groups and numbers of included patients. 
Gastric histopathology group 
Number of patients 
n % 
Normal 86 21.7 
Gastritis B - antrum 10 2.5 
Gastritis B - corpus 1 0.3 
Gastritis C - antrum 2 0.5 
Gastritis C - corpus 3 0.8 
Gastritis B - pangastric 34 8.6 
Foveolar hyperplasia 19 4.8 
Atrophy - antrum 13 3.3 
Atrophy - corpus 43 10.8 
Atrophy - pangastric 5 1.3 
Intestinal metaplasia - antrum 73 18.4 
Intestinal metaplasia - corpus 40 10.1 
Intestinal metaplasia - pangastric 45 11.3 
Low-grade dysplasia - antrum 3 0.8 
Low-grade dysplasia - corpus 5 1.3 
High-grade dysplasia - corpus 1 0.3 
High-grade dysplasia - pangastric 2 0.5 




Figure 3-14 a) Serum pepsinogen 1 concentration, b) serum pepsinogen 2 concentration and c) pepsinogen 1/2 
ratio in subjects with normal or H. pylori associated gastritis only (two-tailed Mann-Whitney tests). 
 
As the premise for PG ratio use in the detection of preneoplasia is based upon the 
predilection of chronic atrophic gastritis (and the subsequent more “severe” lesions) 
for a distribution skewed towards the proximal stomach, we assessed the effect of 
lesion topography on serum PG concentration. For this analysis, we compared 
histologically normal (n=86) with antral preneoplasia (n=89); corpus preneoplasia 
(n=89); pangastric preneoplasia (n=52) and gastric adenocarcinoma (n=12). The 




Table 3-10 Comparison of serum pepsinogen 1 & 2 concentrations and pepsinogen 1/2 ratio for different disease 
distributions. 
 PG 1 (μg/l) PG 2 (μg/l) Ratio PG1:PG2 
 Mean Median p-value Mean Median p-value Mean Median p-value 
Normal 98.89 88.22 - 9.23 8.10 - 11.54 11.23 - 
Antrum preneoplasia 137.7 112.5 0.0002 18.33 15.15 <0.0001 8.80 7.90 <0.0001 
Corpus preneoplasia 98.2 82.16 0.1440 16.0 13.16 <0.0001 5.90 5.84 <0.0001 
Pangastric preneoplasia 106.3 98.13 0.7836 16.66 13.38 <0.0001 6.77 6.57 <0.0001 




Figure 3-15 a) Serum pepsinogen 1 concentration, b) serum pepsinogen 2 concentration and c) pepsinogen 1/2 




As before, each pathology group was compared with “Normal” controls. There was 
no significant difference in serum PG 1 concentration between control and 
pathology groups. In contrast, both serum PG 2 concentrations and PG 1/2 ratios 
were significantly different between controls and pathology groups (p<0.0001, two-
tailed Mann-Whitney test). For both ‘tests’, the magnitude of this effect was not 
diminished by the inclusion of less “severe” preneoplasia cases in the comparison 
group and there was no significant difference observed in either PG 2 concentration 
or PG 1/2 ratio between the pathology group comprising “severe” mucosal changes 
and that containing “all” preneoplasia. Our study was not designed to capture cases 
of gastric adenocarcinoma and so the sample size is small (we included only 12 cases 
in the entire cohort). Nevertheless, both PG 2 concentration and PG 1/2 ratio were 
significantly different in the gastric adenocarcinoma group as compared with normal 
controls (p=0.0014 and 0.0017 respectively, two-tailed Mann-Whitney test). 
  
In our cohort therefore, it seems that serum PG 1 concentration has no discriminant 
value when comparing subjects with normal gastric histology to those with gastric 
preneoplasia. Both serum PG 2 concentration and PG 1/2 ratio seem to discriminate 
between these two groups and so we have examined the usefulness of these “tests” 
as diagnostic or screening tools. The receiver operating characteristic (ROC) curve for 
both measures for the presence of gastric preneoplasia are shown in Figure 3-16. 
 
 
Figure 3-16 ROC curves for a) PG ratio and b) serum PG 2 concentration in gastric preneoplasia. 
 
The PG 1/2 ratio performed better as a diagnostic test than did the PG 2 
concentration, with areas under the curves (AUCs) of 0.80 (p<0.0001, 95% CI: 0.7455 
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to 0.8473 Clopper/Hanley method) and 0.75 (p<0.0001, 95% CI: 0.6947 to 0.8061 
Clopper/Hanley method) respectively. 
 
The ROC curves for PG ratio in groups including “all” neoplasia, “severe” neoplasia 
and gastric adenocarcinoma are shown in Figure 3-17. The AUCs were 0.80 
(p<0.0001, 95% CI: 0.7455 to 0.8473), 0.77(p<0.0001, 95% CI: 0.7158 to 0.8301) and 
0.78 (p=0.0017, 95% CI: 0.6291 to 0.9329) respectively. 
 
 
Figure 3-17 ROC curve for PG ratio in all preneoplasia, severe preneoplasia and gastric adenocarcinoma. 
 
The manufacturer of the PG 1 & 2 ELISA assay kits used in this study suggests that a 
PG 1/2 ratio of less than 3.0 is suggestive of “advanced corpus atrophy” and the 
same level is accepted as an arbitrary cutoff in the majority of relevant 
studies(237,294). In our cohort, a cutoff of <3.0 yielded a sensitivity and specificity of 
15.7% and 100% respectively. Finding the optimal cutoff in our study by drawing the 
tangent to the curve in parallel with its axis gives a PG 1/2 ratio cutoff of 8.8 with a 
sensitivity and specificity of 70.0% and 79.1% respectively (likelihood ratio 3.34). 
 
We also evaluated the addition of elevated fasting serum gastrin concentration and 
H. pylori seropositivity as additional positive tests. Using the same cutoff for PG 1:2 
ratio of <8.8 for the diagnosis of preneoplasia as defined above, we first determined 
the effect of adding fasting hypergastrinaemia as an additional positive test i.e. 
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patients with “normal” PG 1:2 ratio (>8.8) were considered as giving a positive test if 
they exhibited a high fasting serum gastrin concentration. We used cutoffs for serum 
gastrin of 40pM (moderately elevated) and 100pM (high) and evaluated their effects 
on the performance of a combined diagnostic test separately. The data are 
summarised in Table 3-11. Inclusion in the “positive test” group of patients with 
normal PG 1/2 ratio but fasting serum gastrin concentration of ≥40pM increased 
sensitivity (from 70% to 85%) but at the expense of specificity (from 79% to 70%). 
The addition of patients with “high” fasting serum gastrin concentration however 
improved the performance of the combined test. Sensitivity increased (from 70% to 
74%) with unaltered specificity. The resulting effect on the predictive values was to 
increase both positive predictive value (PPV) (from 51% to 52%) and negative 
predictive value (NPV) (from 89% to 91%). These improvements are marginal, but 
suggest that future panels of biomarkers for gastric preneoplasia should include both 
pepsinogen 1/2 ratio and fasting serum gastrin concentration for the best 
performance. 
 
Table 3-11 Diagnostic performance of pepsinogen 1/2 ratio alone and in conjunction with serum gastrin 
concentration. PPV = positive predictive value; NPV = negative predictive value. 
 
Pepsinogen 1/2 ratio 
only 
Pepsinogen 1/2 ratio & 
serum gastrin ≥40pM 
Pepsinogen 1/2 ratio & 
serum gastrin ≥100pM 
 Test + Test - Test + Test - Test + Test - 
Preneoplasia 
+ 160 70 195 35 170 60 
Preneoplasia 
- 18 68 26 60 18 68 
       
Sensitivity % 69.6 84.8 73.9 
Specificity % 79.1 69.8 79.1 
PPV % 50.7 46.4 52.2 
NPV % 89.4 93.7 90.7 
 
 
We adopted the same approach to assess the effect of H. pylori testing in 
combination with the PG 1/2 ratio on the performance of the ‘diagnostic test’ for the 
detection of gastric preneoplasia. Commercially available kits marketed for this 
purpose include a test to determine H. pylori serology status as this would be in 
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keeping with the other noninvasive tests described (i.e. based on blood testing). For 
completeness, we also assessed the contribution of H. pylori histology status. By 
definition, this would not be considered a noninvasive test, as it would 
conventionally require an upper GI endoscopy examination to obtain gastric mucosal 
biopsies. We have included it however as there are alternative noninvasive means of 
testing for ‘current’ H. pylori infection (e.g. C13 urea breath testing or H. pylori faecal 
antigen testing). These modes of testing lack the sensitivity of histological 
examination for the diagnosis H. pylori infection, but we have included the latter as a 
surrogate for the former. We also assessed CagA seropositivity in place of H. pylori 
seropositivity. The data are summarised in Table 3-12. Both H. pylori histology 
positivity and CagA seropositivity adversely affected the performance of the 
combined diagnostic test by their inclusion. In both cases, sensitivity and specificity 
were diminished. In contrast, combining H. pylori serology positivity and PG 1/2 ratio 
proved to be more useful for the diagnosis of gastric preneoplasia than PG 1/2 ratio 
alone. Sensitivity was increased (from 70% to 88%) for a small decrease in specificity 
(79% to 74%). Positive and negative predictive values were both improved (50% to 
52%; 89% to 95% respectively).  
 
Table 3-12 Diagnostic performance of pepsinogen 1/2 ratio in combination with H. pylori serology, histology and 
CagA serology. PPV = positive predictive value; NPV = negative predictive value. 
 
Pepsinogen 1/2 ratio & 
H. pylori serology + 
Pepsinogen 1/2 ratio & 
H. pylori histology + 
Pepsinogen 1/2 ratio & 
H. pylori CagA + 
 Test + Test - Test + Test - Test + Test - 
Preneoplasia 
+ 203 27 180 50 173 57 
Preneoplasia 
- 22 64 21 65 19 67 
       
Sensitivity % 88.3 78.3 75.2 
Specificity % 74.4 75.6 77.9 
PPV % 51.6 49.8 51.3 
NPV % 95.4 91.8 91.1 
 
 
To conclude our assessment of the utility of conventional noninvasive biomarkers of 
gastric preneoplasia in our study cohort, we combined the best performing tests: PG 
 
135 
1/2 ratio, fasting serum gastrin concentration and H. pylori serology. As before, a 
subject was considered to have yielded a positive test if the serum PG 1/2 ratio was 
<8.8 and/or the fasting serum gastrin ≥100pM and/or the H. pylori serology was 
positive. The data are summarised in Table 3-13. The combined test outperformed 
any of the individual tests or other combinations.  
 
Table 3-13 Diagnostic performance of pepsinogen 1/2 ratio in combination with H. pylori serology and fasting 
serum gastrin concentration. PPV = positive predictive value; NPV = negative predictive value. 
 Combined test 
 Test + Test - 
Preneoplasia 
+ 207 23 
Preneoplasia 
- 22 64 
   
Sensitivity % 90.0 
Specificity % 74.4 
PPV % 52.1 




In the present study, we report the effects of various host, environmental and 
microbial factors on the development of gastric preneoplasia. Our study included a 
large number of participants. We hypothesised that a large number of subjects 
would be required in order to include a sufficient population with H. pylori and 
gastric preneoplasia for meaningful analysis. In the event, 1400 study volunteers 
yielded large numbers with gastric preneoplasia (388, 24.5%).  
 
As discussed in chapter 1, in the UK population, demands on healthcare providers 
are inexorably increasing and outpatient endoscopy services are no exception. 
Noninvasive tools, which might dispense with the requirement to proceed to upper 
GI endoscopy, would reduce the burden on these resources and avoid the 
inconvenience, discomfort and risk associated with these procedures. An obvious 
limitation of the present study is that it is based on a relatively homogeneous group 
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of patients recruited at a single centre. The study does however benefit from the 
inclusion of only symptomatic individuals who have been referred for upper GI 
endoscopy, which is arguably the most important group for identification of 
individuals at risk of cancer development.  
 
Another major advantage of our study design is the means by which we obtained 
and assessed gastric mucosal histology specimens. The participation of a single, 
specialist GI pathologist and their use of standardised and validated scoring and 
reporting systems proved invaluable in mitigating the effects of subjectivity and 
eliminating inter-observer variation. There is considerable variation in terminology 
apparent in the literature. In this thesis, I have presented the histological results 
using the terminology agreed upon by our research group with our expert GI 
pathologist in advance of the study commencing. In this context, the terms ‘gastritis 
B’ and ‘H. pylori positive gastritis’ are used interchangeably. The limitations of 
histology as a means of testing for H. pylori are discussed on page 138. We recognise 
that the presence of gastritis in the absence of H. pylori organisms does not exclude 
H. pylori infection as the aetiology in every case but in the interests of clarity, we 
have used the term ‘gastritis C’ to describe this pathological cohort. 
 
Safety and ethical considerations dictated the number of gastric mucosal biopsies 
that we were able to obtain from each subject. Gastric mucosal preneoplastic 
changes are frequently distributed unevenly. As a means of diagnosing and 
determining disease topography therefore, mucosal pinch biopsies are susceptible to 
sampling errors. The recommended sampling protocol for clinical diagnosis would 
include 5 pinch biopsies including one from the angulus incisura (197,199) whereas 
we were limited to 4 specimens.  
 
We tested the majority of our subjects for evidence of H. pylori infection by three 
methods. We were able to evaluate the performance of a commonly used diagnostic 
technique (RUT) in the process. We observed (and previously reported) RUT 
accuracy in the overall study cohort and that sensitivity is adversely affected by 
concurrent PPI use and CagA negative status. Rates of current and previous H. pylori 
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infection and CagA positivity were broadly in line with similar population based 
studies in similar populations(295–297) though it should be noted that our mode of 
testing (ELISA) has been shown to lack sensitivity when compared with western blot 
assay(298). We selected ELISA for this application in the present study due to 
resource constraints. 
 
In section 3.5, I have described how the results of the anti-H. pylori IgG ELISA are 
reported (in accordance with the manufacturer’s instructions) as being ‘positive’, 
‘negative’ or ‘indeterminate’, and how we then grouped the small number (46 cases) 
of ‘indeterminate’ results with the ‘negative’ results for the purposes of our 
analyses. The rationale for doing so was pragmatic – we considered that the effect 
on subsequent analyses of including ‘false positive’ indeterminate cases would be 
more deleterious to our results than that of excluding ‘false negative’ cases. We 
recognise that this distinction might adversely influence the sensitivity of the 
diagnostic biomarker panel described in this chapter but consider that any effect 
would be small given the low number of cases involved. 
 
In section 3.5, we also reported that 48.7% of subjects found to be seropositive for 
H. pylori exhibited no histological evidence of current infection. We categorised 
these individuals as having been ‘previously infected’ and proposed that this group 
comprises those individuals in whom H. pylori infection has been cleared either by 
means of antimicrobial treatment or by host immunity. We recognise however that 
some of these individuals will have been misclassified in this way as a result of the 
vagaries of the two testing modalities in question. As described, a small number of 
false-positive serology might be expected but the impact of false-negative 
histology/RUT is likely to be greater. In particular, H. pylori detection by histology or 
RUT is known to be less sensitive in the presence of hypochlorhydria and the 
commonest cause of this is PPI use. 
 
We found histological evidence of gastric mucosal preneoplasia in 24.5% of patients 
analysed. Our observations corroborated our understanding and expectations of the 
factors associated with preneoplasia development, namely: patients with gastric 
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preneoplasia were more likely to be infected with H. pylori or be seropositive for this 
organism (suggesting previous infection); the effect of H. pylori on preneoplasia 
incidence was potentiated by CagA positivity; and preneoplasia was detected more 
frequently in older subjects. 
 
The effect of gastric preneoplasia on fasting serum gastrin concentration was also in 
line with previous observations. Gastric preneoplasia was associated with elevated 
fasting serum gastrin concentrations and the effect was greater for corpus 
predominant disease than for pangastric disease, which was – in turn – greater in 
effect than antral predominant disease.  
 
Other causes of gastric hypochlorhydria were also associated with an increase in 
fasting serum gastrin concentration. Recent PPI use conferred an increase in fasting 
serum gastrin concentration both in subjects with normal gastric histology and those 
with gastric preneoplasia. 
 
Similarly, the well-reported(36) effect of H. pylori infection upon fasting serum 
gastrin concentrations was replicated in our study. Current H. pylori infection (as 
evidenced by RUT or histology positive testing) was associated with a significant 
increase in fasting serum gastrin concentration in subjects with normal gastric 
mucosal histology. Somewhat unexpectedly, this effect was reversed in those 
patients who had gastric preneoplasia. We speculated that this phenomenon might 
result from the loss of H. pylori infection that is often seen in gastric atrophy 
following chronic gastritis.  
 
Serum pepsinogen 1 and 2 concentrations (and the pepsinogen 1/2 ratio) have been 
well validated(197) in some (particularly far-Eastern) populations as a noninvasive 
means of diagnosing early gastric adenocarcinoma and preneoplastic lesions. The so-
called serologic biopsy has been less well studied in Western populations for the 
identification of preneoplasia. Sensitivity, specificity and negative predictive value of 
serum pepsinogen 1/2 ratio for the detection of gastric preneoplasia were similar to 




Recent studies have also examined the use of a “GastroPanel” for the detection of 
gastric preneoplasia(241). However, the authors concluded that this compound test 
was insufficiently accurate for clinical use. Our compound test performed better in 
this study and the populations were similar. We speculate that this may be due to 
the improved accuracy of gastrin radioimmunoassay over the ELISA test that was 
used in GastroPanel, as the former detects all amidated gastrins whereas the latter is 
said to be specific for only one peptide, namely gastrin-17. 
 
In the present study, we evaluated the performance of a combined diagnostic test 
for gastric preneoplasia comprising assays for serum PG1 and PG2 concentration, 
serum gastrin concentration and H. pylori serology. The analyses described in section 
3.7 were conducted using a defined ‘normal’ histology group as controls. We 
recognise that excluding confounding factors such as concurrent PPI use and H. 
pylori seropositivity from this control group might potentiate the observed 
performance of the diagnostic panel. Further biomarker panel development would 










Following infection with H. pylori, a small minority of individuals goes on to develop 
intestinal type gastric adenocarcinoma. Gastric cancer is very often diagnosed at an 
advanced stage and is associated with very high mortality. The disease develops via a 
series of well-defined preneoplastic steps (known as Correa’s oncogenic cascade) 
and a means to reliably detect the presence of these preneoplastic conditions might 
offer opportunities for surveillance and early treatment. Upper GI endoscopy is 
invasive, costly and probably unreliable for the detection of gastric preneoplasia if 
not performed by properly trained endoscopists and adequate gastric mucosal 
biopsies taken from appropriate sites. Current noninvasive screening tests are 
insufficiently sensitive and/or specific to be used in routine clinical practice. 
 
There is therefore a need to identify novel biomarkers of gastric preneoplasia which 
might be used both in high-risk populations for population screening; and in low-risk 
populations for screening of symptomatic individuals. Such a biomarker might be 
useful in determining the risk of gastric cancer posed to a given individual and assist 
in determining the required surveillance or treatment strategy. 
 
Our group amongst others has previously described the role played by several genes 
and proteins of the gastric epithelium in carcinogenesis. We aimed to assess the 
changes in expression of these genes and proteins in the presence of gastric 
preneoplasia in order to determine their potential utility as biomarkers. 
 
4.2 Materials and Methods 
 





Gastric corpus mucosal pinch biopsies were taken during each study endoscopy and 
stored immediately in RNAlater. These were stored at -20°C prior to RNA extraction 
and reverse transcription. The resulting cDNA was assayed by real-time qPCR. Each 
PCR plate incorporated standards of known concentrations, both for the gene of 
interest and for the housekeeper gene Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). The abundance of both gene transcripts was determined from the 
standard curves. Relative gene transcript abundance was calculated from the ratio of 
candidate gene to housekeeper gene mRNA abundance. 
 
We began the study with a list of candidate genes which are listed in Table 4-1.  
 
Table 4-1 Candidate biomarker genes. 
Candidate Gene Candidate Gene 
(abbreviation) Origin 
Insulin-like growth factor-1 IGF-1 Mesenchymal 
Insulin-like growth factor-2 IGF-2 Mesenchymal 
Matrix metalloproteinase-1 MMP-1 Both 
Matrix metalloproteinase-3 MMP-3 Both 
Matrix metalloproteinase-7 MMP-7 Epithelial 
Plasminogen activator inhibitor-1 PAI-1 Both 
Plasminogen activator inhibitor-2 PAI-2 Both 
Tissue inhibitor of metalloproteinases-1 TIMP-1 Both 
Tissue inhibitor of metalloproteinases-3 TIMP-3 Both 
Tissue inhibitor of metalloproteinases-4 TIMP-4 Both 
Urokinase plasminogen activator uPA Both 
Vimentin - Mesenchymal 
 
4.3 Selection of biomarker gene 
 
The above panel of candidate genes was tested following an initial phase of 
recruitment, which yielded a ‘test group’ – a subset of the final study cohort. In this 
phase, 354 samples were selected from the first 425 patients recruited to represent 
the relevant pathology groups. For these and subsequent biomarker analyses, 
pathology groups were separated along the lines described in chapter 3, with the 
important distinction that cases with oesophageal mucosal pathology (oesophageal 
malignancy and Barrett’s oesophagus) were assigned to their own groups for 
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separate analyses. This was done on the basis that the expression of genes of 
interest could be altered in oesophageal mucosal disease as well as in that of the 
gastric mucosa. One difficulty encountered in implementing this distinction was that 
not all patients whose endoscopy report included mention of Barrett’s oesophagus 
(BO) had biopsies of the distal oesophagus taken to substantiate the diagnosis. 
These cases were therefore excluded from both the gastric ‘control’ group, and from 
the ‘Barrett’s oesophagus’ pathology group as the endoscopic diagnosis of BO is 
notoriously unreliable. When there was an unsubstantiated case of BO in the 
presence of gastric preneoplasia, then that case was counted in the relevant gastric 
pathology group. 
 
As described previously, there were 19 cases in whom a complete set of serum and 
biopsy samples were not obtained, hence the subsequent analyses were performed 
on a total cohort of 1381 cases. As outlined previously, there were 29 additional 
cases whose gastric histology dataset was incomplete (i.e. only antral or only corpus 
samples were taken/analysed). Once cases of gastric cancer, oesophageal cancer and 
histologically proven BO were counted, there were 18 cases of endoscopically 
reported BO without histological support for that diagnosis. Of these, there was 
histological evidence of gastric preneoplasia in 6 individuals and these cases were 
included in the relevant gastric pathology group. The remaining 12 cases were 
removed from further analyses. The ‘pathology’ groups in this analysis are shown in 
Table 4-2. One of the groups listed is ‘normal gastric histology but H. pylori histology 
positive’. This group comprises those individuals in whom the study histopathologist 
reported normal mucosa, but in whom the local hospital pathologist had identified 
H. pylori organisms. We amalgamated small groups into larger categorical groups for 
some analyses. For example, reactive gastritis and foveolar hyperplasia were 
combined into ‘benign disease’ and intestinal metaplasia, atrophy and dysplasia (of 
any grade) were combined into ‘preneoplasia’. 
 
Patient samples were assayed by qPCR for each putative biomarker gene’s 
expression and for that of the reference gene (GAPDH). The relative mRNA 
abundance values for each gene of interest were calculated by normalising the 
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mRNA abundance measured by PCR to that of the reference gene in order to control 




Table 4-2 Gastric pathology groups and numbers of included patients. FH=foveolar hyperplasia; IM=intestinal 
metaplasia; LGD=low-grade dysplasia; HGD=high-grade dysplasia 
 ‘Test’ group n=354 
Total cohort 
n=1381 
Gastric histopathology group 
Number of patients Number of patients 
n % n % 
Normal gastric histology 99 28.0 444 32.2 
Normal histology but H. pylori serology+ 33 9.3 140 10.1 
Normal histology but H. pylori histology+ 0 0.0 21 1.5 
Gastritis B - Antrum 5 1.4 23 1.7 
Gastritis B - Corpus 7 2.0 30 2.2 
Gastritis B - Pangastric 24 6.8 79 5.7 
Gastritis C - Antrum 21 5.9 39 2.8 
Gastritis C - Corpus 4 1.1 5 0.4 
Gastritis C - Pangastric 7 2.0 7 0.5 
FH - Antrum 37 10.5 165 11.9 
FH - Corpus 2 0.6 7 0.5 
FH - Pangastric 4 1.1 7 0.5 
Atrophy - Antrum 7 2.0 19 1.4 
Atrophy - Corpus 12 3.4 55 4.0 
Atrophy - Pangastric 2 0.6 5 0.4 
IM - Antrum 34 9.6 111 8.0 
IM - Corpus 4 1.1 16 1.2 
IM - Pangastric 4 1.1 19 1.4 
IM and Atrophy - Antrum 4 1.1 24 1.7 
IM and Atrophy - Corpus 16 4.5 44 3.2 
IM and Atrophy - Pangastric 3 0.8 5 0.4 
LGD - Antrum 3 0.8 6 0.4 
LGD - Corpus 1 0.3 5 0.4 
LGD - Pangastric 0 0.0 0 0.0 
HGD - Antrum 0 0.0 0 0.0 
HGD - Corpus 0 0.0 1 0.1 
HGD - Pangastric 2 0.6 2 0.1 
Barrett’s oesophagus 8 2.3 54 3.9 
Endoscopy report of Barrett’s oesophagus 2 0.6 12 0.9 
Oesophageal cancer 3 0.8 11 0.8 
Gastric cancer 3 0.8 12 0.9 
Gastric ulcer only 0 0.0 10 0.7 
Antrum MALT only 0 0.0 3 0.2 
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Using the ‘test group’ of patients, we compared the relative mRNA abundances of 
each gene of interest in four groups – histology normal, benign gastric disease, 
gastritis B (H. pylori related gastritis) and preneoplasia. The results are shown in 
Figure 4-1. 
 
In the ‘test group’, only 7 of the 12 proposed biomarker genes exhibited a significant 
difference (p<0.0001, Kruskal-Wallis 1-way ANOVA/Dunn’s multiple comparison test) 
in mRNA relative abundance when comparing subjects with normal gastric histology 
to those with gastric mucosal preneoplasia (IGF-1, IGF-2, MMP-1, MMP-7, TIMP-1, 
TIMP-4 and uPA). Of these, only 3 (TIMP-1, MMP-1 and MMP-7) also exhibited a 
significant increase when comparing benign disease to preneoplasia groups and in 
these three, only MMP-7 showed a highly statistically significant change (p<0.0001, 
Kruskal-Wallis 1-way ANOVA/Dunn’s multiple comparison test).  
 
In the same cohort, mRNA abundances were significantly increased in ‘benign 
disease’ when compared with ‘normal’ samples for only 7 of the 12 genes of interest 
(IGF-1, IGF-2, MMP-1, MMP-7, TIMP-1, TIMP-4 and uPA). Of these, 6 also exhibited a 
significant difference when comparing ‘normal’ to ‘gastritis B’ subjects (IGF-1, IGF-2, 
MMP-1, MMP-7, TIMP-1, and uPA). Only the three previously highlighted genes of 
interest (TIMP-1, MMP-1 and MMP-7) yielded a significant difference in all 
categories described and MMP-7 showed the greatest difference across all four 
comparisons. In the ‘test group’, none of the proposed biomarkers were shown to 
discriminate between subjects with gastritis B and those with gastric preneoplasia. 
 
On the basis of these findings, MMP-7 was selected as the most promising 





Figure 4-1 Mean relative abundance of mucosal biomarker mRNA in subjects with normal gastric histology, 




4.4 Mucosal expression of MMP-7 
 
As described above, cDNA obtained from gastric corpus mucosal pinch biopsies was 
assayed for MMP-7 relative abundance by qPCR. Samples were selected for assay 
based on the histology group to which they belonged. In total, 917 of 1381 samples 
were assayed for MMP-7 relative abundance. The numbers assayed by group are 
summarised in table 4-3. The mean value across the entire cohort was 3.10 (SD 
35.80, SEM 1.182, median 0.3972). We performed Grubbs’ test to identify outliers 
with a two-sided significance level of 0.05. Only one outlier was identified. That 
subject had been assigned to the ‘foveolar hyperplasia – antrum’ pathology group 
and the relative abundance of MMP-7 was 1057.23 as compared to a mean in that 
group excluding the outlier of 1.51. The patient information for the outlier was 
examined (including local hospital pathology report, medication history and medical 
history), but no explanation for such a high mucosal expression of the gene was 
identified. The result was assumed to be spurious and to simplify further analysis this 
patient was excluded. 
 
4.4.1 Control Group 
 
As outlined in section 2.1, we collected data for a large number of variables for each 
patient, many of which were included based on the suspicion that they might 
influence the expression of putative biomarkers. In order that accurate assessments 
of the effect of these variables on mucosal MMP-7 expression could be made, a 
‘control’ group was required. We generated this group from the subjects whose 
gastric histology was reported as “normal” by both the study and local hospital 
pathologists. We then excluded patients whose medical history included chronic 
inflammatory diseases, chronic obstructive pulmonary disease (COPD), ischaemic 
heart disease (IHD) or active cancer. We also removed patients who had reported 
recent use of NSAIDs, aspirin or PPIs and those who had elevated fasting serum 
gastrin concentrations (>40pM). There were 36 patients who had gastric MMP-7 
mRNA relative abundance measured and who fulfilled the above criteria. They are 
 
148 
referred to in the subsequent analyses as the ‘control’ group. The mean values for 
relative abundance of MMP-7 mRNA was 0.549 (SEM ± 0.148) in the ‘normal 
histology’ group as compared to 0.230 (SEM ± 0.054) in this ‘control’ group. The 
difference between the means of the two groups was significant (p=0.044, two-
tailed unpaired t-test/Welch’s correction). The data are illustrated in Figure 4-2. 
 
 
Figure 4-2 Relative mRNA abundance in subjects with normal gastric histology compared with the 'refined' 




Table 4-3 Gastric pathology groups and numbers of patients included for MMP-7 assay. 











n n % % 
Normal gastric histology 444 185 41.7 13.4 
Normal histology but H. pylori serology+ 140 70 50.0 5.1 
Normal histology but H. pylori histology+ 21 7 33.3 0.5 
Gastritis B - Antrum 23 15 65.2 1.1 
Gastritis B - Corpus 30 30 100.0 2.2 
Gastritis B - Pangastric 79 77 97.5 5.6 
Gastritis C - Antrum 39 34 87.2 2.5 
Gastritis C - Corpus 5 5 100.0 0.4 
Gastritis C - Pangastric 7 7 100.0 0.5 
FH - Antrum 165 120 72.7 8.7 
FH - Corpus 7 7 100.0 0.5 
FH - Pangastric 7 7 100.0 0.5 
Atrophy - Antrum 19 17 89.5 1.2 
Atrophy - Corpus 55 53 96.4 3.8 
Atrophy - Pangastric 5 5 100.0 0.4 
IM - Antrum 111 98 88.3 7.1 
IM - Corpus 16 16 100.0 1.2 
IM - Pangastric 19 18 94.7 1.3 
IM AND Atrophy - Antrum 24 15 62.5 1.1 
IM AND Atrophy - Corpus 44 44 100.0 3.2 
IM AND Atrophy - Pangastric 5 5 100.0 0.4 
LGD - Antrum 6 6 100.0 0.4 
LGD - Corpus 5 5 100.0 0.4 
LGD - Pangastric 0 0 - - 
HGD - Antrum 0 0 - - 
HGD - Corpus 1 1 100.0 0.1 
HGD - Pangastric 2 2 100.0 0.1 
Barrett’s oesophagus 54 29 53.7 2.1 
Endoscopy report of Barrett’s oesophagus 12 7 58.3 0.5 
Oesophageal Cancer 11 9 81.8 0.7 
Gastric Cancer 12 10 83.3 0.7 
Gastric Ulcer only 10 10 100.0 0.7 
Antrum MALT only 3 3 100.0 0.2 
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4.5 Mucosal expression of MMP-7 and gastric mucosal pathology 
 
We compared the mean relative mRNA abundance of mucosal MMP-7 in our various 
gastric pathology groups with that in the control group. 
 
Our aims were to examine the effect of the presence of gastric preneoplasia on the 
mucosal expression of MMP-7; to determine how gastric corpus mucosal MMP-7 
expression varied with topographical distribution of gastric mucosal preneoplasia; to 
determine how mucosal MMP-7 expression varied with “severity” of gastric mucosal 
preneoplasia and to establish whether the relative mRNA abundance of MMP-7 
could reliably distinguish between patients with gastric mucosal preneoplasia and 
those with either histologically normal biopsy specimens; “benign” gastric mucosal 
changes (including reactive gastritis (gastritis C) and foveolar hyperplasia) or H. pylori 
associated gastritis. 
 
The comparisons of relative mRNA abundance of MMP-7 are shown for the major 
groups in Figure 4-3. 
 
Figure 4-3 Mean relative mRNA abundance of MMP-7 in controls (n=36) and major gastric pathology groups: 
gastritis C (n=46); foveolar hyperplasia (n=133); gastritis B (n=122); preneoplasia (n=285) and gastric cancer 




As described before, mean relative mRNA abundance of MMP-7 in the control group 
was 0.2298 (median 0.0905, SEM 0.0537). There were small observed increases in 
the abundances seen in gastritis C (mean 0.5839, median 0.1221, SEM 0.1452), 
foveolar hyperplasia (mean 1.423, median 0.2014, SEM 0.3569) and gastric cancer 
(mean 1.336, median 0.8375, SEM 0.4612) groups though none were statistically 
significant (Kruskal-Wallis 1-way ANOVA/Dunn’s multiple comparison test). 
 
There was however a highly statistically significant difference (p<0.0001, Kruskal-
Wallis 1-way ANOVA/Dunn’s multiple comparison test) between the relative mRNA 
abundance of MMP-7 in controls and pathology groups for both H. pylori associated 
gastritis B (mean 1.423, median 0.2014, SEM 0.3569) and for the combined 
preneoplasia group (mean 3.485, median 0.7322, SEM 0.7996). 
 
For completeness, we also compared mucosal mRNA abundance of MMP7 in these 
pathology groups with the ‘normal’ histology group described in section 4.4.1,in 
place of the ‘control’ group. The results are shown in Figure 4-4. As before, there 
was a highly statistically significant difference (p<0.0001, Kruskal-Wallis 1-way 
ANOVA/Dunn’s multiple comparison test) between the mean relative mRNA 
abundance of MMP-7 in the ‘normal histology’ group and that in both H. pylori 




Figure 4-4 Mean relative mRNA abundance of MMP-7 in normal histology group (n=185) and major gastric 
pathology groups: gastritis C (n=46); foveolar hyperplasia (n=133); gastritis B (n=122); preneoplasia (n=285) and 
gastric cancer (n=10) (Kruskal-Wallis 1-way ANOVA). 
 
 
4.5.1 Variation in mucosal MMP-7 expression with distribution of disease 
 
As described in chapter 3, we were able to separate study subjects with gastric 
mucosal disease into groups depending on the topographical distribution of their 
disease as determined by histological examination of antral and corpus biopsies 
separately. Relative abundance of mucosal MMP-7 mRNA was measured in gastric 
tissue obtained from the corpus only and so the effect on MMP-7 relative mRNA 
abundance of topographical variation is important to determine. If “antral only” 
gastric mucosal preneoplasia is seen to result in an increase in corpus mucosal MMP-
7 expression, then our data from this patient group will contribute to the validation 
or otherwise of the gene as a potential biomarker for preneoplasia. If however, 
MMP-7 mRNA expression in corpus mucosa is influenced only by mucosal 
remodelling at the same site then we ought only to interpret corpus-inclusive 
disease groups. We therefore compared antral-only, corpus-only and pangastric 




Figure 4-5 Mean MMP-7 relative mRNA abundance for controls (n=36) and different preneoplasia disease 
distributions: pangastric (n=30); corpus predominant (n=119); antrum predominant (n=136) (Kruskal-Wallis 1-
way ANOVA). 
 
There was a significant difference observed in the relative mRNA abundance of 
MMP-7 in all groups when compared with controls (p<0.0001, Kruskal-Wallis 1-way 
ANOVA/Dunn’s multiple comparison test). However the effect was substantially 
greater in the corpus-only pathology groups than in either the antrum-only (where 
the difference itself was also statistically significant) or pangastric groups. The data 
are summarised in Table 4-4.  
 
For completeness, we again repeated these analyses using the ‘normal histology’ 
group as a comparator in place of the ‘control’ group. The data are illustrated in 
Figure 4-6. As before, there was a significant difference observed in the relative 
mRNA abundance of MMP-7 in all groups when compared with the normal histology 
group (p<0.0001, Kruskal-Wallis 1-way ANOVA/Dunn’s multiple comparison test). 
Similarly, the effect was substantially greater in the corpus-only pathology groups 





Figure 4-6 Mean MMP-7 relative mRNA abundance for normal histology group (n=185) and different 
preneoplasia disease distributions: pangastric (n=30); corpus predominant (n=119); antrum predominant (n=136) 
(Kruskal-Wallis 1-way ANOVA). 
 
Table 4-4 Relative abundance of MMP-7 in different disease distributions. 
 Controls Antrum Corpus Pangastric 
Number of patients 36 136 119 30 
     
Minimum 0.01243 0.00812 0.023 0.02393 
25% Percentile 0.04154 0.1317 0.518 0.2204 
Median 0.09052 0.397 1.424 0.7194 
75% Percentile 0.2913 1.062 4.269 2.078 
Maximum 1.539 60.98 200.2 16.27 
     
Mean 0.2298 2.061 5.436 2.198 
Std. Deviation 0.3221 6.604 19.46 3.686 
Std. Error 0.05368 0.5663 1.784 0.6729 
Fold change 1.000 8.969 23.655 9.565 
Lower 95% CI 0.1208 0.9411 1.904 0.8214 
Upper 95% CI 0.3388 3.181 8.969 3.574 
 
 
These results are interesting – we might have expected an attenuated increase in 
corpus expression of MMP-7 when the histology reflected antral predominant 
disease and the data confirm this. The effect seen in pangastric disease is however 
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somewhat unexpected. We anticipated a similar effect on corpus MMP-7 expression 
in corpus-inclusive disease whether the antrum was involved or not, but observed a 
smaller increase in the ‘pangastric’ group than in the ‘corpus only’ group. The 
number of subjects in the ‘pangastric’ group is small hence the difference between 
the relative mRNA abundance of MMP-7 in this and the ‘corpus only’ group was not 
statistically significant. Further study would be required to adequately characterise 
this response. 
 
4.5.2 Mucosal expression of MMP-7 and severity of preneoplasia 
 
As described earlier, we separated study subjects with gastric preneoplasia into 
pathology groups reflecting the severity of mucosal pathology. We compared these 
groups with controls and each other to determine the effect of preneoplastic disease 
severity on mucosal MMP-7 expression. The data are shown in Figure 4-7.  
 
 
Figure 4-7 Mean relative mRNA abundance of MMP-7 for controls (n=36) and groups of different mucosal 
preneoplastic disease ‘severity’: atrophy (n=75); IM & atrophy (n=64); IM only (n=132); dysplasia (n=14) and 
gastric cancer (n=10) (Kruskal-Wallis 1-way ANOVA). 
 
There was a significant increase in the relative mRNA abundance of MMP-7 in 
‘atrophy’, ‘intestinal metaplasia & atrophy’ and ‘intestinal metaplasia alone’ groups 
(p<0.0001, Kruskal-Wallis 1-way ANOVA/Dunn’s multiple comparison test). We 
observed a smaller increase in MMP-7 mRNA abundance in the ‘dysplasia’ and 
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‘gastric cancer’ groups though these were not statistically significant. Interestingly, 
the magnitude of the change in expression was smaller in the ‘intestinal metaplasia 
only’ group than in the groups showing histological evidence of gastric atrophy and 
the differences between the former and latter groups were statistically significant. 





As before, we repeated this analysis using the ‘normal histology’ group as a 
comparator in place of the ‘control’ group. The data are illustrated in Figure 4-8. The 
increases observed in MMP-7 mRNA abundance remained highly statistically 





Figure 4-8 Mean relative mRNA abundance of MMP-7 for normal histology group (n=185) and groups of different 
mucosal preneoplastic disease ‘severity’: atrophy (n=75); IM & atrophy (n=64); IM only (n=132); dysplasia (n=14) 



























































Table 4-5 Comparison of MMP-7 relative mRNA abundance between groups of varying gastric preneoplastic 
severity. 
 Controls Atrophy 
IM & 
Atrophy IM only Dysplasia 
Gastric 
Cancer 
Number of values 36 75 64 132 14 10 
       
Minimum 0.01243 0.06839 0.04009 0.00812 0.03477 0.03443 
25% Percentile 0.04154 0.4234 0.4388 0.1262 0.08343 0.09882 
Median 0.09052 0.9963 1.188 0.4225 0.3697 0.8375 
75% Percentile 0.2913 3.631 4.027 1.411 1.856 2.722 
Maximum 1.539 50.33 200.2 60.98 5.622 4.099 
       
Mean 0.2298 4.266 5.929 2.097 1.215 1.336 
Std. Deviation 0.3221 9.009 25.06 6.418 1.663 1.459 
Std. Error 0.05368 1.04 3.132 0.5586 0.4445 0.4612 
Fold change 1.000 18.564 25.801 9.125 5.287 5.814 
Lower 95% CI 0.1208 2.193 -0.3308 0.9915 0.2551 0.2924 
Upper 95% CI 0.3388 6.339 12.19 3.202 2.176 2.379 
 
 
To mitigate for any potential effects of the topographical variation in mucosal 
disease distribution, we performed the same analysis for patients with corpus-only 
disease. The data are shown in Figure 4-9. 
 
Figure 4-9 Mean relative mRNA abundance of MMP-7 in controls (n=36) and groups of varying corpus 




The same variation in MMP-7 expression was seen in corpus-only disease as in the 
overall preneoplasia analysis. The relative mRNA abundance of MMP-7 was 
significantly higher in corpus only preneoplasia groups than in controls (p<0.0001, 
Kruskal-Wallis 1-way ANOVA/Dunn’s multiple comparison test). Additionally, the 
relationship between pathology groups was preserved – ‘atrophy and ‘IM & atrophy’ 
both exhibited a significantly higher relative mRNA abundance of MMP-7 than did 
the ‘IM only’ group. The data are summarised in Table 4-6. In the overall analysis 
outlined above, the ‘atrophy’, ‘IM & atrophy’ and ‘IM only’ groups exhibited a fold-
change in mean MMP-7 relative mRNA abundance compared with controls of 18.6, 
25.8 and 9.1 respectively. In the corpus-pathology only analysis, the corresponding 
values were similar at 22.7, 32.2 and 11.0 respectively. 
 
Table 4-6 Comparison of MMP-7 relative mRNA abundance between groups of varying corpus preneoplastic 
severity. 
 Controls Atrophy 
IM & 
Atrophy IM only 
Number of values 36 53 44 16 
 
    Minimum 0.01243 0.06839 0.04009 0.023 
25% Percentile 0.04154 0.5616 0.8211 0.1894 
Median 0.09052 1.911 1.432 0.5463 
75% Percentile 0.2913 5.498 4.403 3.282 
Maximum 1.539 50.33 200.2 18.67 
 
    Mean 0.2298 5.206 7.39 2.516 
Std. Deviation 0.3221 10.23 29.92 4.664 
Std. Error 0.05368 1.405 4.511 1.166 
Fold change 1.000 22.654 32.158 10.949 
Lower 95% CI 0.1208 2.387 -1.707 0.03102 





4.5.3 Comparative analysis of MMP-7 expression in preneoplastic and benign 
gastric mucosal disease 
 
The altered mucosal expression of MMP-7 in gastric preneoplasia suggests that the 
gene products might be useful biomarkers of the same. In the case of gastric 
preneoplasia however, the performance of any putative biomarker is influenced to 
some degree by not only the ability to discriminate between ‘disease’ and ‘normal’, 
but also to distinguish preneoplastic mucosal disease from pathological changes 
unrelated to neoplasia development. We therefore compared the relative mRNA 
abundances of MMP-7 in such so-called ‘benign’ groups with the previously defined 
preneoplasia groups. The results are shown in Figure 4-10. 
 
 
Figure 4-10 Mean relative mRNA abundance of MMP-7 in benign gastric disease groups: gastritis B (n=122); 
gastritis C (n=46) and foveolar hyperplasia (n=133), compared with preneoplastic disease (n=285) (Kruskal-Wallis 
1-way ANOVA). 
 
The relative mRNA abundance of MMP-7 was significantly higher in the combined 
preneoplasia group when compared to either of the ‘benign’ groups i.e. reactive 
gastritis (Gastritis C) or foveolar hyperplasia. The same was true when comparing H. 
pylori associated gastritis (Gastritis B) to benign groups. The observed difference 





In view of the discrepancy between the MMP-7 expression in preneoplasia groups of 
different severity, we compared these groups to the benign groups individually. The 
results are illustrated in Figure 4-11. 
 
 
Figure 4-11 Mean relative mRNA abundance of MMP-7 in benign gastric disease and pathology groups of varying 
preneoplastic severity: gastritis C (n=46); foveolar hyperplasia (n=133); atrophy (n=75); IM & atrophy (n=64) and 
IM only (n=132) (Kruskal-Wallis 1-way ANOVA). 
 
Unsurprisingly (given the results described in section 4.3.2), the ‘atrophy’ and ‘IM & 
atrophy’ groups exhibited the largest differences in MMP-7 expression when 
compared to the ‘benign’ groups and these differences were highly statistically 
significant. There was a small and statistically insignificant difference in the relative 
mRNA abundance of MMP-7 in the ‘IM only” preneoplasia group when compared 
with either of the ‘benign’ groups. This pattern was unaltered when we repeated the 
analyses with corpus-only disease groups. The implication of this finding is that for 
patients with gastric mucosal intestinal metaplasia, a ‘diagnostic test’ based on the 




4.5.4 Mucosal expression of MMP-7 and Barrett’s oesophagus 
 
As described earlier, we recorded both endoscopic and histological diagnoses of 
Barrett’s oesophagus on the basis that oesophageal mucosal disease might exert an 
effect on gastric MMP-7 expression. Thus, cases of oesophageal disease including 
neoplasia and Barrett’s oesophagus were excluded from analysis of gastric mucosal 
MMP-7 expression. For completeness, we examined the effect on expression of 
MMP-7 in the gastric corpus of the presence of Barrett’s oesophagus. The data are 
illustrated in Figure 4-12. 
 
We found that corpus expression of MMP-7 was significantly altered in the presence 
of Barrett’s oesophagus. As described before, mean relative abundance of MMP-7 in 
the control group was 0.2298 (median 0.0905, SEM 0.0537). In the Barrett’s 
oesophagus group, the mean relative abundance of MMP-7 was 1.752 (median 
0.4176, SEM 0.952) and was significantly greater (p=0.0014, Mann-Whitney test) 
than controls. The differences between the preneoplasia (mean 3.485, median 
0.7322, SEM 0.7996) and gastritis B (mean 1.681, median 0.7018, SEM 0.2249) 
groups were also statistically significant (p=0365 and 0.0269 respectively). 
 
Figure 4-12 Mean relative mRNA abundance of gastric MMP-7 in Barrett’s oesophagus (n=29) compared with 
preneoplastic (n=285) and benign disease groups gastritis B (n=122); gastritis C (n=46), and controls (n=36) (two-




To mitigate the effects of hypergastrinaemia on gastric mucosal MMP-7 expression 
on this analysis (described in section 4.5.6), we removed subjects whose fasting 
serum gastrin concentration was greater than 40pM. There were 12 individuals in 
this group with ‘normal’ fasting serum gastrin concentration. The repeated analysis 
is illustrated in Figure 4-13. In the normogastrinaemic Barrett’s oesophagus group, 
the mean relative mRNA abundance of MMP-7 was 1.261 (median 0.4714, SEM 
0.746) and was significantly greater (p=0.0128, Mann-Whitney test) than controls. 
There was no statistically significant difference between this normogastrinaemic 
Barrett’s oesophagus group and the other described pathology groups.  
 
 
Figure 4-13 Mean relative mRNA abundance of MMP-7 in normogastrinaemic Barrett’s oesophagus (n=12) 
compared with preneoplastic (n=285) and benign disease groups gastritis B (n=122); gastritis C (n=46), and 
controls (n=36) (two-tailed Mann-Whitney test). 
 
4.5.5 Mucosal expression of MMP-7 and H. pylori CagA serovar 
 
Several authors have previously described the relationship between H. pylori 
induced gastric inflammation and MMP-7 expression. The data above demonstrate a 
significant increase in mucosal expression of MMP-7 in our study cohort when H. 
pylori associated inflammation (Gastritis B) was present. As outlined in chapter 3, we 
also serotyped all H. pylori positive patients by CagA status. We therefore compared 
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the effect of CagA positive H. pylori infection on MMP-7 expression to CagA negative 
H. pylori infection and controls. The results are illustrated in Figure 4-14. We 
examined the difference in relative abundance of gastric MMP-7 for CagA negative 
and positive subjects in a) all H. pylori positive (by histology or RUT) subjects, b) all 
subjects reported to have H. pylori associated gastritis (gastritis B) by the study 
pathologist and c) all subjects reported to have corpus-inclusive H. pylori associated 
gastritis (gastritis B) by the study pathologist. In each case, both CagA positive and 
CagA negative subjects exhibited significantly higher MMP-7 expression than 
controls (p<0.0001, two-tailed Mann-Whitney tests). The expected and observed 
higher relative abundance in CagA positive subjects was not however statistically 
significant in any group (two-tailed Mann-Whitney tests). 
 
 
Figure 4-14 Mean relative mRNA abundance of MMP-7 in CagA positive and negative patients compared with 
controls for a) all H. pylori positive subjects, b) all subjects with H. pylori associated gastritis on histology and c) 




4.5.6 Mucosal expression of MMP-7 and fasting serum gastrin concentration 
 
Our own group has previously reported an association between hypergastrinaemia 
and increased MMP-7 expression in human and murine stomachs(126). We 
therefore examined our study cohort for evidence of the same effect. For all subjects 
for whom both fasting serum gastrin concentration and mucosal MMP-7 relative 
mRNA abundance were measured (n=916), we observed a significant increase in the 
latter in those with ‘moderate’ (fold change in mean=1.38, p=0.0006) and ‘severe’ 
(fold change in mean=3.79, p<0.0001, two-tailed Mann-Whitney tests) 
hypergastrinaemia. When combining ‘moderate’ and ‘severe’ hypergastrinaemic 
groups, the fold change in mean relative mRNA abundance of MMP-7 was 2.47 
(p<0.0001, two-tailed Mann-Whitney test). The results are illustrated in Figure 4-15. 
 
 
Figure 4-15 Mean relative abundance of MMP-7 in a) normal, moderate and severe hypergastrinaemia; and in b) 
normal and high serum gastrin groups (two-tailed Mann-Whitney tests). 
 
These changes may well reflect the underlying mucosal pathology and so we 
compared hypergastrinaemic with normogastrinaemic subjects in those with 
histologically normal gastric mucosa (n=261). The data are shown in Figure 4-16. In 
this cohort of patients, we observed no significant difference between 
normogastrinaemic subjects and those with moderate hypergastrinaemia. ‘Severe’ 
hypergastrinaemia however conferred a fold change in the mean relative mRNA 
abundance of MMP-7 of 7.42 compared with normogastrinaemic subjects (p<0.0001, 
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two-tailed Mann-Whitney test). Combining hypergastrinaemic groups gave a fold 
change in mean relative mRNA abundance of MMP-7 of 3.67 (p=0.0016, two-tailed 
Mann-Whitney test). These data suggest an independent effect of fasting serum 
gastrin concentration on gastric mucosal MMP-7 mRNA abundance in keeping with 
previous observations.  
 
 
Figure 4-16 Mean relative mRNA abundance of MMP-7 in subjects with normal gastric mucosal histology and a) 
normal, moderate and severe hypergastrinaemia; and in b) normal and high serum gastrin groups (two-tailed 
Mann-Whitney tests). 
 
4.5.7 The effect on mucosal expression of MMP-7 of commonly used drugs 
 
At enrolment, we collected information about prescription or over-the-counter 
(OTC) medication use from each study subject. In particular, we recorded the recent 
use of common drugs known to affect the gastric mucosa: proton pump inhibitors 
(PPIs), non-steroidal anti-inflammatory drugs (NSAIDs) and aspirin. In the group 
reported to have normal gastric mucosal histology, we compared the relative mRNA 
abundance of MMP-7 in those who reported recent use of these drugs with those 
who denied it. The results are depicted in Figure 4-17. There was no significant 
change in the relative mRNA abundance of MMP-7 conferred by either PPI or aspirin 
use. In contrast, subjects who reported recent NSAID use exhibited a fold change in 






Figure 4-17 Mean relative mRNA abundance of MMP-7 in users and non-users of a) PPIs, b) aspirin and c) NSAIDs 
(two-tailed Mann-Whitney test). 
 
These data suggest an independent role of NSAIDs in inducing gastric MMP-7 
expression. We previously published data from this study cohort asserting that other 
extracellular proteolytic protein systems might be implicated in the gastric mucosal 





4.6 Serum concentration of MMP-7 
 
As described above, we determined MMP-7 concentrations in the sera of selected 
subjects by ELISA. We obtained data for 606 patients whose mucosal MMP-7 relative 
mRNA abundance had previously been determined by qPCR. The numbers of 
patients selected to represent the various ‘pathology’ groups are listed in Table 4-7. 
 
4.6.1 Correlation between mucosal mRNA abundance and serum concentration of 
MMP-7 
 
We determined the correlation between the relative abundance of gastric mucosal 
MMP-7 mRNA and serum MMP-7 concentration by comparing these data from 
individual subjects. The data are illustrated in Figure 4-18 and suggest no significant 
correlation between the two sets. 
 
 
Figure 4-18 Correlation between serum concentration and mucosal relative abundance of MMP-7 mRNA. 
  


























Table 4-7 Gastric pathology groups and numbers of patients included for serum MMP-7 assay. 











n n % % 
Normal gastric histology 444 129 29.1 9.2 
Normal histology but H. pylori serology+ 140 9 6.4 0.6 
Normal histology but H. pylori histology+ 21 15 71.4 1.1 
Gastritis B - Antrum 23 16 69.6 1.1 
Gastritis B - Corpus 30 0 0.0 0.0 
Gastritis B - Pangastric 79 64 81.0 4.6 
Gastritis C - Antrum 39 7 17.9 0.5 
Gastritis C - Corpus 5 0 0.0 0.0 
Gastritis C - Pangastric 7 2 28.6 0.1 
FH - Antrum 165 85 51.5 6.1 
FH - Corpus 7 3 42.9 0.2 
FH - Pangastric 7 3 42.9 0.2 
Atrophy - Antrum 19 12 63.2 0.9 
Atrophy - Corpus 55 52 94.5 3.7 
Atrophy - Pangastric 5 5 100.0 0.4 
IM - Antrum 111 43 38.7 3.1 
IM - Corpus 16 10 62.5 0.7 
IM - Pangastric 19 24 126.3 1.7 
IM AND Atrophy - Antrum 24 8 33.3 0.6 
IM AND Atrophy - Corpus 44 44 100.0 3.1 
IM AND Atrophy - Pangastric 5 5 100.0 0.4 
LGD - Antrum 6 3 50.0 0.2 
LGD - Corpus 5 5 100.0 0.4 
LGD - Pangastric 0 0 0.0 0.0 
HGD - Antrum 0 0 0.0 0.0 
HGD - Corpus 1 0 0.0 0.0 
HGD - Pangastric 2 0 0.0 0.0 
Barrett’s oesophagus 54 39 72.2 2.8 
Endoscopy report of Barrett’s oesophagus 12 5 41.7 0.4 
Oesophageal Cancer 11 6 54.5 0.4 
Gastric Cancer 12 7 58.3 0.5 
Gastric Ulcer only 10 2 20.0 0.1 
Antrum MALT only 3 3 100.0 0.2 
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4.6.2 Control group 
 
The cohort described here included 18 subjects from the control group described 
above. In this cohort however, there was no significant difference in mean serum 
MMP-7 concentration (Figure 4-19) between the ‘control’ group (3.627 ng/ml, 
median 2.830, SEM 0,5686) and the ‘normal histology, H. pylori negative’ group 
(n=129, 3.520 ng/ml, median 3.03 ng/ml, SEM 0.1645). For subsequent analyses, we 
have therefore compared ‘pathology’ groups with the ‘normal histology, H. pylori 
negative’ group, hereafter referred to as ‘normal histology’. 
 
 
Figure 4-19 Mean serum MMP-7 concentration - comparison between subjects with normal gastric histology and 





4.6.3 Serum MMP-7 concentration and gastric mucosal pathology 
 
Using this commercially available ELISA kit, we set out to determine the effect of 
gastric mucosal pathology on the measured fasting serum concentration of MMP-7. 
Although we did not anticipate as pronounced an effect as that seen with the 
mucosal mRNA abundance PCR assays, we made the same comparisons to those 
described above with similar aims, namely: to determine the effect of presence of 
gastric preneoplasia on the serum concentration of MMP-7; to establish the 
usefulness of serum MMP-7 concentration for distinguishing between preneoplastic 
and ‘benign’ gastric mucosal disease and to determine how the serum concentration 
of MMP-7 varied with ‘severity’ of preneoplasia.  
 
We compared the mean serum MMP-7 concentrations in the various pathology 
groups. The data are illustrated in Figure 4-20. 
 
Figure 4-20 Mean serum MMP-7 concentration comparison between subjects with normal histology (n=129) 
various pathology groups: foveolar hyperplasia (n=91); gastritis B (n=87); preneoplasia (n=211) and gastric cancer 




The mean serum concentration of MMP-7 in the ‘normal histology’ group was 3.520 
ng/ml (median 3.03 ng/ml, SEM 0.1645). There was no significant increase observed 
in any of the other groups (Gastritis B, foveolar hyperplasia or gastric cancer) except 
for preneoplasia (p<0.01, Kruskal-Wallis 1-way ANOVA/Dunn’s multiple comparison 
test) where the mean was 4.279 ng/ml (median 3.700 ng/ml, SEM 0.1730). Again, 
our study was inadequately powered to determine the role of MMP-7 in gastric 
cancer. For these analyses there were only 7 cases included in the gastric cancer 
group where the mean serum concentration of MMP-7 was 7.406 ng/ml (median 
4.200 ng/ml, SEM 2.483) and the difference from that of the ‘normal’ group was not 
statistically significant (Kruskal-Wallis 1-way ANOVA/Dunn’s multiple comparison 
test).  
 
Furthermore, the same statistical interpretation of the difference between the 
preneoplasia group and the included ‘benign’ gastric disease groups. There were no 
significant differences between the preneoplasia group and either ‘gastritis B’ or 
‘foveolar hyperplasia’. This observation would suggest that the use of this assay for 
the determination of serum MMP-7 concentration would not be useful in 
discriminating preneoplastic from benign gastric mucosal diseases. 
 
4.6.4 Serum concentration of MMP-7 and severity of preneoplasia 
 
In section 4.3.2, we described the variation in mucosal expression of MMP-7 with 
increasing ‘severity’ of gastric preneoplasia. We therefore repeated this comparison 
for serum MMP-7 concentration. The results are summarised in Figure 4-21. 
Although there was a small observed increase in all preneoplasia pathology groups 
compared with ‘normal’ subjects, none were statistically significant with the 
exception of the ‘intestinal metaplasia and atrophy’ group, in which the mean serum 
concentration of MMP-7 was 4.658 ng/ml (median 3.920 ng/ml, SEM 0.4161, p<0.05 




Figure 4-21 Mean serum MMP-7 concentration - comparison between subjects with normal gastric histology 
(n=129) and groups of varying preneoplastic ‘severity’: atrophy (n=69); IM & atrophy (n=57); IM only (n=77); 
dysplasia (n=8) and gastric cancer (n=7) (Kruskal-Wallis 1-way ANOVA). 
 
4.6.5 Serum concentration of MMP-7 and Barrett’s oesophagus 
 
We compared the major histology groups with the group comprising cases of 
Barrett’s oesophagus (Figure 4-22). There was a small increase in serum 
concentration of MMP-7 in the Barrett’s oesophagus group (mean 4.074 ng/ml, 
median 3.470 ng/ml, SEM 0.3379) compared with the normal histology group but 
this was not statistically significant. Similarly, the relationship between serum MMP-
7 concentration in the preneoplasia and Barrett’s oesophagus groups echoed that 
seen in the mucosal MMP-7 mRNA abundance assays though the difference in this 




Figure 4-22 Mean serum MMP-7 concentration - comparison between subjects with normal gastric histology 
(n=129), major gastric histology groups: foveolar hyperplasia (n=91); gastritis B (n=87) and preneoplasia (n=211); 
and Barrett’s oesophagus (n=39) (Kruskal-Wallis 1-way ANOVA). 
 
4.6.6 Serum concentration of MMP-7 as part of a ‘diagnostic test’ 
 
In section 3.5, we described the performance of conventional non-invasive 
biomarkers in identifying or excluding gastric mucosal preneoplasia in our study 
population. We concluded that a ‘test’ panel comprising serum pepsinogen 1/2 ratio, 
fasting serum gastrin concentration and H. pylori serology identified or excluded 
preneoplasia with high sensitivity (90.0%), specificity (74.4%) and positive/negative 
predictive values of 52.1% and 96.0% respectively. It might be expected that adding 
serum MMP-7 concentration might enhance the discriminative ability of this 
combined test.  
 
Alone, serum concentration of MMP-7 performs poorly as a diagnostic ‘test’ for 
gastric preneoplasia. The ROC curve is shown in Figure 4-23. The AUC was 0.61 
(p=0.0005, 95% CI: 0.5506 - 0.6747). Finding the approximate optimal cutoff in our 
study by drawing the tangent to the curve in parallel with its axis gives a serum 
MMP-7 concentration cutoff of 3.0ng/ml with a sensitivity and specificity of 66.4% 




Figure 4-23 ROC curve for serum MMP-7 concentration for the detection of gastric preneoplasia. 
 
For completeness, we combined this with the previously evaluated biomarkers listed 
above. For any given study subject, a ‘test’ was regarded as ‘positive’ if the serum PG 
1/2 ratio was <8.8 and/or the fasting serum gastrin ≥100pM and/or the H. pylori 
serology was positive and/or the serum concentration of MMP-7 was ≥3.0ng/ml. The 
results are summarised in Table 4-8. Sensitivity and negative predictive value were 
both substantially increased over the previous combination, but at the expense of 
specificity and positive predictive value. 
 
Table 4-8 Diagnostic performance serum MMP-7 concentration in combination with pepsinogen 1/2 ratio, H. 
pylori serology, histology and CagA serology. PPV = positive predictive value; NPV = negative predictive value. 
 Combined test 
 Test + Test - 
Preneoplasia 
+ 209 4 
Preneoplasia 
- 41 28 
   
Sensitivity % 98.1 
Specificity % 40.6 
PPV % 33.8 




4.6.7 Mucosal abundance of MMP-7 mRNA as part of a ‘diagnostic test’ 
 
Given the suboptimal performance of the ‘off-the-shelf’ MMP-7 ELISA as a diagnostic 
or screening test described in section 4.6.6, we hypothesised that a technique for 
determining serum MMP-7 concentration which better reflects gastric mucosal 
expression might substantially improve the performance of said test. The 
development of such techniques is dependent on future study, but to assess the 
potential influence of an accurate assay on the combined diagnostic test, we used 
gastric mucosal MMP-7 relative mRNA abundance as a surrogate.  
 
Alone, the gastric mucosal MMP-7 relative mRNA abundance outperforms the serum 
concentration as determined by the ELISA described earlier. The ROC curve is shown 
in Figure 4-24. The AUC was 0.76 (p<0.0001, 95% CI: 0.7135 - 0.8004). 
 
 
Figure 4-24 ROC curve for gastric mucosal MMP-7 relative mRNA abundance for the detection of gastric 
preneoplasia. 
 
The optimal cut-off for MMP-7 relative mRNA abundance was determined as being 
≥0.33 (giving sensitivity and specificity values of 67.7% and 73.5% respectively) and 
we combined this as before with H. pylori serology, fasting serum gastrin 
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concentration and serum pepsinogen 1/2 ratio. The data are summarised in Table 
4-9. 
 
Table 4-9 Diagnostic performance gastric mucosal MMP-7 relative mRNA abundance in combination with 
pepsinogen 1/2 ratio, H. pylori serology, histology and CagA serology. PPV = positive predictive value; NPV = 
negative predictive value. 
 Combined test 
 Test + Test - 
Preneoplasia 
+ 195 7 
Preneoplasia 
- 10 29 
   
Sensitivity % 96.5 
Specificity % 68.8 
PPV % 48.8 




In comparison with the combined test described in section 3.7 (incorporating H. 
pylori serology, fasting serum gastrin concentration and serum pepsinogen 1/2 
ratio), the addition of mucosal MMP-7 relative mRNA abundance improves both 
sensitivity and NPV at the expense of specificity and PPV. Compared to the test 
incorporating serum MMP-7 concentration (described in section 4.6.6), sensitivity 




At the inception of this study, we identified a group of 12 proteins, whose expression 
we hypothesised might be implicated in the development of gastric mucosal 
preneoplasia and its subsequent progression to adenocarcinoma. This preliminary 
selection was based on previous work published by our own research group and 




I have outlined the process by which we identified one of these genes – MMP-7 – as 
the most promising candidate for further study. Of the 12 candidate genes, only 3 
MMP-7, MMP-1 and TIMP-1) exhibited the characteristics desired from a potential 
biomarker, namely a significant difference in expression between the disease state 
of interest (gastric preneoplasia) and other pathology or normal controls. Of these 
three genes, MMP-7 exhibited the greatest and most statistically significant 
difference between the relevant groups and so was selected for further study. There 
is a sound rationale for further studying the roles of MMP-1 and TIMP-1 in the 
development of gastric adenocarcinoma but the scale of the present study 
precluded additional analyses at this time.  
 
The large number of patients recruited to our study also enabled us to identify 
‘control’ subjects in whom factors likely to affect MMP-7 expression could be 
excluded. We identified 36 such individuals as described in section 4.2.1 and 
demonstrated that the mean mucosal relative mRNA abundance in this groups was 
significantly lower than in the group comprising subjects with ‘normal histology’ but 
other variables unfiltered.  
 
We observed that H. pylori associated mucosal inflammation (gastritis B) was 
associated with increased MMP-7 expression compared with a) controls and b) 
gastritis of alternative aetiologies. This corroborates earlier work(51,300,301) and 
supports the first tenet of our thesis – that MMP-7 participates in mucosal 
remodelling following H. pylori infection. Recent studies in murine models(302,303) 
suggest that MMP-7 acts to ‘restrain’ gastric inflammation and preneoplastic 
remodelling after H. pylori infection. In this study, the authors report that mmp-7-/- 
mice exhibit augmented gastric mucosal inflammation and increased epithelial cell 
proliferation and apoptosis compared to wild type mice following colonisation with 
H. pylori. 
 
Upregulated MMP-7 expression has previously been demonstrated in gastric 
adenocarcinoma(304–307) but our observation that MMP-7 expression is increased 
in the presence of gastric mucosal preneoplastic lesions is novel. The present study 
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was not intended to study the effects on mucosal MMP-7 mRNA abundance of 
gastric cancer and includes only 12 cases. There was an increase in mucosal MMP-7 
mRNA abundance in this group but the difference between this and controls was 
statistically insignificant.  
 
The response in mucosal MMP-7 expression to H. pylori mediated inflammation 
might have led us to predict that ongoing mucosal remodelling (as seen in 
preneoplasia) would also require increased MMP-7 activity. We did not however 
predict the attenuation of this effect that we observed in the ‘intestinal metaplasia 
only’ group. In this group, subjects whose gastric histology reports included atrophy 
were excluded. The implication of this is that the gastropathy described is further 
along the ‘pathway’ towards carcinogenesis than either the ‘atrophy‘ or ‘intestinal 
metaplasia & atrophy’ groups that conceptually precede it. Though the difference in 
mucosal MMP-7 mRNA abundance between this group and controls was significant, 
the abundance was significantly less than in other the other two major preneoplasia 
groups. 
 
Further studies are required to clarify the mechanism responsible for this effect. We 
might speculate that ‘atrophy-inclusive’ gastric preneoplasia represents a disease 
state in which mucosal remodelling is proceeding at greater intensity. In multifocal 
atrophic gastritis, chronic, active inflammation leads to loss of mucosal cells 
(particularly chief and parietal cells) and their replacement by fibrosis or metaplasia. 
It might be suggested that once chronic atrophic gastritis gives way to intestinal 
metaplasia, mucosal inflammation is attenuated and cellular/extracellular matrix 
turnover is diminished. 
 
The present study examined mucosal MMP-7 mRNA abundance in biopsy specimens 
obtained from the gastric corpus only. As outlined in chapter 1, the disease 
phenotype associated with gastric preneoplasia following H. pylori infection is one of 
pangastric inflammation followed by multifocal atrophic gastritis (MAG). Antrum-
restricted atrophic gastritis is thought of as a distinct disease phenotype with a lower 




We have shown that mucosal MMP-7 mRNA abundance in corpus mucosa was 
significantly increased in the presence of gastric preneoplasia irrespective of disease 
distribution. As might be expected however, abundance was greatest in cases of 
corpus predominant disease than in antrum predominant preneoplasia. We were 
surprised however, to find that in cases of pangastric preneoplasia (i.e. where 
preneoplastic lesions were reported in both antrum and corpus specimens), the 
mucosal abundance of MMP-7 mRNA was significantly diminished compared with 
corpus predominant cases and in fact were comparable to antrum predominant 
cases. The mechanism responsible for this effect is unclear and further studies will 
be required to characterise this.  
 
When considering MMP-7 as a potential biomarker, the assessment of mucosal 
mRNA abundance is rather moot, as upper GI endoscopy is required to obtain tissue. 
We therefore examined the performance of circulating MMP-7 concentration as a 
surrogate biomarker.  
 
We determined serum MMP-7 concentration using a commercially available ELISA 
kit. We anticipated that the specificity of such assays for gastric MMP-7 might be 
poor and found this to be the case. Gratifyingly, we observed increases in serum 
MMP-7 concentration in the same groups in which mucosal abundance of the gene 
transcript was increased. However, the only group in which the observed increase 
was significant was the gastric preneoplasia group. The bulk of this effect was 
attributed to the ‘intestinal metaplasia & atrophy’ group in which we also observed 
the greatest increase in MMP-7 mRNA mucosal abundance. This pattern suggests 
that the concentration of MMP-7 in the circulation is influenced by gastric mucosal 
expression but that the assay used in neither sensitive nor specific enough to be 
considered diagnostically accurate. The development of a more accurate assay 
(ELISA or otherwise) is required before the performance of serum MMP-7 as a 





5 The Effect of Single Nucleotide Polymorphisms of MMP-7 on Gastric Mucosal 




As outlined in chapter 1, matrix metalloproteinase (MMP)-7 is one of a family of 
proteolytic enzymes responsible for extracellular proteolysis during tissue 
homeostasis, healing and host defence. The expression and activity of MMPs and 
their inhibitors (tissue inhibitors of metalloproteinase (TIMPs)) is carefully regulated 
in normal physiology and their dysregulation has been implicated in pathological 
inflammation and cancer formation(308–310). Single nucleotide polymorphisms 
(SNPs) are genetic variations of a single nucleotide in the DNA sequence, which occur 
commonly within a given population. SNPs in various genes are reported to affect 
gene expression, gene product structure or function and have been implicated in 
disease susceptibility. 
 
MMP-7 gene SNPs have been shown to confer increased risk for the development of 
a variety of gastrointestinal cancers(311–316) including gastric adenocarcinoma, 
oesophageal squamous cell carcinoma, gallbladder adenocarcinoma and colorectal 
carcinoma. We selected MMP-7 SNPs for genotyping in our study population to 
determine a) whether MMP-7 SNPs influence susceptibility towards developing 
gastric mucosal preneoplasia and b) if MMP-7 SNPs affect gastric mucosal MMP-7 
expression. 
 
5.2 Materials & Methods 
 
Detailed materials and methods are described in chapter 2 and are summarised here 
for convenience. 
 
Symptomatic adults referred to the Royal Liverpool University Hospital for upper 
gastrointestinal endoscopy were recruited to the study as described in chapter 3. We 
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recorded demographic details, drug history, relevant family history and medical 
history including specific details of any pulmonary, cardiovascular or gastrointestinal 
disease. During upper GI endoscopy, gastric biopsies were taken to enable 
identification of mucosal pathology including preneoplasia. Gastric biopsies were 
also used to obtain RNA and cDNA by subsequent reverse transcription. The mucosal 
mRNA abundance of putative biomarkers of preneoplasia was determined by qPCR 
and the results have been described in chapter 4. Whole blood was also taken and 
stored at -20°C before subsequent DNA extraction. We used the Chemagen magnetic 
bead separation method to extract genomic DNA and this was subsequently stored 
at 4°C before genotyping. Single nucleotide polymorphisms in the MMP-7 gene were 
selected for genotyping (as described in chapter 2) and this was performed using off-
the-shelf TaqMan allelic discrimination assays and the Applied Biosystems HT7900 
real-time PCR system with supplied SDS software. 
 
5.3 MMP-7 single nucleotide polymorphisms in the study population 
 
Table 5-1 describes the MMP-7 SNPs, genotype and allelic frequencies in the study 
population. Eight of the nine SNPs selected were polymorphic and met the 
expectation that the minor allele frequency (MAF) should be greater than 0.05. The 
ninth SNP (rs11568819) was also polymorphic but only 3 cases (0.22%) of the 1349 
genotyped were homozygous for the minor allele. Although the MAF for rs11568819 
was found to be marginally below the 0.05 frequency threshold (0.049) it was still 
included in further analyses. Two of the SNP assays (for rs10502001 and rs10750646) 
were less reliable than the remainder and genotyping was only obtained for 1034 
and 999 subjects respectively. All SNPs were found to be distributed in line with 




Table 5-1 Description of SNPs, genotype and allelic frequencies in all subjects genotyped. AA = major allele 
homozygote; AB = heterozygote; BB = minor allele homozygote. 
 
 
The genotype frequencies observed in our study broadly matched those reported in 
previous series. As a reference, we used the data from the largest reported 
European genome database – (HapMap-CEU). The comparisons are shown in Table 
5-2. 
 
Table 5-2 Comparison of study genotype frequencies with reference database (HapMap-CEU) frequencies. AA = 
major allele homozygote; AB = heterozygote; BB = minor allele homozygote. 
SNP 
Study genotype frequency (%) Reference genotype frequency (%) 
AA AB BB AA AB BB 
rs11568818 31.1 50.8 18.1 32.1 42.0 25.9 
rs17352054 60.7 33.8 5.5 61.9 34.5 3.5 
rs12285347 31.3 50.8 17.9 31.7 43.3 25.0 
rs11225297 78.0 21.1 0.8 77.0 22.1 0.9 
rs11225307 60.1 34.4 5.5 61.9 34.5 3.5 
rs17098318 46.2 44.3 9.5 48.3 36.7 15.0 
rs10502001 58.6 35.7 5.7 62.5 33.9 3.6 
rs10750646 55.7 38.4 5.9 56.2 36.6 7.1 
rs11568819 90.4 9.4 0.2 88.5 11.5 0.0 
 
 
5.4 MMP-7 single nucleotide polymorphisms and the development of gastric 
mucosal preneoplastic pathology 
 
We proceeded to examine the association between the described MMP-7 gene SNPs 













AA AB BB HWE p 
rs11568818 1352 promoter A>G 43.5 31.1 50.8 18.1 0.217 
rs17352054 1356 intron A>C 22.4 60.7 33.8 5.5 0.343 
rs12285347 1349 intron T>C 43.3 31.3 50.8 17.9 0.212 
rs11225297 1357 3’ FR A>T 11.4 78.0 21.1 0.8 0.076 
rs11225307 1350 intron A>G 22.7 60.1 34.4 5.5 0.471 
rs17098318 1341 promoter G>A 31.7 46.2 44.3 9.5 0.398 
rs10502001 1034 exon C>T 23.5 58.6 35.7 5.7 0.775 
rs10750646 999 intron A>G 74.9 55.7 38.4 5.9 0.494 
rs11568819 1349 promoter G>A 4.9 90.4 9.4 0.2 0.872 
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so, we compared affected individuals with those whose gastric biopsies were 
reported as normal and whose testing for current infection by H. pylori (i.e. rapid 
urease test and histology) had been negative. These individuals are referred to as 
“normal” for the purposes of the following analyses and the detailed description of 
this group can be found in section 4.4.1.  
 
Genotype frequencies in the “pathology” group were compared with the 
corresponding values from the “normal” group. Table 5-3 lists the genotype 
frequencies in both groups for each SNP.  
 
Table 5-3 Genotype frequencies for each SNP in the 'normal' histology group and in the preneoplastic 'pathology' 
group. AA = major allele homozygote, AB = heterozygote, BB = minor allele homozygote. 
SNP 
Genotype frequency (%) – Normal Genotype frequency (%) – Pathology 
AA AB BB AA AB BB 
rs11568818 30.9 51.5 17.6 35.2 45.7 19.1 
rs17352054 63.4 31.0 5.6 56.3 33.4 10.2 
rs12285347 31.0 51.6 17.4 31.8 48.1 20.1 
rs11225297 79.4 19.4 1.2 76.6 22.7 0.6 
rs11225307 63.4 31.0 5.6 59.1 35.3 5.6 
rs17098318 45.1 46.3 8.6 41.3 48.2 10.6 
rs10502001 62.5 32.2 5.3 57.0 37.4 5.7 
rs10750646 52.6 39.4 8.0 57.1 38.5 4.4 
rs11568819 91.8 8.0 0.2 88.9 10.8 0.3 
 
We compared the genotype frequencies using χ2 tests to generate odds ratios. These 
data are summarised in Table 5-4 and are illustrated in Figure 5-1. 
 
Table 5-4 Association of gastric mucosal preneoplasia with MMP-7 SNPs comparing the reference genotype 
(major allele homozygote, AA) with AB (heterozygote) and BB (minor allele homozygote) genotypes. Significant 
association shown in bold. 
SNP 
AB genotype BB genotype 
OR (95% CI) p-value OR (95% CI) p-value 
rs11568818 0.7778 (0.5617 to 1.077) 0.1297 1.051 (0.6914 to 1.597) 0.8168 
rs17352054 1.213 (0.8853 to 1.663) 0.2289 2.07 (1.184 to 3.618) 0.0095** 
rs12285347 0.9061 (0.6486 to 1.266) 0.5632 0.8861 (0.5782 to 1.358) 0.5787 
rs11225297 1.211 (0.8467 to 1.732) 0.2937 0.5814 (0.1118 to 3.023) 0.514 
rs11225307 1.222 (0.8908 to 1.677) 0.2133 1.084 (0.5664 to 2.076) 0.807 
rs17098318 1.139 (0.8350 to 1.553) 0.4117 0.745 (0.4412 to 1.258) 0.2698 
rs10502001 1.275 (0.8882 to 1.830) 0.1875 1.167 (0.5486 to 2.484) 0.6874 
rs10750646 0.8992 (0.6245 to 1.295) 0.5679 0.5123 (0.2351 to 1.116) 0.0878 
rs11568819 1.399 (0.8455 to 2.314) 0.1897 0.6939 (0.04318 to 11.15) 0.7953 
 
Figure 5-1 Relative genotype frequencies (shown as percentages) in subjects with normal gastric mucosal histology compared to those in subjects with gastric mucosal preneoplasia in the 
MMP-7 SNPs a) rs11568818; b) rs17352054; c) rs12285347; d) rs11225297; e) rs11225307; f) rs17098318; g) rs10502001; h) rs10750646; and i) rs11568819.
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The relative genotype frequency differed significantly between normal and 
preneoplasia groups for only one MMP-7 SNP genotype - rs17352054 CC (minor 
allele homozygote). For this genotype, the minor allele homozygote genotype 
represented 10.2% of the preneoplasia pathology group as compared with only 5.6% 
of the normal histology group. Comparison using the χ2 test gave an odds ratio of 
2.07 (95% CI = 1.184 to 3.618). 
 
5.4.1 Gastric preneoplasia following H. pylori infection 
 
One of the objectives of this study was to determine some of the factors responsible 
for influencing the outcome of H. pylori infection in favour of preneoplasia 
development. We therefore repeated the analysis described above for patients with 
H. pylori seropositivity (implying current or previous infection). First we compared 
SNP genotype frequencies in preneoplasia groups compared with H. pylori 
seropositive individuals with normal histology or gastritis B (H. pylori associated 
gastritis). The genotype frequencies in this ‘seropositive’ group are shown compared 
with the genotype frequencies in the ‘pathology’ group in Table 5-5. 
 
Table 5-5 Genotype frequencies for each SNP in the ‘seropositive’ group and in the preneoplastic 'pathology' 
group. AA = major allele homozygote, AB = heterozygote, BB = minor allele homozygote. 
SNP 
Genotype frequency (%) – Seropositive Genotype frequency (%) – Pathology 
AA AB BB AA AB BB 
rs11568818 14.7 29.0 56.3 19.0 30.2 50.7 
rs17352054 57.3 36.8 5.9 60.0 36.6 3.4 
rs12285347 30.2 56.2 13.6 30.6 50.0 19.4 
rs11225297 71.7 27.5 0.8 77.7 22.3 0.0 
rs11225307 56.3 37.7 6.0 60.3 36.3 3.4 
rs17098318 45.8 45.4 8.8 47.8 42.9 9.4 
rs10502001 53.4 39.8 6.8 57.4 39.4 3.2 
rs10750646 56.9 38.7 4.4 56.0 38.7 5.3 
rs11568819 93.2 6.8 0.0 89.3 10.2 0.5 
 
Again, we compared the genotype frequencies using χ2 tests to generate odds ratios. 





Table 5-6 Association of gastric mucosal preneoplasia with MMP-7 SNPs comparing the reference genotype 
(major allele homozygote, AA) with AB (heterozygote) and BB (minor allele homozygote) genotypes from 
contingency of H. pylori seropositive individuals with normal gastric histology or gastritis B, and preneoplasia 
groups. 
SNP 
AB genotype BB genotype 
OR (95% CI) p-value OR (95% CI) p-value 
rs11568818 0.8623 (0.5651 to 1.316) 0.4920 0.8058  (0.4588 to 1.415) 0.4518 
rs17352054 0.9507 (0.6451 to 1.401) 0.7982 0.5501 (0.2173 to 1.393) 0.2018 
rs12285347 0.8795 (0.5794 to 1.335) 0.5461 0.7067 (0.4028 to 1.240) 0.2255 
rs11225297 0.7491 (0.4887 to 1.148) 0.1843 0.2312 (0.0110 to 4.854) 0.1895 
rs11225307 0.8993 (0.6099 to 1.326) 0.5918 0.5388 (0.2127 to 1.365) 0.1863 
rs17098318 0.9048 (0.6131 to 1.335) 0.6145 0.9852 (0.5036 to 1.927) 0.9653 
rs10502001 0.9199 (0.5919 to 1.430) 0.7104 0.4408 (0.1512 to 1.285) 0.1250 
rs10750646 1.016 (0.6466 to 1.596) 0.9451 1.226 (0.4414 to 3.406) 0.6925 
rs11568819 1.573 (0.8062 to 3.068) 0.1811 0.2620 (0.0106 to 6.473) 0.2599 
 
Figure 5-2 Relative genotype frequencies (shown as percentages) in subjects with H. pylori seropositivity and normal histology or gastritis B, compared to those in subjects with gastric 
mucosal preneoplasia in the MMP-7 SNPs a) rs11568818; b) rs17352054; c) rs12285347; d) rs11225297; e) rs11225307; f) rs17098318; g) rs10502001; h) rs10750646; and i) rs1156881
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In this comparison, there were no significant differences between the genotype 
frequencies observed in H. pylori seropositive patients with normal gastric histology 
or gastritis B and those with gastric preneoplasia.  
 
To mitigate the effects of active H. pylori infection on this analysis, it was repeated, 
this time comparing SNP genotype frequencies in preneoplasia groups with those in 
H. pylori seropositive individuals with normal gastric histology only. The genotype 
frequencies in this ‘H. pylori’ group are shown compared with the genotype 
frequencies in the ‘pathology’ group in Table 5-7. 
 
Table 5-7 Genotype frequencies for each SNP in the ‘H. pylori’ group and in the preneoplastic 'pathology' group. 
AA = major allele homozygote, AB = heterozygote, BB = minor allele homozygote. 
SNP 
Genotype frequency (%) – H. pylori Genotype frequency (%) – Pathology 
AA AB BB AA AB BB 
rs11568818 16.8 26.9 56.3 19.0 30.2 50.7 
rs17352054 53.3 42.2 4.4 60.0 36.6 3.4 
rs12285347 29.9 56.0 14.2 30.6 50.0 19.4 
rs11225297 66.2 32.4 1.5 77.7 22.3 0.0 
rs11225307 51.9 43.7 4.4 60.3 36.3 3.4 
rs17098318 49.2 41.7 9.1 47.8 42.9 9.4 
rs10502001 49.5 45.7 4.8 57.4 39.4 3.2 
rs10750646 57.6 37.6 4.7 56.0 38.7 5.3 
rs11568819 93.3 6.7 0.0 89.3 10.2 0.5 
 
Once again, we compared the genotype frequencies using χ2 tests to generate odds 
ratios. These data are summarised in Table 5-8and illustrated in Figure 5-3. 
 
Table 5-8 Association of gastric mucosal preneoplasia with MMP-7 SNPs comparing the reference genotype 
(major allele homozygote, AA) with AB (heterozygote) and BB (minor allele homozygote) genotypes from 
contingency of H. pylori seropositive individuals with normal histology and those with gastric preneoplasia. 
Significant association shown in bold. 
SNP 
AB genotype BB genotype 
OR (95% CI) p-value OR (95% CI) p-value 
rs11568818 0.8018 (0.4736 to 1.355) 0.4081 0.9936  (0.4996 to 1.976) 0.9854 
rs17352054 0.7702 (0.4907 to 1.209) 0.2559 0.6829 (0.2209 to 2.112) 0.5056 
rs12285347 0.8720 (0.5312 to 1.431) 0.5878 0.7481 (0.3810 to 1.496) 0.3986 
rs11225297 0.5881 (0.3612 to 0.9575) 0.0319* 0.1128 (0.0054 to 2.377 0.0611 
rs11225307 0.7138 (0.4548 to 1.120) 0.1420 0.6640 (0.2146 to 2.054) 0.4747 
rs17098318 1.060 (0.6683 to 1.681) 0.8045 0.9425 (0.4285 to 2.073) 0.8829 
rs10502001 0.7425 (0.4458 to 1.237) 0.2520 0.5843 (0.1614 to 2.115) 0.4082 
rs10750646 1.057 (0.6056 to 1.846) 0.8446 1.167 (0.3339 to 4.077) 0.8090 
rs11568819 1.607 (0.7123 to 3.624) 0.2497 0.4835 (0.0195 to 11.97) 0.4072 
 
Figure 5-3 Relative genotype frequencies (shown as percentages) in subjects with H. pylori seropositivity and normal histology compared to those in subjects with gastric mucosal 
preneoplasia in the MMP-7 SNPs a) rs11568818; b) rs17352054; c) rs12285347; d) rs11225297; e) rs11225307; f) rs17098318; g) rs10502001; h) rs10750646; and i) rs11568819
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In this series, we found a small but significant difference in genotype frequency for 
one of the 9 SNPs between H. pylori seropositive individuals with normal gastric 
histology and those with preneoplasia. Heterozygotes for SNP rs11225297 (AT) were 
less frequent in the preneoplasia group (22.3%) than in H. pylori seropositive but 
normal histology group (32.4%) implying a negative association between the minor 
allele and gastric preneoplasia. Using the χ2 test gave an odds ratio of 0.59 (p=0.03, 
95% CI = 0.361-0.968). In such cases, we would anticipate seeing a similar if not 
greater effect in homozygotes for the minor allele but the frequency of that 
genotype was very low in our study cohort (0.8%) and so we were unable to detect 




5.5 MMP-7 single nucleotide polymorphisms and gastric mucosal MMP-7 mRNA 
abundance 
 
We also examined the association between MMP-7 SNPs genotypes and gastric 
mucosal expression of MMP-7 as evidenced by the relative mRNA abundance 
determined by qPCR. Here we compared the relative mucosal mRNA abundance of 
MMP-7 in individuals with the reference (major allele homozygote) genotype to that 
of individuals with the heterozygote genotype and of those with the minor allele 
homozygote genotype. Mean relative abundances were compared using the Kruskal 
Wallis ANOVA with Dunn’s multiple comparison tests. The data are summarised in . 
 
 
Table 5-9 and are illustrated in Figure 5-4. 
 
 
Table 5-9 Comparison between mean relative (rel.) abundance of gastric mucosal MMP-7 mRNA in the reference, 
major allele homozygote (AA) genotype with that in the heterozygote (AB) and minor allele homozygote (BB) 
genotypes for MMP-7 SNPs. *** = p<0.001; *** = p<0.01. 
SNP 
AA genotype  AB genotype  BB genotype  
Mean MMP-7 
rel. abundance  
(SEM) 
Mean MMP-7 
rel. abundance  
(SEM) 
Fold-change 
rel. to AA 
Mean MMP-7 
rel. abundance  
(SEM) 
Fold-change 
rel. to AA 
rs11568818 0.61 (0.15) 1.79 (0.24) 2.9*** 3.06 (0.82) 5.0*** 
rs17352054 1.24 (0.14) 3.31 (0.79) 2.7*** 1.97 (0.54) 1.6 
rs12285347 3.02 (0.81) 1.80 (0.24) -1.7** 0.67 (0.16) -4.5*** 
rs11225297 1.82 (0.32) 2.56 (0.57) 1.4 0.71 (0.24) 0.4 
rs11225307 1.26 (0.14) 3.28 (0.79) 2.6** 1.73 (0.41) 1.4 
rs17098318 2.40 (0.56) 1.82 (0.28) -1.3 0.80 (0.27) -3.0*** 
rs10502001 1.11 (0.14) 3.29 (0.98) 3.0*** 1.86 (0.63) 1.7 
rs10750646 1.95 (0.30) 1.75 (0.29) 0.9 1.54 (0.38) 0.8 
rs11568819 1.84 (0.29) 3.11 (0.89) 1.7 1.37 (1.22) 0.7 
 
Figure 5-4 Comparison of mean relative abundance of gastric mucosal MMP-7 mRNA in different genotypes for SNPs: a) rs11568818; b) rs17352054; c) rs12285347; d) rs11225297; e) 
rs11225307; f) rs17098318; g) rs10502001; h) rs10750646; and i) rs11568819. n=number of patients.
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As can be seen, there was a significant difference in mucosal MMP-7 relative mRNA 
abundance between genotypes for six of the nine SNPs: rs11568818; rs17352054; 
rs12285347; rs11225307; rs17098318; and rs10502001 (labelled ‘a’, ‘b’, ‘c’, ‘e’, ‘f’ 
and ‘g’ respectively in Figure 5-4 ).  
 
For SNPs rs11568818; rs17352054; rs11225307 and rs10502001 (labelled ‘a’, ‘b’, ‘e’ 
and ‘g’ in the figure), we observed an increased relative abundance of MMP-7 mRNA 
in the presence of the minor allele compared with the reference genotype. In the 
case of SNPs rs17352054; rs11225307 and rs10502001 (labelled ‘b’, ‘e’ and ‘g’ in the 
figure), this phenomenon was only true for the heterozygote genotype and the 
minor allele homozygote was not significantly different. This might be attributable to 
the comparatively low numbers of minor allele heterozygotes included for these 
SNPs. 
 
SNP rs11568818 was associated with a significant increase in mean MMP-7 relative 
mRNA abundance in the presence of both the heterozygote (2.9-fold) and the minor 
allele homozygote (5-fold) genotypes compared with the reference genotype. There 
was also a significantly greater mean relative abundance in the minor allele group 
compared with the heterozygote group (1.7-fold). 
 
In contrast to these SNPs, presence of the minor allele in rs12285347 and 
rs17098318 (labelled “c” and “f” respectively in the figure) was associated with a 
decrease in the relative abundance of MMP-7 mRNA compared with the reference 
genotype. 
 
The heterozygote and minor allele homozygote genotypes for rs12285347 were 
associated with statistically significant 1.7-fold and 4.5 fold decreases in mean MMP-
7 relative mRNA abundance compared with the reference genotype respectively. For 
rs17098318, the observed difference between the heterozygote and reference 
genotypes was not statistically significant but there was a highly significant 3.0-fold 
decrease in the relative mRNA abundance of MMP-7 between homozygote 
genotypes. For both of these SNPs, there was a significant decrease in MMP-7 
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The studies conducted to-date on MMP-7 polymorphisms have largely focused on 
epithelial cancers and inflammatory diseases. For gastric cancer in particular, there is 
a lack of studies reporting on MMP-7 polymorphisms and their functional effects in 
European populations. Additionally, studies examining such polymorphisms have 
largely ignored the question of influence on the development of preneoplastic 
lesions. 
 
The best studied SNPs with regards gastric cancers are rs11568818 and rs11568819. 
Both have been shown to be associated with increased frequencies in gastric cancer 
and have also been associated with more ‘aggressive’ tumour behaviour including 
enhanced invasiveness, metastasis and lymph node invlovement.  
 
In this study, we found no associations between these polymorphisms and gastric  
preneoplasia, though both exhibited an increased expression of mucosal MMP-7 
with carriage of the minor allele. For rs11568819, this was not statistically significant 
and there were insufficent subjects with the minor allele homozygote genotype to 
adequately characterise its effect. For rs11568818 however, there was a significant 
and stepwise increase in mucosal MMP-7 expression between major allele 
homozygote, heterozygote and minor allele homozygote. The converse was true for 
rs17098318, where there was a significant and stepwise decreease in mucosal MMP-
7 mRNA abundance in the same direction, though this too was not translated into a 
measurable effect on the risk of preneoplasia.  
 
We have however identified two other MMP-7 SNPs whose genotypes seem to be 
associated with the presence of gastric preneoplasia. In the comparision between all 
individuals with gastric preneoplasia and all those with normal stomach histology, 
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rs17352054 minor allele homozygosity was slightly but signnificantly more frequent 
in the preneoplasia group. When comparing individuals with gastric preneoplasia to 
those with normal stomach histology but evidence of H. pylori infection, rs11225297 
heterozygosity was negatively associated with preneoplasia. The minor allele 
homozygote is insufficiently frequent in Europeans for us to have been able to 
measure an effect. Neither SNPs have previously been described in association with 
GI cancer, though both have been studied for their effect on breast cancer survival 
and susceptibility and rs11225297 has previously been associated with improved 
breast cancer survival in a Chinese study (311,317). Neither SNP has previously been 
reported as having disease-associations in a European population.These SNPs 
therefore warrant further investigation in other European cohorts with gastric 




6 A pilot study of the novel gastrin antagonist netazepide (YF476) for the 




Autoimmune chronic gastritis is a condition characterised by the autoimmune-
mediated loss of oxyntic glands from the corpus mucosa(243). The resulting 
hypochlorhydria leads to unopposed gastrin secretion by antral G-cells. Gastrin 
exerts both stimulatory and trophic effects on ECL-cells. In some cases, gastrin-
dependent ECL-cell hyperplasia can progress to dysplasia and ECL-cell tumour 
(gastric neuroendocrine tumour) formation. Gastric neuroendocrine tumours of this 
aetiology are categorized as type 1 NETs. They are typically multiple, small and 
located in the gastric corpus and fundus(259,258). 
 
Although increasing in incidence, type 1 gastric NETs are rarely diagnosed and so 
evidence to guide their management is limited. Small tumours (smaller than 10mm) 
typically exhibit an indolent natural history. They grow slowly, rarely metastasise and 
are generally associated with a favourable prognosis. Conservative treatment and 
surveillance is the widely accepted strategy for managing this group of 
patients(265,318–320). Larger tumours are regarded as having the potential to grow 
more rapidly and metastasise. Surgical antrectomy can induce tumour regression by 
removing the source of gastrin but is not universally effective and carries the 
associated risks of surgery. Long acting somatostatin analogues such as octreotide 
have been shown to reduce tumour size, number and circulating biomarkers but 
require parenteral administration and are not always well tolerated.  
 
Many gastrin/CCK-2 receptor antagonists have been described, but they have proven 
limited in terms of their potency, selectivity and bioavailability. None have been 
developed as a medicine(11). Netazepide is a potent, orally bioavailable and highly 




The present study describes the first clinical use of netazepide. Our objectives were 
to assess the safety, tolerability and efficacy of netazepide in patients with 
autoimmune chronic atrophic gastritis and type 1 gastric NETs. 
 
6.2 Study design 
 
The study methodology is described in detail in chapter 2 and is summarised here for 
convenience. Patient recruitment took place over a 12-month period. Subjects who 
satisfied the inclusion criteria were treated in two stages. 
 
Stage 1 comprised 12 weeks of treatment with netazepide 50mg daily and a 12-week 
follow-up period (after discontinuing netazepide treatment). There were 6 study 
visits. At baseline (0 weeks), 3, 6, 9, 12 and 24 weeks we collected blood for 
determination of fasting serum gastrin and chromogranin A concentrations along 
with routine ‘safety’ parameters (full blood count, urea and electrolytes, liver 
function tests, lipid profile and fasting glucose concentration). Patients underwent 
gastroscopy at baseline (0 weeks) and at 6, 12 and 24 weeks to measure and 
photograph gastric lesions and to obtain biopsies of gastric mucosa and visible 
tumours. Assays for plasma netazepide concentration were performed on blood 
samples taken for trough (prior to dosing) and peak levels (1 hour after dosing) at 
each visit. 
 
Stage 2 comprised 52 weeks of treatment with netazepide. Patients were eligible for 
inclusion in the second stage if they were considered to have benefited from the 
primary treatment course. All eight patients from stage 1 were included. There were 
5 study visits. At 0, 12, 24, 36 and 52 weeks, we collected blood for gastrin, CgA, and 
netazepide assays along with ‘safety’ monitoring as before. We performed 
gastroscopy at baseline (0 weeks), 24 and 52 weeks as before. There was no follow-
up study visit after this stage and patients were returned to routine clinic follow-up. 




There was considerable variation across the study cohort in the time interval 
between completion of stage 1 (including the 12 week follow-up period) and 
commencement of stage 2 (range 22-66 weeks, mean 46 weeks, median 47 weeks). 
For one patient (patient 8), this interval was less than 6 months and so repeat 
endoscopy prior to restarting netazepide was considered unnecessary. 
 
Table 6-1 Investigations performed at each study visit. 
Stage 1 
       
Weeks 0 3 6 9 12 24 
On treatment  y y y y  
Blood tests y y y y y y 
Endoscopy y  y  y y 
       
Stage 2 
       
Weeks 0 12 24 36 52  
On treatment  y y y y  
Blood tests y y y y y  
Endoscopy y  y  y  
 
 
6.3 Patient characteristics 
 
Patients were recruited to the present study from the professorial tertiary referral 
neuroendocrine tumour outpatient clinic at the Royal Liverpool University Hospital 
as described in chapter 2. We enrolled 8 patients to the trial over a 12-month period. 
4 were female. The mean age was 66 years (range 56-76 years). Patient 
characteristics are summarised in Table 6-2. Prior to enrolment, all patients had 
undergone baseline investigations and had been shown to have a) histologically 
proven type 1 gastric neuroendocrine tumour(s); b) chronic atrophic gastritis and 
vitamin B12 deficiency and c) no evidence of metastatic disease either by computed 




All patients were found to have anti-parietal cell antibodies and two also had anti-
intrinsic factor antibodies. There were a variety of well-controlled chronic 
comorbidities reported by study subjects and careful records of medication use were 
made prior to and during the trial. 
 
Table 6-2 Patient characteristics. AG = atrophic gastritis, IM = intestinal metaplasia, ECL-L = linear ECL-cell 
hyperplasia, ECL-M = micronodular ECL-cell hyperplasia, ECL-D = ECL-cell dysplasia, NET = neuroendocrine 
tumour. 
 Patient number 
 1 2 3 4 5 6 7 8 
Age 60 64 67 69 76 67 55 66 
Gender Female Female Male Male Female Female Male Male 
Number of gastric 
polyps 8 8 4 9 30 10 12 10 
Size of largest 













































Serum gastrin by 
RIA (pmol/L) 800 800 580 960 1050 470 1750 520 
Serum gastrin by 
ELISA (pmol/L) 531 494 414 645 655 332 953 415 
Serum CgA (U/L) 25.2 52.6 54 33 93 56 128 64 
H. pylori histology Negative Negative Negative Negative Negative Negative Negative Negative 
H. pylori serology Negative Negative Negative Not done Negative Positive Negative Positive 
Vitamin B12 
deficiency Yes Yes Yes Yes Yes Yes Yes Yes 
Anti-parietal cell 
antibody Positive Positive Positive Positive Positive Positive Positive Positive 
Anti-intrinsic 





6.3.1 Tumour number and size 
 
At baseline gastroscopy, all 8 patients had visible gastric tumours. The median 
number was 10 (range 4–30), and the mean diameter of the largest tumour was 6.75 
mm (range 3–15 mm). 
 
6.3.1.1 Stage 1 
 
After 6 weeks of treatment, five of the patients had fewer tumours and in two of 
these, a further reduction in number was observed after 12 weeks of treatment. Two 
patients exhibited no change in tumour number and we recorded a slight increase in 
the number of visible tumours for the remaining patient. After 6 and 12 weeks’ 
treatment, the mean decrease in the number of tumours relative to baseline was 24 
and 30%, respectively (p=0.041 and 0.046 respectively, Wilcoxon signed ranks test).  
At 24 weeks, 12 weeks after completion of treatment, findings were similar to those 
at 12 weeks.  The mean decrease relative to baseline was 29% (p=0.092, Wilcoxon 
signed ranks test). 
 
All but one of the patients (patient 7) had a decrease in the diameter of their largest 
tumour after 6 and/or 12 weeks’ treatment. The mean decrease relative to baseline 
was 20 and 33%, respectively (p=0.026 and 0.018 respectively, Wilcoxon signed 
ranks test).  None of the largest tumours had increased in size at 12 weeks after 
stopping treatment, and 2 of them were slightly smaller.  The mean decrease 
relative to baseline was 40% (p=0.017, Wilcoxon signed ranks test). The endoscopic 





Figure 6-1 Stage 1 endoscopic tumour characteristics: (a) number of tumours; (b) size of largest tumour, and (c,d) 
% change from baseline after 6 and 12 weeks’ netazepide treatment, and at follow-up at 24 weeks, 12 weeks 
after end of treatment. Note image ‘p’ in right panel recorded in greyscale due to a technical fault. 
 
Illustrative endoscopic images taken at baseline and at week 24 (12 weeks after 
completing 12 weeks treatment with netazepide) are shown in Figure 6-2 (note 
image ‘p’ in right panel was recorded in greyscale due to a technical fault with the 




Figure 6-2 Illustrative endoscopic photographs taken at gastroscopy from patients 1 (a, b); 2 (c, d); 3 (e, f) and 4 
(g, h) in left panel and patients 5 (i, j); 6 (k, l); 7 (m, n) and 8 (o, p) (in right panel) at baseline and 24 weeks 
respectively. 
 
6.3.1.2 Stage 2 
 
In the interval between completing stage 1 and beginning stage 2, we observed small 
but significant increases in tumour number and size in most subjects. As described 
above, patient 8 did not undergo a repeat gastroscopy prior to starting stage 2. Of 
the remaining 7 subjects, 6 were reported to have more visible tumours at the start 
of stage 2 than on completion of stage 1 (Figure 6-3a). One patient (patient 7) had 
fewer visible tumours. The mean increase in visible tumour number was 55% 
(p=0.034, Wilcoxon signed ranks test). Of the same 7 patients, 6 developed an 
increase in the size of their largest visible tumour in the interval period and 1 
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(patient 1) was unchanged (Figure 6-3b). The mean increase in the diameter of the 
largest tumour was 38% (p=0.023, Wilcoxon signed ranks test). 
 
 
Figure 6-3 a) Mean tumour number and b) Mean size of largest tumour at completion of stage 1 compared with 
the start of stage 2. 
 
After 24 weeks of treatment with netazepide in stage 2, 6 patients had fewer 
tumours and in 2, the numbers were unchanged. After 52 weeks of treatment, there 
had been an increase in tumour number in 3 patients, including 2 in whom the 
number had initially decreased. One patient (patient 1) exhibited a complete 
endoscopic response with no visible tumours after 24 weeks and no recurrence after 
52 weeks. Patient 3 had started stage 1 with a small number (4) of diminutive 
tumours (largest 3mm). At the start of stage 2, we recorded 2 tumours with the 
largest being 4mm. We recorded no visible tumours after 24 weeks of treatment but 
after 52 weeks reported 1 tumour, 1mm in diameter. In retrospect, it seems possible 
that this tumour was present but not seen at the 24 week examination. After 24 and 
52 weeks of treatment, the mean decreases in tumour number were 36% (p=0.026) 
and 32% (ns p=0.127, Wilcoxon signed rank tests) respectively.  
 
All but one of the patients (patient 5) exhibited a decrease in the size of their largest 
tumour after 24 weeks of treatment. After 52 weeks, the size of the largest tumour 
had decreased in all 8 patients compared with the endoscopy performed at the start 
of stage 2. Interestingly, the patient whose macroscopic response had been 
negligible in stage 1 actually showed a small decrease in visible tumour number and 
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a significant decrease in the size of his largest tumour in stage 2. The mean 
decreases in the size of the largest tumour after 24 and 52 weeks of treatment were 
50% (p=0.017) and 57% (p=0.011, Wilcoxon signed rank tests) respectively. The 
endoscopic findings from stage 2 of the study are summarised in Figure 6-4. 
 
 
Figure 6-4 Stage 2 endoscopic tumour characteristics: (a) number of tumours; (b) size of largest tumour, and (c,d) 
% change from pre-treatment measurements after 24 and 52 weeks’ netazepide treatment. 
 
Illustrative endoscopic images taken at the start of stage 2 and after 52 weeks of 





Figure 6-5 Illustrative endoscopic photographs taken at gastroscopy from patients 1 (a, b); 2 (c, d); 3 (e, f) and 4 
(g, h) (in left panel) and patients 5 (i, j); 6 (k, l); 7 (m, n) and 8 (o, p) (in right panel) at the start of stage 2 and after 
52 weeks of netazepide treatment respectively. 
 
6.3.2 12 month follow-up 
 
On completion of stage 2, all 8 subjects were returned to routine follow-up care in 
the regional neuroendocrine tumour outpatient clinic. As part of their routine 
surveillance, all 8 underwent repeat upper GI endoscopy approximately 12 months 
after the final study visit. Though not included in the study protocol, we report the 
results for completeness. 
 
In the 12-month period between completing the study and the repeat endoscopy, 
three patients (patients 2, 3 and 4) were reported to have fewer tumours and 
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another three (patients 1, 7 and 8) exhibited no change. Patient 6 who had 
concluded the study with only one visible polyp, 2mm in diameter was reported to 
have 2 visible tumours at follow-up, the largest estimated to be 3mm. Only patient 5 
who had 12 diminutive tumours at the end of stage 2 (largest 2mm) really seemed to 
have a significant increase in tumour number. At her follow-up endoscopy, she was 
reported to have 20 tumours (largest 2mm). Patient 1, in whom we reported a 
complete response to netazepide treatment, was still free of visible tumours. Patient 
3 had been reported to have a single; 1mm polyp at the end of stage 2 had no visible 
tumours reported at follow-up. 
 
At follow up endoscopy, four patients (patients 4, 5 and 8) exhibited no increase in 
the size of their largest tumour. Patients 1 and 3 had no visible tumour. There were 
three patients in whom the size of the largest tumour was reportedly increased. 
Patients 6 and 7 had an increase in tumour size of 1 and 2mm respectively. Only 
patient 2 exhibited a clinically significant change as her largest tumour had increased 




All 8 patients had low-grade type 1 gastric NETs prior to enrolment.  Seven still had 
low-grade NETs at baseline; the other had micronodular ECL-cell hyperplasia 
throughout the study.  All gastric corpus mucosal biopsies showed ECL-cell 
hyperplasia throughout the study, but there were no further morphological or 
histopathological changes. Histological findings from endoscopic biopsies are 




Table 6-3 Histological findings of endoscopic biopsies. NET - neuroendocrine tumour, ECL-L - linear ECL cell 
hyperplasia, ECL-M - micronodular ECL-cell hyperplasia, ECL-D - ECL-cell dysplasia. 
 Stage 1 Stage 2 
 
Week 0 Week 6 Week 12 Week 24 Week 0 Week 24 Week 52 
P1 NET ECL-M ECL-M ECL-M NET ECL-M ECL-M 
P2 NET NET NET ECL-M ECL-D ECL-M ECL-M 
P3 ECL-M ECL-M ECL-M ECL-M ECL-M ECL-M ECL-L 
P4 NET ECL-M ECL-M NET ECL-M ECL-M ECL-M 
P5 NET NET NET NET NET ECL-M NET 
P6 NET NET ECL-M NET NET NET NET 
P7 NET NET NET NET NET NET NET 
P8 NET NET NET ECL-M n/a ECL-M ECL-M 
 
 
6.3.4 Plasma chromogranin A and fasting serum gastrin concentrations 
 
6.3.4.1 Stage 1 
 
CgA and gastrin concentrations at baseline, 3, 6, 9 and 12 weeks and at follow-up at 
24 weeks are shown in Figure 6-6 and Figure 6-7 respectively.  
 
After 3 weeks of netazepide treatment, plasma CgA concentration had decreased in 
all subjects (Figure 6-6); mean decrease relative to baseline was 70% (p=0.001 two-
tailed Mann-Whitney test).  The response was sustained throughout treatment; 
mean decrease at 12 weeks relative to baseline was 69% (p=0.002 two-tailed Mann-
Whitney test).  Patient 5 appeared to respond less favourably and her diary card 
entries and capsule counts showed erratic treatment compliance.  At follow-up, 12 
weeks after treatment cessation, plasma CgA was elevated again in all patients 
(mean = 82% of baseline). In two patients (patients 1 and 2) plasma CgA 
concentration was higher than at baseline but for the remaining 6 patients, it was 
lower. The difference between baseline and follow-up (week 24) concentrations was 




Figure 6-6 a) Individual and b) mean fasting plasma chromogranin A (U/L) concentration at baseline, after 3, 6, 9 
and 12 weeks’ netazepide treatment, and at follow-up at 24 weeks, 12 weeks after end of treatment. 
 
All patients had a high serum gastrin concentrations at baseline (Table 6-2); mean 
(range) was 866 pM (490–1010 pM) by RIA (Figure 6-7a), and 555 pM (331–953 pM) 
by ELISA (Figure 6-7b).  There were no significant changes during treatment. 
 
 
Figure 6-7 Fasting serum gastrin (pmol/L) concentrations measured by RIA (a) and ELISA (b) at baseline, after 3, 6, 
9 and 12 weeks’ netazepide treatment, and at follow-up at 24 weeks, 12 weeks after end of treatment. 
 
 
6.3.4.2 Stage 2 
 
CgA and gastrin concentrations at the start of stage 2 (0 weeks) and after 12, 24, 36 
and 52 weeks of treatment with netazepide are shown in Figure 6-8 and Figure 6-9 
respectively. 
 
In keeping with our observations from stage 1, plasma CgA concentrations 
diminished significantly during treatment with netazepide. After 12 weeks of 
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treatment in stage 2, the mean decrease in plasma CgA was 64%. There appeared to 
be a modest attenuation of this effect as the course of treatment proceeded. The 
mean decrease in plasma CgA concentration relative to week 0 at 12, 24, 36 and 52 
weeks was 64%, 64%, 58% and 54% respectively (p=0.019, 0.011, 0.047, and 0.070 
respectively, two-tailed Mann-Whitney tests). This stage of the study did not include 
a formal follow-up study visit to determine plasma CgA concentrations after 
cessation of prolonged netazepide treatment. 
 
 
Figure 6-8 a) Individual and b) mean fasting plasma chromogranin A (U/L) concentration before restarting 
netazepide and after 12, 24, 36 and 52 weeks’ of treatment. 
 
Given the results obtained in the first stage, we did not anticipate a significant 
change in fasting serum gastrin in these patients during treatment with netazepide. 
Therefore, for convenience, serum gastrin concentration was determined by ELISA 
alone. There was no significant change in fasting serum gastrin concentration during 
netazepide treatment in the second stage of the study. 
 
Figure 6-9 Fasting serum gastrin (pmol/L) concentrations measured by ELISA before restarting netazepide and 




6.3.5 Gastric mucosal biomarkers 
 
6.3.5.1 Stage 1 
 
Real-time PCR mRNA abundances of the ECL-cell constituents CgA and HDC, 
normalised for the housekeeper gene GAPDH, decreased relative to baseline in all 
patients during netazepide treatment, and increased again after treatment 
cessation.  Mean real-time PCR abundance of CgA mRNA relative to baseline was 
31% at 6 weeks (p=0.012) and 35% at 12 weeks (p=0.012).  At 24 weeks, it was 138% 
of baseline (p=0.779, Wilcoxon signed ranks tests).  Mean real-time PCR abundance 
of HDC mRNA relative to baseline was 38% at 6 weeks (p=0.012) and 59% at 12 
weeks (p=0.050).  At follow-up, it was 179% relative to baseline (p=0.674, Wilcoxon 
signed ranks tests).  Mean real-time PCR abundance of MMP-7 mRNA relative to 
baseline was 82% at 6 weeks (p=0.161) and 56% at 12 weeks (p=0.017).  At follow-
up, it was 116% relative to baseline p=0.779, Wilcoxon signed ranks tests). The real-
time PCR abundances of PAI-1 and PAI-2 mRNA did not change significantly. The real-




Figure 6-10 Individual and mean relative abundance of a,b) CgA; c,d) HDC; e,f) MMP-7; g,h) PAI-1 and i,j) PAI-2 at 





6.3.5.2 Stage 2 
 
Based on our observations in stage 1, we excluded PAI-1 and PAI-2 from the mucosal 
biomarker analyses in the second stage of this study. We therefore proceeded to 
analyse the mucosal abundance of CgA, HDC and MMP-7 at the specified treatment 
intervals. In this series, we also incorporated samples obtained from the baseline 
endoscopy (prior to starting netazepide treatment in stage 1). 
 
In the interval between completion of stage 1 and restarting netazepide, we 
observed a small increase in the relative mucosal abundance of CgA and small 
decreases in the relative mucosal abundances of HDC and MMP-7 (Figure 6-11). 
None were statistically significant.  
 
 
Figure 6-11 Mean relative abundance of a) CgA b) HDC and c) MMP-7 prior to netazepide treatment in stage 1 
(baseline) and prior to treatment in stage 2 (week 0). 
 
In keeping with the observations made during stage 1, the relative mucosal mRNA 
abundances of both CgA and HDC decreased in all but one patient following 
treatment with netazepide. Mucosal MMP-7 mRNA abundance did not change 
significantly during this phase of the study. These data are summarised in Figure 
6-12. 
 
7 of the patients showed a decrease in gastric mucosal CgA mRNA abundance after 
24 weeks of treatment, which was sustained after 52 weeks. Patient 6 exhibited a 
small increase in the relative mRNA abundance of CgA at 24 weeks but the value at 
52 weeks was lower than the corresponding measurement at both week 0 and week 
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24. After 24 and 52 weeks of treatment, the mean relative mucosal abundances of 
CgA mRNA were 17% (p=0.017) and 10% (p=0.012, Wilcoxon signed rank tests) of the 
abundance recorded prior to restarting netazepide (week 0). 
 
All patients exhibited diminished relative abundance of HDC mRNA after 24 weeks 
and 52 weeks of netazepide treatment. The mean relative mRNA abundances after 
24 and 52 weeks of treatment were 21% (p=0.012) and 28% respectively (p=0.012, 
Wilcoxon signed rank tests). 
 
 
Figure 6-12 Individual and mean relative mRNA abundance of a,b) CgA; c,d) HDC and e,f) MMP-7 prior to 







Plasma netazepide trough and peak concentrations did not change significantly 
during treatment in either stage of the present study (data not shown). 
 
6.3.7 Safety, tolerability and compliance 
 
There were no adverse events that could be reasonably attributed to netazepide, 
and there were no clinically relevant changes in safety assessments.  There was no 
evidence of a drug-drug interaction in those patients taking concomitant medication. 
 
6.3.8 Discussion  
 
In the present study, we report the first clinical trial of netazepide in two stages. In 
both stages, netazepide was safe, well tolerated and appeared efficacious. 
 
The first outcome measures we described were the macroscopic changes reported 
at upper GI endoscopy. We observed a significant reduction in both the size of the 
largest gastric tumour and in overall tumour number. We strove to limit the 
subjectivity of these observations by having a single endoscopist and assistant 
perform all study procedures and conducting these according to a strict routine. 
During each procedure, standard views of the gastric mucosa were photographed 
and compared in real-time to images recorded at the preceding procedures. 
Estimation of lesion size at fibreoptic video endoscopy is notoriously unreliable, but 
we ensured that we measured largest tumour dimensions in a standardised fashion 
(by comparing their diameter to the open jaws of adjacent biopsy forceps). We 
recognise the limitations of recording endoscopic findings as described in this study. 
Firstly, estimation of tumour size and number are inherently subjective and open to 
observer bias(321). Secondly, we acknowledge that the effect on tumour size of 
taking biopsies at each procedure may have been a significant contributor to the 
observed decrease in dominant tumour size. 
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The second outcome measure reported above is the described effect of netazepide 
treatment on circulating levels of CgA. This ECL-cell product is a well-recognised 
biomarker of ECL-cell mass and activity(322). It has been suggested that chronic 
atrophic gastritis and hypergastrinaemia result in an increase in circulating CgA 
concentration with or without gastric neuroendocrine tumour development. In our 
patients, the circulating CgA can be attributed both to hyperstimulated ECL-cells in 
non-dysplastic gastric mucosa and to the ECL-cell tumours themselves. Netazepide 
acts to antagonise the effects of gastrin on ECL-cells irrespective of their location and 
the decrease in plasma CgA concentration probably reflects the effect of the drug on 
ECL-cells located both in non-dysplastic mucosa and in NETs. In the first stage of this 
study, we repeated our measurement of plasma CgA concentration 12 week after 
completing the initial 12-week treatment period. By this time, mean CgA 
concentration had risen, though not quite to pre-treatment levels. The difference 
between baseline and follow-up levels was not statistically significant though the 
finding that macroscopic features (tumour size and number) remained diminished 
would suggest that the follow-up period of 12 weeks was insufficient for the ECL-cell 
population to ‘recover’. 
 
Arguably the most compelling evidence for the efficacy of netazepide in this study is 
the effect on mucosal biomarkers of ECL-cell activity. In both stages, we reported 
significant and sustained decreases in the mRNA abundances of the ECL-cell 
products CgA and HDC in gastric corpus mucosa. In the first stage, we also observed 
a decrease in MMP-7 mRNA abundance, but this effect was not seen in stage 2. 
 
Finally, plasma concentrations of netazepide in CAG patients were similar to those in 
treated healthy subjects(288,323). Such concentrations cause substantial 
antagonism of gastrin/CCK2R-mediated responses in healthy volunteers. Some oral 
drugs require low gastric pH to facilitate absorption. Netazepide appears to be well 
absorbed in the hypochlorhydric stomachs of patients with CAG. 
 
Although serum gastrin concentrations by ELISA were lower than by RIA, both results 
followed the same pattern.  RIA and ELISA are known to give different results for 
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serum gastrin(324,325). RIA probably measures all active forms of gastrin, whereas 
that is less certain for ELISA. Netazepide did not affect serum gastrin concentrations 
in CAG patients, whereas it does in rodents and healthy subjects due to suppression 
of gastric acid secretion. The absence of a significant effect of netazepide on serum 
gastrin concentration in CAG patients confirms the diagnosis of achlorhydria. It also 
emphasises that the effect of netazepide on type 1 gastric NETs is exerted indirectly 
via suppression of serum gastrin. 
 
In stage 1, twelve-weeks of netazepide did not induce complete tumour regression 
in any of the 8 subjects, though all but one had smaller and fewer tumours than 
before treatment. In a series of similar patients treated by antrectomy (to abrogate 
gastrin production), tumour regression was seen to occur as late as twelve months 
following surgery(269). The extended dosing employed in stage 2 matched this and 
in one subject (patient 1) we did report complete and sustained tumour regression 
after 24 weeks of treatment. A second patient also appeared to have demonstrated 
complete tumour regression at 24 weeks but we subsequently reported a single, 
diminutive tumour (1mm in diameter) at the 52-week examination. In retrospect, 
this tumour was probably present but not identified at the preceding endoscopy. In 
stage 2 of the study, all but one patient showed a decrease in the number and size of 
gastric tumours. It must also be remembered that the macroscopic gastric tumours 
are not necessarily related to neuroendocrine tumour disease and that type 1 gastric 
NETs might coexist in the same individual with polyps/tumours of other aetiologies 
such as fundic cystic glandular polyps.  
 
There were limitations in the study design; it was open-label, lacked controls and 
involved only a small number of patients, and there was a possibility of observer bias 
by the endoscopist.  We decided upon an open, uncontrolled study design for 
several reasons.  First, we took measures to minimise observer bias by the 
endoscopist.  Second, plasma CgA and real-time PCR mRNA abundances are valid 
outcome measures.  Third, type 1 gastric NETs are rare, (258) and we wanted to 
offer all patients the possibility of active treatment.  Fourth, it was the first 
netazepide study in patients, and a ‘proof-of-principle’ study.  Overall, the findings – 
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clinical and laboratory – have face validity and provide the first evidence of efficacy 
by a gastrin/CCK2 receptor antagonist in the treatment of type 1 gastric NETs.  That 
conclusion is strengthened by a parallel study in patients with multiple type 1 gastric 
NETs, using a similar protocol, which also showed that netazepide reduced tumour 






7.1 Biomarkers of gastric mucosal preneoplasia following infection with 
Helicobacter pylori 
 
The aims of this study were to investigate the roles played by various genes and 
proteins during human gastric carcinogenesis following infection with H. pylori. In so 
doing we hoped to identify novel mucosal biomarkers of preneoplastic mucosal 
lesions in the stomach, which in future might offer non-invasive means of identifying 
individuals who have an increased risk of developing gastric cancer.  
 
To do this, we measured the mRNA abundance of several putative biomarkers in 
gastric mucosal biopsies obtained from 1400 study subjects, for whom we had 
standardised histopathology reports and data from serological analyses including 
gastrin and pepsinogen concentrations as well as H. pylori antibody and CagA status. 
 
Having identified matrix metalloproteinase-7 as the most promising of these 
putative biomarkers, we sought to determine the effects on its gastric mucosal 
expression of genetic polymorphisms, and the effect of these polymorphisms on the 
likelihood of developing gastric preneoplasia. 
 
7.1.1 Gastric preneoplasia 
 
Our study cohort of 1400 subjects included 573 (43.3%) with H. pylori seropositivity, 
51.3% of whom also had evidence of current infection with this bacterium. Of the 
1381 study subjects for whom we obtained gastric histology data, 338 were reported 
to have histological evidence of gastric preneoplasia. Interestingly, only 14 of these 
were reported as having preneoplastic lesions macroscopically at upper GI 
endoscopy, underlining the poor performance of routine endoscopy in detecting 




The central hypothesis – that H. pylori mediated inflammation is largely responsible 
for initiation of the cascade of preneoplastic changes – was substantiated by this 
study. H. pylori infection was significantly more prevalent in the individuals who had 
preneoplasia than in those without (OR 3.8) and the same was true for more virulent 
strains of this organism as evidenced by CagA seropositivity (OR 2.1).  
 
There are several pieces of evidence to suggest that the antral hormone gastrin plays 
an important role in gastric carcinogenesis. CCK2R expression increases with the 
progression of CAG(327) and is found in a large proportion of gastric 
adenocarcinomas(328). Gastrin induces apoptosis in cancer cell lines(329) and 
potentiates the expression of mucosal proteases implicated in carcinogenesis 
including the MMPs, TIMPs and members of the uPA system(33,56). Of course, 
preneoplasia of the gastric corpus also entails the loss of native functional glandular 
units and the resulting hypochlorhydria leads to the unregulated stimulation of 
gastrin secretion.  
 
Our study findings were in line with this hypothesis in that we found fasting serum 
gastrin concentrations to be significantly higher in individuals with gastric mucosal 
preneoplasia than in those without. Unsurprisingly, we demonstrated that this effect 
was greater for those subjects whose gastric preneoplasia was confined to the 
corpus than those with pangastric disease, which in turn was greater than those with 
antral-only disease. 
 
The best-studied non-invasive biomarker of gastric preneoplasia and cancer to date 
is serum pepsinogen concentration. Analyses of circulating levels of PG1 or PG1/2 
ratio are used frequently in some high-risk populations but comparatively few 
studies have examined their use in lower-risk areas(197,330,331). Several authors 
have reported improved diagnostic performance when serum pepsinogen analyses 
are combined either with H. pylori serology, serum gastrin concentration or both. A 
commercially available kit – GastroPanel – is available based on ELISAs for serum 
PG1 and PG2, H. pylori IgG antibody and serum gastrin-17. Its use in clinical practice 
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is yet to be adequately validated and indeed, a recent study in Spain suggested that 
its sensitivity for gastric disease was inadequate for clinical use(241). 
 
In the present study, we found that serum PG2 concentration and PG1/2 ratio were 
significantly different in individuals with gastric preneoplasia compared to those with 
normal stomach histology. Again, this difference was unsurprisingly greater when 
comparing corpus-only preneoplasia to normal histology groups. As a diagnostic test 
for gastric preneoplasia, PG1/2 was better than PG2 alone, with areas under the ROC 
curve of 0.8 and 0.75 respectively. Combining serum PG1/2 ratio with H. pylori 
serology and serum gastric concentration gave a diagnostic test which had good 
sensitivity (90%) and negative predictive value (96%) for gastric preneoplasia in 
symptomatic individuals. Whilst this would appear to endorse the approach 
suggested by the manufacturers of GastroPanel, it is important to highlight that 
whilst serum pepsinogen and H. pylori serology assays were performed by ELISA in 
this study, we used radioimmunoassay to determine serum gastrin concentrations. 
ELISA is a comparatively poor technique for this purpose but is readily available and 
inexpensive(324,325). Whilst RIA is superior, it is no longer widely available. It may 
be that the future clinical use of biomarker screening panels for the noninvasive 
detection and risk stratification of gastric preneoplasia will be dependent on the 
development of more reliable gastrin assays. 
 
7.1.2 MMP-7 expression in gastric preneoplasia 
 
Helicobacter pylori, its constituents and particularly the more virulent strains of the 
bacterium stimulate the expression of MMP-7, which is also overexpressed in gastric 
cancer. Its expression in cancer tissue (and circulating levels) seem to correlate with 
stage of disease, degree of invasiveness and metastatic behaviour(53,332).  
 
We found that gastric mucosal expression of MMP-7 was significantly increased in 
preneoplastic gastric disease (CAG and IM) and to a lesser degree, in gastric 
inflammation associated with H. pylori infection. The effect was greatest for corpus-
 
222 
only preneoplasia, which is probably the phenotype that is associated with the 
highest risk for cancer development. We observed an increase in MMP-7 expression 
with increasing ‘severity’ of preneoplasia i.e. expression was greater for subjects 
with IM and atrophy than in subjects with gastric atrophy alone though this 
difference was not statistically significant. Interestingly, where IM was reported in 
the absence of atrophy, the increase in MMP-7 expression over controls was less 
marked (and did not reach statistical significance). This suggests that the IM in this 
group might include different metaplastic variants which are not associated with 
atrophy as a precursor and that these patients may have an attenuated risk for 
cancer development. 
 
We also demonstrated that mucosal MMP-7 expression was significantly greater in 
preneoplasia and H. pylori associated inflammation than in the ‘benign’ gastric 
mucosal conditions of reactive/chemical gastritis (gastritis C) and foveolar 
hyperplasia. This is an important feature for a putative biomarker. Interestingly, we 
found that the magnitude of increase in MMP-7 expression for those subjects who 
were infected with the CagA serovar was not significantly greater than those who 
were infected with CagA negative strains of H. pylori.  
 
MMP-7 expression has been shown to be driven in part by gastrin(126) and this 
phenomenon may play a part in regulating epithelial cell migration and 
invasion(333,334). In our study, gastric MMP-7 expression was 2.5 times greater in 
hypergastrinaemic subjects than in controls. Moreover, in subjects with ‘severe’ 
hypergastrinaemia (>100pM), the increase was almost 4-fold. When we controlled 
for the effect of preneoplasia by comparing MMP-7 mRNA abundance in subjects 
with normal gastric histology, we found that the severe hypergastrinaemia group 
exhibited a 7.4-fold change in MMP-7 expression. This suggests that serum gastrin 
concentration exerts an independent effect on gastric mucosal MMP-7 expression.  
 
We concluded our investigation of MMP-7 as a potential biomarker of gastric 
preneoplasia by studying the circulating concentrations of the protein. The assay 




Serum concentration of MMP-7 was significantly greater in the preneoplasia group 
than in subjects with normal gastric histology, but the magnitude of this change was 
much smaller than that observed for mucosal MMP-7 expression. When we 
examined the differences between normal controls and preneoplasia in different 
topographical sites, only corpus-limited preneoplasia was associated with a 
significant increase in serum MMP-7 concentration. In the present study, serum 
MMP-7 concentration was also significantly higher in individuals with gastric 
preneoplasia when compared with those exhibiting ‘benign’ gastric disease. 
 
There are two major applications of noninvasive biomarkers of gastric preneoplasia 
and the clinical relevance of such ‘tests’ is dependent on the burden of disease in the 
population in question. In high-risk populations, population-based screening is 
already employed for the detection of early gastric cancer. In these populations, this 
is predominantly conducted endoscopically or radiologically, but these systems are 
expensive and inconvenient, and their sensitivity questionable(197). In the case of 
gastric preneoplasia, serological testing may indeed prove more sensitive than the 
incumbent methods, which would make for a simpler, cheaper means of screening 
large numbers of people. 
 
Our study was not conducted with cancer diagnosis in mind. We identified only 12 
cases of gastric adenocarcinoma, which was insufficient to evaluate the performance 
of MMP-7 as a biomarker. This has been studied previously for other epithelial 
cancers (colorectal and pancreatic) and in small series for gastric cancer. Blanco-
Calvo et al. examined the diagnostic performance of serum concentrations of MMP-
7 and GDF15 in 52 cases of gastric cancer (and 23 controls). The area under the ROC 
curve for MMP-7 as a diagnostic test for gastric cancer was 0.86 with a reported 
sensitivity and specificity of 79% and 87% respectively. Yeh et al. published their 
findings from a series of 201 patients including 55 gastric cancers. They reported 
serum concentrations of MMP-7 (along with MMPs -3 and -9) and found an optimal 
sensitivity and specificity of the former for the diagnosis of gastric cancer of 66% and 
67% respectively. In that study, the authors concluded that increasing serum 
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concentrations of both MMP-3 and -7 were associated with diminishing survival 
rates from gastric cancer. Before non-invasive methods for the diagnosis and risk-
stratification of gastric preneoplasia are accepted in these populations, they would 
need to be shown to be at least as effective for the diagnosis of early cancer as the 
current modalities.  
 
Less attention has been paid to the diagnosis of preneoplastic lesions, as there has 
previously been limited evidence to guide subsequent surveillance and 
management. A landmark in this field has been the development of the 
OLGA/OLGIM scoring systems(227,229) – themselves developments of the Sydney 
scoring system(199). Using a standardised sampling protocol, gastric mucosal 
biopsies can be used, not only to diagnose the presence if preneoplastic disease but 
also to estimate the risk of future cancer development. In low-risk gastric cancer 
populations such as those found in Western Europe and the United States, these 
systems could be used to accurately identify those patients who have a substantially 
increased risk of gastric cancer development and in whom it might be appropriate to 
offer a surveillance regimen. It is impractical however to implement endoscopic, 
population-based screening in these populations. In these settings, symptomatic 
individuals or those at higher risk (such as those with family histories etc.) could be 
screened using a non-invasive biomarker panel. If the results suggested a diagnosis 
of gastric preneoplasia, then upper GI endoscopy with Sydney-protocol biopsies 
could be undertaken and the patient’s risk of cancer development determined using 
the OLGA/OLGIM systems. Based on the risk-stratification determined from gastric 
‘mapping’ biopsies, individuals could then be enrolled into an endoscopic 
surveillance system if appropriate. The available data suggest that the cancer risk in 
patients with gastric preneoplasia is similar to that reported in Barrett’s oesophagus 
and the benefit of making earlier diagnoses in these cancers is analogous as both 
tumours usually present late and are associated with very poor survival. It should be 
noted however, that in these low-risk populations, individuals for whom upper GI 
endoscopy is currently indicated (older patients, ‘alarm’ symptoms, iron-deficiency 
etc.) would not be safely spared such examination by negative serological biomarker 
testing alone.  
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7.1.3 Genetic polymorphisms in MMP-7 
 
Single nucleotide polymorphisms in MMP-7 have been associated with an increased 
risk of developing digestive (including oesophageal adenocarcinoma, oesophageal 
squamous-cell carcinoma, colorectal carcinoma and gastric carcinoma), 
gynaecological and breast cancers(313,335). The best studied of these is rs11568818 
(usually referred to in the literature as ‘MMP-7 -181A>G’). Wu et al. conducted a 
meta-analysis of 27 case-control studies(314) and concluded that the G allele was 
associated with a significantly increased risk of cancer in Asian populations but not in 
Europeans. Conversely, for gastric cancer, Fang et al. reported an association study 
and meta-analysis which suggested an increased risk of gastric cancer for the A allele 
of this SNP(336). European studies are however comparatively scarce. Kubben et al. 
found that the G allele at rs11568818 was found more frequently in gastric cancer 
cases than in controls and that this was associated with poorer survival(337). The 
role of MMP-7 SNPs in the development of preneoplastic lesions of the stomach has 
not been studied extensively. Hellmig et al. reported that carriage of the G allele of 
rs11568818 was associated with gastric ulcer development(338), while Achyut et al. 
found that the same allele was associated with an increased risk of lymphoid follicle 
formation in dyspeptic patients with H. pylori infection(339).  
 
The present body of literature therefore asserts that although there appears to be 
an association between SNPs of MMP-7 and gastric cancer, the supporting evidence 
is sometimes conflicting and this association has not been extensively examined in 
European populations. Additionally, few studies have examined the influence of 
MMP-7 polymorphisms upon the development of gastric preneoplasia. 
 
In the present study, we demonstrated that the nine SNPs studied were distributed 
in Hardy-Weinberg equilibrium and that for SNP (rs17352054), the minor allele 
homozygote was significantly more frequent in cases of gastric preneoplasia than in 
normal controls. We demonstrated that carriage of the minor allele for SNP 
rs11225297 was assoicated with gastric preneoplasia amongst individuals with H. 
pylori seropositivity. We also studied the influence of these polymorphisms on 
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mucosal expression of MMP-7. Six SNPs were associated with a significant increase 
in mucosal MMP-7 mRNA abundance in their minor allele homozygote form, 
heterozygote form or in both. We have also shown that in our European cohort, the 
SNPs commonly associated with gastric cancer in the literature were not associated 
with the presence of preneoplasia. The identification of rs17352054 and rs11225297 
as a polymorphism associated with gastric preneoplasia is novel and merits further 
study, not least in cases of gastric cancer. 
 
7.1.4 Strengths and limitations of the study 
 
The present study design proffered several advantages. First, the large number of 
study subjects provided us not only with a substantial number of individuals in 
whom we identified H. pylori infection and gastric preneoplasia but also a sufficiently 
large group of individuals with normal gastric mucosal histology that we were able to 
generate statistically powerful control groups. This allowed us to control for 
variables such as PPI use, which might not have been possible in a smaller study 
population. Secondly, we benefitted from the input of a single, expert GI pathologist, 
whose reporting of all pathology specimens obviated the risk of interobserver 
variance, thus yielding highly consistent pathology reports. 
 
There were however some limitations to the present study. In a disease process such 
as gastric preneoplasia, there is considerable field variation in histological changes 
across the mucosal surface. We were limited by ethical and safety considerations in 
the number of biopsies we were able to take. Although we were able to obtain 
sufficient biopsies to satisfy the minimum criteria for Sydney scoring, additional 
mucosal biopsies might have increased our pickup rate of gastric preneoplasia and 
better defined the topographical phenotypes being studied. We have asserted that 
the biomarkers of gastric preneoplasia described in this thesis can be used to 
estimate the ‘stage’ or ‘severity’ of disease. It could be argued that the finding of 
intestinal metaplasia in histology series from a patient with gastric atrophy is 
representative of more severe atrophy than of a more advanced lesion per se. The 
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conventional view however is that IM itself confers an increased risk of malignant 
remodelling  (as per Correa’s cascade of gastric oncogenesis). 
 
Secondly, we did not set out to include gastric cancer in this study. Those small 
number of cases included were captured ‘fortuitously’ and are too small to inform 
meaningful conclusions about biomarker performance. Before moving forward with 
the development of noninvasive biomarkers for gastric preneoplasia, the 
performance of these biomarkers should be validated for the diagnosis of gastric 
cancer in the same study setting. 
 
It is also worthy of note that we omitted testing for serological biomarkers of 
pernicious anaemia/autoimmune atrophic gastritis in this study. We recognise that 
this disease would account for a small proportion of the cases we included in our 
‘preneoplasia’ group. In European populations, the prevalence of PA is estimated to 
be less than 5% and the sensitivity of antibody serology for the syndrome to be less 
than 80%(340,341). Assuming that these estimates are broadly applicable to our 
study population, the number of cases of pernicious anaemia/autoimmune atrophic 
gastritis included in our ‘preneoplasia’ group is likely to be small and unlikely to 
substantially affect our results and conclusions. On this basis and given resource 
constraints, we elected not to perform anti-gastric parietal cell and anti-intrinsic 
factor antibody serology in this study. 
 
 
We have also not yet described the effect on MMP-7 protein abundance in this 
study, although work is currently underway to determine this using 









This study has provided evidence to support the hypothesis that the gastric epithelial 
protease MMP-7 is overexpressed in the presence of gastric preneoplasia. Based on 
previous experimental work, it seems likely that this response to H. pylori induced 
chronic inflammation is one of the factors responsible for driving mucosal 
remodelling towards cancer development. We have shown that MMP-7 has the 
potential for clinical use in combination with other established methods as a 
noninvasive biomarker of gastric mucosal preneoplasia. Development of MMP-7 as a 
biomarker will however require a number of additional steps. Its use as a biomarker 
will depend on its ability to reliably detect (or reliably exclude) gastric cancer. An 
accurate assay for circulating MMP-7 in this context will also be required and our 
group is presently working on such an assay. Finally, biomarker performance will 
require validation in populations of different ethnicity. 
 
We have highlighted the role of genetic polymorphisms in MMP-7 in affecting gastric 
mucosal expression and in the case of SNPs rs17352054 and rs11225297, identified 
SNP genotypes which might predispose individuals from this European population to 
gastric preneoplasia development.  
 
These data might contribute towards a means of determining an individual’s risk of 
developing gastric cancer either in place of or in conjunction with histopathological 
sampling and scoring systems such as OLGA/OLGIM. This is likely to be most relevant 
in high-risk populations. 
 
7.2 The use of netazepide for the treatment of type 1 gastric neuroendocrine 
tumours 
 
The development of CCK2R ligands for therapeutic purposes outside the CNS has 
been grounded in the observations that amidated gastrins are major hormonal 
regulators of gastric acid secretion and that they exert trophic effects on a range of 
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tissues including several neoplasms. There has been recent work describing 
immunotherapy for gastrin using G17DT in pancreatic cancer(342). Our own work on 
netazepide has been published, as has that of a group who performed a parallel 
study(326,343).  
 
In the present study, we demonstrated the efficacy of the novel gastrin/CCK2R 
antagonist netazepide for the treatment of type 1 gastric NETs. The drug was safe 
and well tolerated and the 8 patients in the study all exhibited a decrease in the size 
and/or number of gastric tumours, along with a decrease in both mucosal and 
circulating biomarkers of ECL-cell population and activity. Randomised, placebo-
controlled trials are now required to validate this treatment. Type 2 gastric NETs are 
also dependent on gastrin for growth and proliferation. A trial of the use of 
netazepide for this indication is ongoing. 
 
There are several other potential clinical uses for gastrin/CCK2R antagonists. 
Histamine receptor antagonists (H2RAs) and proton-pump inhibitors (PPIs) are 
effective treatments for acid-secretory disorders and exhibit low toxicity. 
Nevertheless there continues to be interest in the development of CCK2R 
antagonists as anti-secretory agents for two reasons. First, suppression of acid 
secretion reduces the feedback-inhibition of gastrin release, resulting in 
hypergastrinaemia which can lead to a rebound in acid secretion on cessation of 
treatment; the “acid-rebound” effect has been shown to persist for up to 8 weeks 
after discontinuing PPI use, and can lead to a state of physiological dependence by 
patients using anti-secretory drugs. Second, in patients on long-term therapy acid 
suppressing therapies (e.g. for the treatment of gastro-oesophageal reflux disease, 
GORD), there has been speculation that the resulting hypergastrinaemia might 
increase the risk of developing gastrointestinal malignancies. Netazepide has 
previously been shown to be well tolerated and orally active in inhibiting acid 
secretion(288,323). A dose of 25 mg was superior to 150 mg ranitidine in raising 24-
hour gastric pH, and the inhibition lasted longer. The data contribute to the idea that 
gastrin is a physiological regulator of acid secretion in man, and this paves the way 
for future trials involving this compound. With respect to gastrin-related risks from 
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PPIs, recent work in Mongolian gerbils has shown that PPI treatment increases the 
risk of developing H. pylori -induced gastric adenocarcinoma(344). However, while 
some patients taking PPIs may be at risk of developing ECL cell hyperplasia, there 
does not at present appear to be evidence of an increased incidence of gastric 
neuroendocrine tumours in humans(345). A recent Cochrane review of 7 
randomised controlled trials examining the effect of long-term PPI use on the 
development of gastric preneoplasia concluded that there was no clear evidence 
causation or accelerated development of gastric preneoplasia(346). Moreover, no 
increase in gastric adenocarcinoma was found amongst PPI/H2RA users in a 
prospective cohort study(347), and in a recent case–control study, there was no 
association between PPI use and pancreatic cancer(348). These studies did not, 
however, stratify subjects by serum gastrin concentration, and so they leave open 
the question of a role for hypergastrinaemia in a subset of patients in whom CCK2R 
antagonists might be beneficial. 
 
Previous clinical trials of CCK2R antagonists in gastrointestinal cancer have largely 
focused on the treatment of pancreatic cancer. A benzodiazepine-derived CCK2R 
antagonist, Z-360, which has good oral activity and high receptor affinity, was shown 
in a small phase Ib/IIa trial (33 patients) to result in no improvement in tumour 
control in advanced pancreatic cancer, but there was an encouraging trend towards 
improved survival when Z-360 plus chemotherapy was given compared with 
chemotherapy alone(349). It should be noted, however, that in a mouse model of 
cancer pain, Z-360 inhibited ephrin B1 gene expression and phosphorylation of the 
NR2B subunit of N-methyl-D-aspartate receptor, and that the CCK1R antagonist, 
devazepide, had similar effects(349). Moreover, in another model of induced pain, 
the same group found that Z-360 had analgesic actions that were replicated by 
devazepide but not by netazepide(350). It seems therefore that in some 





7.2.1 Limitations of the study 
 
There were a number of limitations of this study. The study design was one of an 
open-label, uncontrolled pilot study and only eight patients were included. Though 
the observed effects on endoscopic characteristics and biomarkers were statistically 
significant, the nature of the study allows for a number of sources of bias. The 
inclusion of endoscopic characteristics as a means to monitor disease response was 
important but particularly prone to inconsistency – though the procedures were 
conducted by a single endoscopist, he was an investigator in the trial and thus open 
to observer bias. Not only this, but the endoscopic assessment of tumour size is 
notoriously inconsistent(321,351) and involved determining very small changes in 
already very small tumours. Finally on this point, the use of largest tumour size as a 
measure of disease response might have been affected by the requirement to biopsy 




We have shown that netazepide is an efficacious, safe and well-tolerated treatment 
for type 1 gastric NETs. Larger, randomised, placebo-controlled trials are now 
required to validate our findings. We have also shown that serum CgA concentration 
and mucosal abundance of CgA, HDC and MMP-7 mRNA are useful biomarkers of 
disease activity and treatment response. 
 
It is also clear that there are other potential clinical uses of gastrin/CCK2R 
antagonists and this study provides proof-of-principle that netazepide inhibits 
gastrin stimulation of the receptor in patients in order to deliver a clinical response. 
Trials of its use and of other small-molecule antagonists of the CCK2 receptor are 
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Histology study code: ………  
 
Gastric biopsy 
Standard histopathological report 
Patient identification 
Name (given name / family name):…………………………………..Bi rth:.……………… 
Gender (M / F):…. 
Endoscopy pocedure:…………………………..…………………………….……………  
Clinical diagnosis:…………………………………………………………….…..  ………  
Serum sample available (Y / N) 
-----------------------------------------------------------------------------------------------------------  
Clinical data:……………………………………………………………………………..  
        Basic sampling: (representative / not representative) 
 
 
     
Special stains: H&E, PAS-AK, Giemsa, Congo, other.:………………………………………. 
Immunohistochemistry:…………………………………………………………………… ….. 
HISTOPATHOLOGY 
Type of gastritis: A / B / C  / other  / other alterations:………………………………………… 
……………………………………………………………………………………………………  
Helicobacter pylori-associated inflammation                                       
(Modified Sydney classification: Dixon, DF. Am.J.Surg.Pathol.1996) 
extension, localisation (antrum / body; superficial / transmucosal) 
lymphocytes, monocytes :   0 1 2 3 4 5 6 
activity (granulocytes)      0  1 2 3 4 5 6 
mucosal atrophy (body)    0 1 2 3 4 5 6 
Helicobacter pylori colonisation  0 1 2 3 4 5 6 
Foveolar epithel damage   0 1 2 3 4 5 6 
Intestinal metaplasie (type, extension)  0 1 2 3 4 5 6 
Sydney score:                   ………/ 36 
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Others:      MALT acquisition / MALT lymphoma / other lymphoma 
Pancreas acinaris metaplasia (PAM) 
Neuroendocrine hyperplasia 
Foveolar hyperplasia 
Chief cell / parietal cell hyperplasie / dilated glands 
Blood capillar dilatation / lymphangiectasie 
IEL / granuloma / eosinophilia / mastocytosis 
Erosion / ulcer 
Other microbas (f.e. H. heilmanni):………………………………….. 
Other/s:……………………………………………………………….. 
Padova classification (1998) 
1. Negative for dysplasia 
   1.0. normal 
   1.1 reactive foveolar hyperplasia 
   1.2. intestinale metaplasia 
    1.2.1. IM complet (I.type) 
    1.2.2. IM incomplet (II. and III. type) 
2. Indefinitive for dysplasia 
  2.1. foveolar hyperproliferation 
  2.2. hyperproliferative IM 
3. Non-invasive neoplasia („flat” or „elevated”, synonyma.: adenoma) 
  3.1. LG 
  3.2. HG  
   3.2.1. carcinoma suspicion without invasion  
   3.2.2. carcinoma without invasion  
4. Invasíve carcinoma suspicion 
5. Invasíve adenocarcinoma 
 
Modified Vienna classification  (2000, 2002) 
  1. category: 0 (negativ for neoplasia / dysplasia) 
2. category: ANDD (indefinitive for neoplasia / dysplasia)  
3. category:  LGD/LGA   
4. category: „intramucosal borderline neoplasia „ 
4.1. HGD/HGA 
4.2. intramucosalis carcinoma (pTis), well differentiated   
5. definite  carcinoma  
   5.1. Intramucosal carcinoma, moderately or poorly differenciated                                                                                                      












1. Senior pathologist    2. Junior pathologist 
















Factors Which Affect the Outcome Of  
Helicobacter Pylori Infection in the Stomach 
You are being invited to take part in a research study.  Before you decide, it is important 
for you to understand why the research is being done and what it will involve.  Please 
take time to read the following information carefully and discuss it with friends, relatives 
and your family doctor (GP) if you wish. If there is anything that is not clear, or if you 
would like more information, please ask.  
 
This is a voluntary project and, if you would prefer not to take part, your decision will be 
accepted without question and will not affect the standard of care you receive.  
 
What is the purpose of the study? 
 
Cancer of the stomach is the second most common cause of cancers worldwide. There 
are several important factors that have been identified that are associated with the 
development of stomach cancer. Infection of the stomach with bacteria – Helicobacter 
pylori - in addition to causing inflammation and ulcer of the stomach, also increases the 
risk of stomach cancer. However, only a small proportion of people who have this 
infection go on to develop stomach cancer. Therefore additional factors must be involved. 
Recent studies by our research group have identified several proteins in the stomach that 
have been shown to play a part in this process.  
 
In this new research, we wish to study these proteins and genes that could possibly make 
people susceptible to the development of stomach cancer. The results could in the long 
term help in developing new ways to halt the progression of cancer in the stomach. 
 
We aim to recruit about 1000 patients who have had a gastroscopy (a camera into the 
stomach /duodenum) for investigation of stomach problems. Patients will be identified 
and recruited for the study from the endoscopy unit at the Royal Liverpool University 
Hospital. 
 
Why have I been chosen? 
 
You have been chosen for the study because you are attending for a gastroscopy to 













Do I have to take part? 
 
No, it is up to you to decide whether or not to take part.  If you do decide to take part, you 
will be given this information sheet to keep and be asked to sign a consent form.  You are 
still free to withdraw from the study at any time without giving a reason. This will not affect 
the standard of care you receive in any way.  
 
What will happen to me if I take part? 
 
All patients who decide to take part in this study will receive the usual clinical care. That 
is, you will have had a gastroscopy as part of your routine clinical care and will still remain 
under the care of your clinician. If you decide to take part, the following will also take 
place 
  During the camera test, routine biopsy samples will be taken to examine the lining of 
the stomach under a microscope. Taking a biopsy involves taking a small piece of your 
stomach lining (smaller than a pinhead) using a specially designed piece of equipment. 
All of this is done down the middle of the camera, at the time of your procedure. Taking 
a biopsy sample is completely painless and extremely safe, and is a routine part of any 
camera procedure. The samples are then processed and examined in a laboratory. As 
well as routine biopsy samples of your stomach being taken, we would like to take 
some additional biopsy samples in order to process these in our research 
 
  An additional blood sample (approximately 20 ml), will be taken to try to identify genes 
and their products important in the development of stomach cancer  
 
  We will also ask you a few questions about your general health and that of your family 
in relation to stomach disease, in the form of a questionnaire 
 
  A review of your medical casenotes will be carried out by the research doctor. 
 
What are the possible disadvantages and risks of taking part?  
 
There may be some minor but short-lasting discomfort from having a blood test. You 
won’t feel anything while the biopsies are being taken. There is a very small risk of 
complications (such as bleeding or perforation) from having any biopsy of the stomach, 
but it is important to note that the biopsy will be taken by an experienced endoscopist and 
will be done in a unit which has extensive experience of this procedure.  Taking part in 
the study will not affect your current treatment, nor will it affect your ability to obtain 
insurance for health purposes. 
 
What are the possible benefits of taking part?  
 
The study will not be of direct benefit to you; however, it may benefit patients in the future 
who develop stomach cancer. 
 
What will happen to my biopsies and blood test? 
 
Blood will be divided into serum and genetic samples which will be stored at the 
University of Liverpool. 
DNA will also be extracted from the genetic sample at the University. It will used to look at 
genes that may be involved in causing the development of stomach cancer.  We will look 






Our aim is to develop a test that predicts the development of stomach cancer, and this 
may allow us to prevent its development in the future.  Your sample will be stored at the 
University of Liverpool until it is used up. The serum samples will be used to look for 
markers that define the development of stomach cancer. Again, the aim here is to 
develop tests that allow us to predict the development of cancers.  
 
From the biopsies we will look at the expression of various genes which will tell us how 
the stomach responds to Helicobacter pylori infection.  Some of the results obtained from 
these blood and biopsy tests will be linked with information that we obtain about your 
current and past medical history from the questionnaire and from your casenotes. 
 
It is important to note that all blood and biopsy samples going outside the hospital, and 
any notes relating to it, will be identified only by a code number. All clinical details will be 
kept securely, either at the Royal Liverpool University Hospital or the University of 
Liverpool. Once the study has been completed, we will anonymise your clinical details 
and blood and biopsy samples, and therefore it will not be possible to trace the samples 
back to you.  After anonymisation, it will also not be possible for you to withdraw the 
samples.  Once anonymised, the DNA samples may be used for other research, but as 
this cannot be traced back to you, it will have no direct bearing on your clinical care. 
Approval will be sought from the Ethics Committee for any future studies. 
 
Your blood and biopsy samples will be considered to be a gift to the University of 
Liverpool, which will act as custodian of all the samples obtained as part of this project.  
In some cases, a small amount of your sample will be provided to other researchers 
either in the UK or other parts of the world.  However, it is important to remember that this 
will only be identified by a code.  
 
In the short-term, it is unlikely that the samples will be of any commercial value to the 
University or the hospital. However, it is possible that they may be some commercial 
value in the future, although it is important to note that any commercial value is likely to 
be due to findings in a group of patients rather than from samples from a single patient.  
You will not be paid for taking part in the study, nor will you get financial benefit from 
future discoveries. 
 
Will my taking part in this study be kept confidential? 
 
As stated above, your sample will be anonymised, and therefore the genetic information 
obtained from it will be kept strictly confidential and not be disclosed to anyone.  All 
information collected about you during the course of the research will also be kept strictly 
confidential.  Any information about you, which leaves the research centres taking part, 
will have your name and address removed so that you cannot be recognised from it. We 
will inform your family doctor (GP) that you have participated in the study. 
 
What will happen to the results of the research study? 
 
Results from the project will be published in leading international medical journals. 
 
Who is organising and funding the research? 
 
This study has been designed by The University of Liverpool and the Royal Liverpool and 











The principal investigators are Professor A Varro and Professor D M Pritchard. 
 
Who has reviewed the study? 
 










If you need further information or are worried about any 
aspect of the study, please do not hesitate to contact Dr 
Andrew Moore, the Research Fellow running the study. 
 








Author: Dr Andrew Moore 
Date: March 2011 
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